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Abstract
DNA methylation is one of the key epigenetic marks extensively studied for its association
with environmental exposures and human diseases. DNA methylation can be proled by a
range of methods which dier drastically in their genomic coverage, throughput and
resolution. The present thesis encompasses a series of bioinformatic solutions for tackling
related data analysis problems.
First, comprehensive and user-friendly tools were developed for processing and primary
analysis of bisulte-based DNA methylation data. The R-package RnBeads supports analysis
of genome-scale proles from Innium microarrays and bisulte sequencing, while BiQ
Analyzer HT and HiMod enable complete and interactive analysis of deep locus-specic
sequencing assays of 5-methylcytosine and its oxidative derivatives. Second, to address
cellular heterogeneity in a genome-wide DNA methylation study of birth-weight we
proposed an original approach for correcting the statistical analysis. Third, a novel
deconvolution method MeDeCom was developed that facilitates data-driven exploration of
heterogeneous DNA methylomes.
Collectively, the results of the present thesis comprise dierent data analysis facets of a
large-scale DNA methylation study. Most of the presented bioinformatic solutions already
facilitate epigenetic research in numerous life-science groups worldwide.
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Kurzfassung
DNA Methylierung ist eine wichtige epigenetische Modikation, die besonders in Hinblick
auf ihre Assoziation mit Umwelteinüssen und Krankheiten intensiv untersucht wird. DNA
Methylierung kann durch verschidene von Methoden, die sich stark in Bezug auf ihre
genomische Abdeckung, den Probendurchsatz sowie ihre Auösung unterscheiden, ermittelt
werden. Die vorliegende Arbeit umfasst eine Reihe bioinformatischer Lösungen, um
relevante Probleme der Datenanalyze zu beheben:
Erstens, umfassende und benutzerfreundliche Werkzeuge zur Verarbeitung und primären
Analyse von Bisult-basierten DNA Methylierungsdaten. Ein R-Paket RnBeads unterstützt
die Analyze von genomweiten Innium Bead Arrays und Bisultsequenzierungen. BiQ
Analyzer HT und Himod ermöglichen eine volle und interaktive Analyse von
lokus-spezischer Bisult-Tiefensequenzierung von 5-Methylcytosin und seinen oxidativen
Derivaten.
Zweitens, ein neues Verfaren zur Korrektur der statistischen Analyse, um das Problem
der Zellularer Heterogenität des Methyloms in genomweiten DNA Methylierungsstudien zum
Einuss des Geburtsgewichtes zu lösen.
Drittens, eine neue Dekonvolutionsmethode “MeDeCom”, die die Referenz-freie
Untersuchung heterogener Datensätze erlaubt.
Zusammengenommen umfassen die Ergebnisse der vorliegenden Arbeit verschiedene
Aspekte der Datenanalyse im Rahmen einer großangelegten DNA Methylierungsstudie. Die
hier dargestellten Lösungen vereinfachen die Arbeit von Biowissenschaftlern in vielen
Forschungsgruppen weltweit.
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Chapter 1
Introduction
Preface
Epigenetics has greatly contributed to our understanding of how complex and versatile cell
phenotypes arise through the interaction of a relatively constant genetic background with
environmental inuences. Among the so far known epigenetic mechanisms, the phenomenon
of DNA methylation has for a long time been in the central focus.
The present thesis deals with methodological aspects of DNA methylation data analysis
and provides concrete computational and bioinformatic solutions for its specic problems.
Nevertheless, it appears important to rst answer the following questions: What is DNA
methylation and where is it found with respect to the genome? How are the DNA methy-
lation patterns established and get diverse in dierent cells of an organism? How similar are
methylation proles of dierent individuals and what are the reasons behind the dierences?
What are the functions of DNA methylation and which relation does it have to the genetic
information? How is DNA methylation linked to diseases and how can this association be
studied? Which methods exist to map DNA methylation and what are their strong and weak
sides? Which diculties are they associated with, both wet and dry lab, and which bioin-
formatic solutions exist for these diculties? What is understood under DNA methylation
heterogeneity? When is it a problem and how can it be addressed experimentally and compu-
tationally?
The purpose of this introduction is to provide a minimal yet sucient background for un-
derstanding the projects summarized in this thesis. The introduction is organized in three
parts. Section 1.1 provides basic knowledge about DNA methylation, its genomic and intra-
and inter-organismal patterns, functional role and link to diseases. Section 1.2 gives a detailed
introduction into the methods for mapping DNA methylation, their limitations and data analy-
sis aspects. Section 1.3 outlines the problem of methylome heterogeneity, introduces available
experimental and computational methods for addressing it.
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1.1 DNA Methylation
The four letter DNA alphabet has been most likely inherited by all known species from their
last common ancestor [Szathmáry, 2003]. The canonical chemical structure of the the four
nitrogenous bases is studied in sucient detail (Figure 1.1) [Townsend, 2013]. DNA methyla-
tion refers to a covalent modication of the bases directly in DNA by the addition of methyl
groups at strictly dened positions. The most widespread form of DNA methylation is methy-
lation of cytosine at the fths carbon atom of the pyrimidine ring. The resulting base variant
is commonly known as 5-methylcytosine (the rightmost structure in Figure 1.1).
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Figure 1.1: Bases of DNA and 5-methylcytosine.
1.1.1 Early observations and the cellular memory hypothesis
Strikingly, the presence of 5-methylcytosine in a living organism, bacteria Mycobacterium tu-
berculosis, was for the rst time detected long before anything was known about DNA and
its biological role [Ruppel, 1898]. Later it was also found in other prokaryotes [Dunn and
Smith, 1955], mammals [Hotchkiss, 1948] and plants [Wyatt, 1951]. While the function of
DNA methylation in prokaryotes as a mechanism in a restriction-modication host deference
system was elucidated quite early [Arber and Dussoix, 1962; Smith et al., 1972], little was
known about what role it played in higher organisms. Even more puzzling was the complete
or near-complete absence of DNA methylation in several important model species such as
yeast S. cerevisia and the fruit y D. melanogaster [Capuano et al., 2014].
Observations of the early studies [Srinivasan and Borek, 1964] crystallized into a hypothe-
sis stating that DNA methylation could be a mitotically heritable mechanism of cellular mem-
ory about gene activity states [Holliday and Pugh, 1975; Riggs, 1975]. Evidence supporting
the cellular memory hypothesis came from four major directions: i) non-random patterns of
5-methylcytosine across the genome and dedicated molecular mechanisms to propagate these
patterns between the cell generations; ii) diversity of methylation patterns across the cells of
the same organism; iii) inter-individual dierences; iv) participation in mechanisms control-
ling activity of the underlying genomic sequence. Each of these aspects are covered in detail
below.
1.1.2 Genomic distribution, enzymatic seing and removal
CpGs and mitotic heritability of DNA methylation paerns
The cellular memory hypothesis took into account an earlier nding that in vertebrate genomes
5-methylcytosine was predominantly found to precede a guanine base, i.e. at dinucleotide CpG
motifs or, shortly, CpGs [Doscocil et al., 1962]. The fact that CpG is palindromic, i.e. repeats
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itself in an anti-parallel fashion on both strands of the same DNA molecule, is directly linked
to the propagation of the methylation patterns through the cell divisions. It was shown that af-
ter the duplication of methylated DNA the methylation marks were introduced into the newly
synthesized DNA strands [Bird, 1978]. Importantly, methyl groups were transferred only to
those CpGs which have already been methylated in the original DNA molecule, reproducing
its methylation pattern [Bird, 1978; Pollack et al., 1980; Stein et al., 1982a]. These ndings were
advocating for the earlier suggested semi-conservative mechanism behind the mitotic inheri-
tance of the DNA methylation [Holliday and Pugh, 1975], establishing the latter as a plausible
cellular memory phenomenon.
Genome-wide picture: CpG-dense islands in the genomic sea of methylation
CpG dinucleotides are drastically underrepresented in vertebrate genomes, comprising ap-
proximately a quarter of the expected number [Swartz et al., 1962] and have a very non-
uniform distribution across the genome. Experiments with CpG-cutting restriction enzymes
revealed that CpGs are clustering in short stretches of 1 to 2 kb where their frequency is an
order of magnitude higher than average [Bird et al., 1985; Cooper et al., 1983]. These genomic
regions were termed CpG islands [Bird, 1986].
It was also shown that most of the CpGs are methylated, i.e. contain 5-methylcytosine [Bird
and Taggart, 1980; Ehrlich et al., 1982]. Failure to repair deaminated methylcytosines in the
germline could explain the observed CpG depletion taking place along the evolutionary his-
tory [Bird, 1980; Coulondre et al., 1978]. The most likely reason behind the local enrichment of
CpG sites was the fact that, unlike the rest of genomic CpGs, the majority of the island CpGs
were unmethylated [Bird, 1986].
Since then CpG islands have occupied a central place in our view of DNA methylation
landscapes. There were several attempts to devise a quantitative denition for a CpG island
and its borders which would enable their automatic search and annotation [Gardiner-Garden
and Frommer, 1987; Hackenberg et al., 2006; Takai and Jones, 2003]. More recent genome-
wide studies extended the perception of a CpG island. In particular, it turned out that DNA
methylation is more dynamic in the regions surrounding the islands which obtained a term
“CpG island shores” [Irizarry et al., 2008]. CpG island shores are now dened as 2 kb regions
anking a CpG island upstream and downstream. Furthermore, 2 kb regions anking the
shores are now referred to as “CpG island shelves” [Bibikova et al., 2011].
Seing and maintenance by DNA methyltransferases
An important and ubiquitous biological mechanism implies the presence of a dedicated en-
zymatic machinery. The cellular memory hypothesis suggested two classes of enzymes re-
sponsible for setting methylation marks, de novo methyltransferases, methylating previously
unmodied DNA, and maintenance methyltransferases copying the established pattern to a
newly synthesized DNA strand [Holliday and Pugh, 1975]. Subsequently, the rst eucaryotic
DNA methyltransferase (DNMT1) was discovered [Bestor and Ingram, 1983; Gruenbaum et al.,
1982] and subsequently cloned from the mouse [Bestor et al., 1988] and human genomes [Yen
et al., 1992]. Due to a clear preference for a hemimethylated substrate, DNMT1 was assigned
with the maintenance role. Later another family of DNMTs was cloned, which included two
candidate de novo DNMTs, DNMT3A and DNMT3B [Okano et al., 1999]. Further research
added new dimensions to the initial simple model of the DNA methylation enzymes [Arand
et al., 2012], but the concepts of the maintenance and de novo activity are still at the core of
our understanding about how methylation patterns are established [Jones and Liang, 2009].
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Removal by TETs, oxidative DNA modifications
A more recent advance in DNA methylation research was the discovery of oxidative 5-methyl-
cytosine varieties in mammalian brain [Kriaucionis and Heintz, 2009; Tahiliani et al., 2009].
Simultaneously, the key players were identied to be the family of ten-eleven translocation
(TET) enzymes, TET1, TET2 and TET3 [Tahiliani et al., 2009]. TETs oxidize 5-methylcytosine
to 5-hydroxymethylcytosine with the assistance of α-ketoglutarate and Fe2+ cations [Delatte
et al., 2014]. Furthermore, it was shown that TETs are capable of catalyzing further oxidation
leading to 5-formyl- and 5-carboxycytosine [Ito et al., 2011; Tahiliani et al., 2009]. Among other,
the evidence was collected that oxidation of 5-methylcytosine by TETs is the initial event of
the demethylation cascade [Guo et al., 2011]. The removal of the mark could proceed either as
passive dilution due to inability of DNMT1 to use 5-hydroxymethylcytosine as substrate, or
as an active elimination by base-excision repair machinery [Delatte et al., 2014].
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Figure 1.2: Oxidative derivatives of 5-methylcytosine.
Summary: the dynamic DNA methylation landscape
The DNA methylation landscape and its dynamics in a typical vertebrate genome looks roughly
as follows. 5-methylcytosine is found with almost no exception within CpG dinucleotides,
although in certain mammalian cell types, such as stem cells and adult neurons, abundant
non-CpG methylation was reported [Lister et al., 2013, 2009]. The genome as a whole has
low CpG density and is hypermethylated, while the short CpG dense islands are predomi-
nantly unmethylated. Methylation patterns are set by de novo methyltransferases DNMT3A
and DNMT3B and maintained by DNMT1. Furthermore, methylcytosine can be present in ox-
idized forms established by TETs. Oxidation by TETs usually precedes the removal of methy-
lation. The genomic DNA methylation prole and its temporal changes have to be considered
when studying it genome-wide.
1.1.3 Origins and cell type-specificity of DNA methylation paerns
In addition to a complex and, with a high probability, functionally relevant distribution of 5-
methylcytosine across the genome it was also noticed that the extent and patterns of DNA
methylation vary between dierent cells of an organism. In early studies these dierences
were detected both by bulk and locus-specic DNA methylation measurements [Gruenbaum
et al., 1981; Mandel and Chambon, 1979; Shen and Maniatis, 1980]. Later genome-scale pro-
ling in multiple tissues, cell types and lineages conrmed and extended this knowledge, in
particular in human [Eckhardt et al., 2006; Varley et al., 2013; Zhang et al., 2009; Ziller et al.,
2013]. The current view goes as far as stating that each individual human cell has a poten-
tially unique pattern of methylation at approximately 27 million CpGs present in the haploid
genome, collectively denoted as the DNAmethylome [Pelizzola and Ecker, 2011]. It is stunning
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that all the observed methylome diversity originates from a single methylation pattern of the
zygote.
Global DNA methylation changes in early embryonic development
Valuable insights about the origins of the intra-organismal diversity of the cell methylomes
were provided by embryological studies in mammals. It was shown that shortly after fer-
tilization the paternal and maternal genomes undergo fast and dramatic DNA methylation
changes [Feng et al., 2010; Mayer et al., 2000; Oswald et al., 2000; Rougier et al., 1998]. First,
a fast TET-mediated demethylation of the paternal genome starts with much of the 5-methyl-
cytosine being substituted by 5-hydroxymethylcytosine prior to the rst DNA replication [Iqbal
et al., 2011; Wossidlo et al., 2011]. It is followed by a slower demethylation of the maternal
genome, taking place over the rst several replication cycles [Feng et al., 2010; Geiman and
Muegge, 2010]. Both pronuclei lose almost a half of the methylcytosine by the time of im-
plantation [Allis et al., 2007]. The lowest level of genome-wide methylation is observed in the
preimplantation blastocyst where only 25% of CpGs are methylated [Lee et al., 2014]. The set
of genomic loci maintaining methylation includes, among other, the repetitive elements, such
as Intracisternal A-Particle (IAP), and the imprinted loci.
Embryonic stem cells provide a model of the methylome “ground state”
From the bottom levels observed in the blastocyst prior to the implantation, re-establishment
of DNA methylation begins, in which a decrease of the TET activity and an increase of de
novo methylation DNMT3A/3B play a decisive role [Lee et al., 2014]. Since studying DNA
methylation in a developing embryo is dicult many insights were obtained using embryonic
stem (ES) cells. Depending on the culturing conditions ES cells come in two avours [Ficz
et al., 2013; Habibi et al., 2013]. The “naive” ES cells have a very low global DNA methyla-
tion level and directly correspond to the inner cell mass (ICM) of the pre-implantation mam-
malian embryo. The hypermethylated “primed” ES cells correspond to the ICM after a large
re-methylation wave taking place around the implantation time [Lee et al., 2014]. They turned
out to be even slightly hypermethylated compared to fully dierentiated tissues, which im-
plies that the establishment of tissue- and cell type-specic methylomes is also linked to a loss
of methylation [Ziller et al., 2013]
High-resolution proling of the human ES cells showed that DNA methylation at a large
portion of CpGs is dynamic and changes throughout the development [Hodges et al., 2011; Lau-
rent et al., 2010; Lister et al., 2009; Smith et al., 2012; Ziller et al., 2013]. Computational analysis
revealed that ES cells seem to be constantly renewing their methylome to maintain a “clean”
epigenetic ground state [Landan et al., 2012]. A high methylome turnover rate at this tran-
sition stage is conrmed by the analysis of hydroxymethylation in “primed” ES cells [Booth
et al., 2012; Ficz et al., 2013]. A stochastic and non-uniform setting of DNA methylation pat-
terns during the transition between the “primed” and “naive” states most probably under-
lies the ever increasing diversion of the cell methylomes in the subsequent embryonic and
postnatal development [Lee et al., 2014]. Thereby emerging heterogeneity can have several
possible molecular mechanisms, including dierential expression or targeting of TETs and
DNMTs, strand-specic eects of de novo methylation and oxidation, as well as inecient
maintenance [Lee et al., 2014].
6
CHAPTER 1. INTRODUCTION
Lineage-commitment leads to a cell type-specific methylome
Diversion of methylation patterns continues during the later developmental stages. A large-
scale comparative study of tissues from three dierent germ layers discovered numerous CpG
positions specically methylated in endoderm, mesoderm and ectoderm [Irizarry et al., 2009].
Lineage determination in hematopoietic cells was shown to cause well dened changes all
across the methylome [Ji et al., 2010]. Similar processes were reported to happen during neu-
ronal dierentiation [Kim et al., 2014]. As a result, virtually every tissue, cell type and cell
population in an adult mammalian organism is characterized by a specic DNA methylation
signature [Lister et al., 2013; Varley et al., 2013; Ziller et al., 2013].
1.1.4 Individual dierences
The next dimension of DNA methylation diversity was discovered when studying dierences
between individuals [Bock et al., 2008; Eckhardt et al., 2006]. The major drivers of these dier-
ences in a population of healthy human subjects include genetic variation, gender and age [Pi-
razzini et al., 2012].
Interplay with the genotype
Large-scale studies showed that genetic variation explains a signicant portion of the observed
DNA methylation dierences [Gutierrez-Arcelus et al., 2013; van Dongen et al., 2016]. This sta-
tistical association can have several aspects. First, given that the majority of somatic cells are
diploid, the methylation state of CpGs can dier between the two homologous chromosomes,
the phenomenon known as allele-specic methylation (ASM). ASM was shown to be abun-
dant in the human genome and mostly driven by polymorphisms directly aecting the CpG
cytosines [Shoemaker et al., 2010]. Second, cis-acting genetic variants can be quantitatively
associated with the bulk methylation level at neighboring CpG positions. This type of genet-
ically inuenced regions were termed methylation quantitative trait loci (methQTLs) [Rakyan
et al., 2011].
Gender
Chromosomal basis of sex determination in mammals implies that males and females have
dierent DNA methylation landscapes already due to a dierent number of genomic CpGs.
The hemizygous state of chromosome X in human male organisms limits the potential num-
ber of possible methylation states at almost 2.5 million CpG positions. On the other hand
chromosome Y carries CpG positions which are absent in female organisms. Except for such
trivial dierences sex-specic methylation on the autosomal loci was observed in numerous
studies [El-Maarri et al., 2007; Sarter et al., 2005]. This was later conrmed by several genome-
scale screens [Boks et al., 2009; Liu et al., 2010; van Dongen et al., 2016].
Age
Maintenance errors can accumulate over the lifespan of an individual, resulting in stochastic or
directed changes of the methylome. Decrease of 5-methylcytosine abundance over the lifespan
was observed very early in multiple vertebrate species [Berdyshev et al., 1967; Vanyushin
et al., 1973; Wilson et al., 1987]. The age-related global hypomethylation was subsequently
conrmed in human [Fuke et al., 2004]. In addition to this pan-genomic eect, it was noticed
that selected, CGI-overlapping loci gain methylation with age [Issa, 2003; Nakagawa et al.,
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2001; Shen et al., 2003] later associated with the bivalent domains [Rakyan et al., 2010]. In
humans these changes seem to occur with a very similar rate across all tissues [Jones et al.,
2015], which allowed the creation of a surrogate DNA methylation age calculator [Bocklandt
et al., 2011; Horvath, 2013; Weidner et al., 2014].
On the conceptual level the current view is that age-related changes are a result of two
independent phenomena, the epigenetic drift which is a, supposedly, stochastic divergence of
epigenomes from the common origin over time, and the epigenetic clock implying directed
changes of methylation at certain sites [Jones et al., 2015; Teschendor et al., 2013]. It was,
however, also shown that due to cell type specicity of DNA methylation age-related changes
can at least in some cases be a result of changed cellular composition [Jae and Irizarry, 2014;
Weng et al., 2009].
1.1.5 Biological function
Highly non-random distribution of methylation and CpG dinucleotides over the genomes,
the presence of a specialized enzymatic machinery, dierences across tissues and cell types
as well as variation between individuals suggests that DNA methylation is playing a signi-
cant functional role. Furthermore, the importance of DNA methylation was conrmed by the
loss-of-function experiments, which showed that the DNMTs are essential for the mammalian
embryonic development [Li et al., 1992; Okano et al., 1999].
Association with global repression: X chromosome inactivation, imprinted genes
and silencing of transposons
The idea that DNA methylation is directly linked to silencing of the underlying genomic re-
gions was expressed already as a part of the epigenetic memory hypothesis [Holliday and
Pugh, 1975; Riggs, 1975] and supported by gene-specic [Bird, 1978; Christman et al., 1977;
Desrosiers et al., 1979; McGhee and Ginder, 1979] and transfection-based experiments [Stein
et al., 1982b; Vardimon et al., 1982]. Later research revealed the essential role of the DNA
methylation in key repressive epigenetic phenomena. First, it was shown that the methyla-
tion level of the genes on the inactivated X chromosome is substantially higher compared
to the active one [Wolf et al., 1984] and that they can be derepressed by the use of DNMT-
inactivating nucleotide analogue 5-azacytidine [Mohandas et al., 1981; Venolia et al., 1982].
Second, the imprinted genes with parent-of-origin-dependent expression were related to clus-
ters of allele-specic dierentially methylated regions marking the suppressed allele from the
corresponding gamete down to the somatic cells [Bartolomei et al., 1993; Ferguson-Smith et al.,
1993; Liu et al., 2000; Shemer et al., 1997; Takada et al., 2002]. Third, since a large portion of the
hypermethylated mammalian genome consists of transposable elements, such as L1 and Alu
elements in human, which endanger genomic stability, it was suggested that DNA methylation
might be a host defence mechanism of suppressing their activity [Yoder et al., 1997].
Methylation at gene promoters
More than a half of the genes in mammalian genomes overlap with CpG islands [Jones, 2012].
A direct silencing-by-methylation model is apparently not applicable here, since the over-
whelming majority of them are unmethylated in most of the somatic cells [Jones, 1999]. Nonethe-
less, the transcription at the overlapping start sites can be blocked irrespectively of their
methylation status [Bestor et al., 2015a], apparently involving other mechanisms such as his-
tone modications, binding of the Polycomb complex and alike. Some genes do have methy-
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lated CpG islands overlapping with their TSS, however, most of them are the already described
imprinted, X-chromosome and germline-specic genes [Jones, 2012].
The methylation at non-CGI promoters was reported to have a more direct relation to
DNA methylation [Jones, 2012], although this has been put in question [Bestor et al., 2015a].
Genome-wide analysis showed that genes with low CpG density at promoters show inverse
correlation of their expression and methylation levels [Gal-Yam et al., 2008]. This is of partic-
ular importance for certain tissue-specic genes, promoters of which are losing methylation
only in dened cell types [Han et al., 2011]. One speculated view that can explain the ob-
served statistical relations between methylation and transcriptional activity is an epigenetic
“lock” model, where DNA methylation is acting as a stabilizer of the inactive state established
through other mechanisms [Jones, 2012].
Methylation of gene bodies and regulatory elements
Gene bodies, as regions generally having low CpG density, are methylated [Jones, 2012]. This
might be necessary to suppress numerous repetitive elements. Moreover, it was also observed
that methylation of the gene bodies is positively correlated to the transcriptional level of re-
spective genes [Jones, 2012]. This might be linked to the necessity of suppressing alternative
transcription initiation sites [Maunakea et al., 2010] and is speculated to play a role in splic-
ing [Laurent et al., 2010; Maunakea et al., 2010].
Methylation was found to have a particular pattern at genomic regulatory regions. En-
hancers, which are key to the ne cell type-specic control of gene activity, were associated
with low methylated regions (LMRs) [Stadler et al., 2011]. The LMRs either indicate a very dy-
namic methylation of enhancers or the presence of several cell subpopulations. Finally, DNA
methylation was implicated with altering the functional state of insulators which control the
action of enhancers [Jones, 2012].
Summary: DNA methylation may not be the major regulator, but it is a reliable
marker
It is now apparent that the direct silencing of genes by de novo methylation, suggested a part
of the epigenetic memory hypothesis, is not a universal mechanism of gene regulation [Jones,
2012]. Although the association with repression is strong in phenomena as X chromosome in-
activation and imprinting, subsequent research has revealed numerous exceptions and coun-
terexamples to the simple model of mechanistic gene deactivation [Schübeler, 2015]. The very
question whether DNA methylation plays any causal role in regulation or is merely an indi-
cator mark which faithfully follows other driving regulatory mechanisms remains a matter
of a erce scientic debate [Bestor et al., 2015a,b; Ngo and Sheppard, 2015; Wilkinson, 2015].
Nonetheless, even if the latter is true this does not diminish the importance of DNA methyla-
tion mapping. DNA methylation may not be instructive in the dierentiation process, but it
provides a reliable record of the current functional state of a cell reecting cell type, subtype
or population which is of utter importance for many applications [Schübeler, 2015].
1.1.6 Association with human disease
Regardless of its causality, the strong association with gene activity and regulation automati-
cally implies that DNA methylation can be changed when the gene function is distorted as a
result of certain environmental inuences as well as pathological conditions. Below the major
results of DNA methylation research in the context of diseases and environmental exposures
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are reviewed. The concept of DNA methylation association studies, which are the primary
instrument of this research eld, is introduced at the end.
Imprinting disorders and other “monogenic” diseases
Overwhelming evidence about epigenetic diseases was obtained in single-gene disorders af-
fecting the imprinted genes. Beckwith-Wiedemann syndrome characterized by growth ab-
normalities at birth is the most well-known example of such disorder. It was shown that the
aected individuals have DNA methylation defects in the imprinted cluster which includes
H19/IGF2, SLC22A1, LIT1 and several other genes [Feinberg, 2007]. Several other similar disor-
ders were described (Prader-Willy, Angelman, PHPIA syndromes) which are associated with
lesions at the SNURF-SNRPN/UBE3A imprinted locus [Horsthemke and Buiting, 2006]. In ad-
dition to the imprinting disorders, several diseases are known that are directly linked to muta-
tions in epigenetic machinery proteins. For instance, mutations in MeCP2 gene are associated
with Rett syndrome, while ICF (immunodeciency, centromeric instability, facial anomalies)
is apparently caused by mutations of DNMT3B [Feinberg, 2007].
Cancer
Cancer cells have widespread perturbations of their epigenomes, involving drastic changes of
the DNA methylation landscape [Feinberg, 2007]. A widely accepted model associates the ma-
lignant transformation with global hypomethylation and locus-specic hypermethylation [Es-
teller, 2007].
Cancer-related hypomethylation [Feinberg and Vogelstein, 1983] was shown to play a role
in erroneous activation of tissue-specic CGI-promoters, normally expressed only in dened
tissues [Feinberg and Tycko, 2004]. Famous examples include the testicle-specic MAGE and
CAGE, hypomethylated and expressed in melanoma and digestive tract malignancies, respec-
tively. Furthermore, since DNA methylation is a known mechanism of transposone silencing,
widespread hypomethylation is a hallmark of a global or focused genomic instability associ-
ated with severe chromosomal abnormalities in several cancers [Feinberg, 2007].
More recently discovered focal hypermethylation is known to occur at specic promoters,
many of which are of the tumor-suppressor genes [Feinberg and Tycko, 2004]. Retinoblastoma
gene (RB) was the rst well-described and proved example of a tumor-suppressor which is
hypermethylated in the corresponding cancer type [Greger et al., 1989; Sakai et al., 1991].
Since then the cancer-attributed hypermethylation was described at many other loci, such as
p16(INK4), CDKN2A, VHL, MLH1 etc.
Subsequent research revealed that the involvement of epigenetic phenomena might be
fundamentally linked to the malignant transformation. It was discovered that many types of
cancer are associated with mutations in one or more key players [Plass et al., 2013]. For in-
stance, TET2 mutations were detected in multiple blood cancers, while DNMT3A is frequently
aected in acute myeloid leukemia [Schübeler, 2015].
Despite the stunning aberrations cancer cell methylomes maintain the signature of the cell
type they originated from [Chen et al., 2016]. In the future this should enable the tissue-of-
origin detection based on the proling of a tumor sample particularly useful in te analysis of
metastasis [Heyn and Esteller, 2012].
The initial success in nding associations between DNA methylation and cancer provoked
large scientic eorts aimed at comprehensive characterization of the cancer methylome.
DNA methylation is one of the focuses in such large research consortia as The Cancer Genome
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Atlas (TCGA) [Noushmehr et al., 2010] and the International Cancer Genome Consortium
(ICGC) [Hudson et al., 2010].
Complex diseases and environmental influences, EWAS
DNA methylation changes were a matter of research in other common diseases, such as car-
diovascular disorders, metabolic syndrome, autoimmunity, neurodegeneration etc [Michels
et al., 2013]. Most of the investigations are performed in a form of epigenome-wide association
studies (EWAS) analogously to the genome-wide ones (GWAS) [Rakyan et al., 2011]. As a rule,
EWAS use one of the available genome-scale technologies to prole methylation in aected
individuals and unaected control subjects. EWAS aim to detect single CpGs or complete
loci (commonly referred to as biomarkers) that are statistically associated with the phenotype
or exposure. In order to guarantee the statistical soundness and biological reproducibility
EWAS are required to fulll a number of technical, design-related and reporting standards,
thoroughly reviewed elsewhere [Heijmans and Mill, 2012; Michels et al., 2013; Rakyan et al.,
2011].
So far, the results of several hundred DNA methylation EWAS were published, which vary
widely in the target phenotype or environmental factor, study design (case-control cohorts,
monozygotic twins, family trios), sampled tissue or cell type and the used proling technol-
ogy [Michels et al., 2013]. The non-cancer EWAS predominantly use whole blood as a DNA
source since the aected tissue is either unknown or dicult to sample.
Among the plethora of EWAS there are a few success stories. Several potentially causal
DNA methylation variants were detected in a large study for rheumatoid arthritis [Liu et al.,
2013]. Based on an EWAS in the post-mortem brain tissue ANK1 and several other genes
were found to be signicantly associated with the Alzheimer’s disease [Lunnon et al., 2014].
Furthermore, EWAS approach was successful in identifying the inuence of environmental
eects such as smoking, diet or exposure to potentially dangerous substances and physical
factors. For instance, in a well-designed EWAS the smoking status was credibly associated
with DNA methylation changes at F2RL locus [Breitling et al., 2011].
One particular environmental exposure has direct relation to the present thesis. In the
context of the metabolic syndrome it was hypothesized that the so called fetal programming,
i.e. predetermination of the metabolic patterns in utero, may play a role. DNA methylation
is one of the speculated mechanism behind such programming [Heijmans et al., 2008]. An
EWAS study presented in Chapter 2 tests this hypothesis in a cohort of monozygotic and,
hence, genetically identical twins severely discordant for birth weight.
1.1.7 Dimensions of the DNA methylome variability
A brief review of DNA methylation given above can be summarized as a diagram in Figure 1.3.
One can stratify three major directions of DNA methylation variability in a xed species. The
rst dimension is the characteristic non-random distribution of DNA methylation across the
genome, which is usually understood as the dynamic DNA methylation landscape. The second
dimension is the variability between cells of the same organism, determined by cell linage, type
and population. The third important coordinate is represented by dierences between organ-
isms in a population, driven by genetic factors, gender, age and disease-related environmental
factors. The temporal coordinate reecting DNA methylation changes with time is convoluted
into each of the thee dimensions above. The biological function of methylation can be seen
as a resulting vector in these three variability dimensions. A typical DNA methylation study
cannot capture the complete variability space and can be compared with a lower-dimensional
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plane providing for a cross-sectional view. The task of the subsequent computational analy-
sis is largely aimed at reconstructing the complete picture based on an achievable projection.
The experimental and computational methodology behind the DNA methylation analysis is
introduced below.
Disease
Function
Genome
Organism
Population
Figure 1.3: Dimensions of the DNA methylation variability. The genomic, intra-organismal and pop-
ulational components are represented by coordinates of a three-dimensional variability
space. The basis is orthonormal for the sake of demonstration, as in reality the above
components are clearly not independent. The profile along the genomic coordinate rep-
resents a typical DNA methylation landscape with an overall high methylation level but
featuring focally absent or decreased methylation at CpG islands and regulatory elements.
Cells of dierent types (color coded) carrying type-specific variants of this landscape are
representing the intra-organismal variability dimension. Finally, the individual variability
of the global and cell type-specific landscapes, supplemented by genetic, gender-specific
and age-aributed eects is visualized by human figures along the “Population” coordi-
nate. The resulting cellular function of a cell type- and individual-specific methylome can
be seen as a (doed green) vector in this three-dimensional space representing a combi-
nation of all three variability components. The two-dimensional plane represents a cross-
sectional approach behind a typical DNA methylation study that tries to stratify certain
variability sources of interest and diminish the irrelevant ones (allegorized by the angle of
the plane).
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1.2 Profiling DNA methylation
The current view of DNA methylation, briey outlined above, is a result of an immense
progress in the methodology over the last several decades [Harrison and Parle-McDermott,
2011]. In this period the throughput and resolution of the proling methods grew from bulk
measurements of total 5-methylcytosine in a biological specimen to the single-CpG and single-
molecule resolution maps available at the moment. This section rst gives a brief retrospective
overview of early approaches, then describes the bisulte method that topped the early devel-
opment eorts, and nally introduces two classes of high-throughput bisulte-based proling
strategies of great relevance for the present work. The section is concluded by an overview of
the technology-specic and more general data analysis aspects.
1.2.1 Overview of early approaches
First methods for DNA methylation analysis did not produce proles of any kind, but allowed
bulk measurements of relative 5-methylcytosine content using various types of chromatog-
raphy [Bestor et al., 1984; Kuo et al., 1980], radiolabeling [Wu et al., 1993] and immunola-
beling [Wu et al., 1993]. Later the gene-specic techniques came of age, based on the ac-
tion of methylation-sensitive restriction enzymes combined with radiolabeling and subse-
quent thin-layer smears [Cedar et al., 1979] or Southern blotting. This method was later ex-
tended to a genome-wide setting and became known as restriction landmark genomic scanning
(RLGS) [Hatada et al., 1991; Hayashizaki et al., 1993; Kawai et al., 1993]. The antibody-based
methods enjoyed intensive development in subsequent years. Immunolabeling combined with
uorescent microscopy has become a workhorse method in developmental biology [Mayer
et al., 2000; Oakeley et al., 1997; Santos et al., 2002] facilitating the studying of DNA methyla-
tion on the cell-to-cell basis, and is widely used till today. With the boost of microarray and
next-generation sequencing technologies, immunoprecipitation of methylated DNA formed
a basis of several high-throughput methods [Keshet et al., 2006; Weber et al., 2005]. Despite
the signicant progress, all the above approaches had limited capacity for gene-specic and
especially genome-wide studies and were superseded by the methods based on the bisulte
conversion.
1.2.2 The bisulfite method
Sulfonation of certain pyrimidines by sodium bisulte was known long before it was applied
to DNA methylation proling [Hayatsu et al., 1970]. It was later shown that this reaction had
dierent kinetics for cytosine and 5-methylcytosine [Wang et al., 1980]. Finally, Frommer et
al. demonstrated that these dierences could be used to study DNA methylation patterns using
sequencing [Frommer et al., 1992].
The idea of the bisulte method is to transform the initial methylation mark into a base-
change detectable by a variety of existing methods. The bisulte conversion is a three-step
procedure schematically illustrated in Figure 1.4. Its nal result is a conversion of an un-
methylated cytosine to a uracil. Eectively, when applied to a pool of DNA molecules the
bisulte conversion leads to a substitution of the unmethylated cytosines with uracils, while
the methylated ones remain cytosines.
Bisulte-induced base changes can be read out using a number of methods. Early non-
sequencing approaches were predominantly adaptations of well established genetic analysis
methods, and included methylation-specic (MS-) variants of PCR [Herman et al., 1996], single
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Figure 1.4: Bisulfite conversion of cytosine to uracil.
nucleotide primer extension (MS-SNuPE) [Gonzalgo and Jones, 1997], single-strand confor-
mation analysis (MS-SSCA) [Bianco et al., 1999]. Such methods as, for instance, the combined
bisulte restriction analysis (COBRA) [Xiong and Laird, 1997] make use of the emergence or
loss of restriction cutting sites to determine the methylation state of a CpG position. Finally,
a number of more exotic methods was developed, for instance, the high-resolution melting
curve analysis [Wojdacz and Dobrovic, 2007]. Nevertheless, sequencing methods reviewed
below have been proven as the most ecient way to read out the bisulte-based methylation
information.
A modified treatment detects oxidative methylcytosine derivatives
Oxidative forms have dierent reactivity in the ordinary bisulte conversion. 5-hydroxy-
methylcytosine stays predominantly unconverted, while 5-formyl- and 5-carboxylcytosine
are deaminated to uracil [Huang et al., 2010; Nestor et al., 2010]. In other terms, the ordi-
nary bisulte readout corresponds to a bulk measurement of 5-methyl- and 5-hydroxymethyl-
cytosines. Newly invented techniques enable detection of such modications by combining
ordinary bisulte with a modied treatment which has a dierent outcome. For instance,
oxidative bisulte protocol applies a soft oxidizing agent KRuO4 to convert 5-hydroxy- to 5-
formylcytosine [Booth et al., 2012]. The bisulte readout after the oxidative step results in a
5-methylcytosine prole with a single-basepair resolution. By comparing the readouts with
and without the oxidative step one can estimate a bulk amount of 5-hydroxymethylcytosine
at each CpG. Similar techniques were developed to enable estimation of 5-hydroxymethyl-
cytosine as well as other oxidative modications [Ito et al., 2011; Song et al., 2013]. More
detailed background about these methods, their capacity and limitations is given in Chapter 5.
Problems of the bisulfite method
It is important to understand that bisulte conversion, just like any other chemical reaction,
can never guarantee a 100% yield. In the context of methylation state calling, both errors are
possible, – underconversion, when unmethylated cytosines are not converted to uracils, and
overconversion, when methylated cytosines are deaminated to uracils [Genereux et al., 2008].
Proper consideration of the inevitable conversion errors is an important part of the bisulte-
based data analysis.
Another important problem is that bisulte treatment is causing strand breaks in DNA [Mun-
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>>CCGGCATGTTTAAACGCT>><<GGCCGTACAAATTTGCGA<<
mC mC
mC mC mC
>>UCGGUATGTTTAAACGUT>> <<GGUCGTACAAATTTGCGA<<Bisulfite conversion
Top strand Bottom strand
OT >>TCGGTATGTTTAAACGTT>>CTOT <<AGCCATACAAATTTGCAA<< >>CCAGCATGTTTAAACGCT>> CTOB<<GGTCGTACAAATTTGCGA<< OB
PCR amplification
Figure 1.5: General scheme of bisulfite sequencing. Each of the four strands at the boom can give rise
to a sequence read. OT, original top strand; OB, original boom strand; CTOT, complement
of the original top strand; CTOB, complement of the original boom strand. The figure
was adapted from [Krueger et al., 2012]
son et al., 2007]. This decreases the applicability of bisulte-based methods to low-input sam-
ples and in certain protocols requiring that the DNA fragments remain intact after the treat-
ment (e.g. if they were preliminary ligated to adaptors).
1.2.3 Bisulfite sequencing
Sequencing was originally the rst method to read out the methylation signal from the bisul-
te converted DNA. Along with the bisulte treatment a subsequent PCR amplication was
introduced [Clark et al., 1994; Frommer et al., 1992] which is currently an integrative step of all
bisulte sequencing protocols. In accordance with the base-pairing rules the uracils, substitut-
ing the previously unmethylated cytosines, are replaced by thymines in the PCR (Figure 1.5).
Later, bisulte converted DNA was sequenced using Sanger machines in such assays as
direct sequencing [Eckhardt et al., 2006; Rakyan et al., 2004], giving a quantitative readout per
CpG, and clonal bisulte sequencing, generating full methylomes for a representative sample
of several dozen DNA molecules. First bioinformatic solutions were developed, e.g. ESME,
optimizing the signal processing of electropherograms [Lewin et al., 2004], and BiQ Analyzer,
automating the laborious and time-consuming analysis of the clonal sequences [Bock et al.,
2005].
Next-generation sequencing (NGS) revolutionized the eld enabling DNA methylation
proling on an earlier unseen scale and resolution [Laird, 2010]. The line of method develop-
ment bifurcated at the trade-o between the genome coverage, i.e. the number of sequenced
base-pairs of the genomic reference and the sequencing depth, i.e. the average number of times
a given genomic base-pair is covered by sequence reads. Locus-specic approaches utilize the
large amounts of reads to achieve very high sequencing depth at selected regions of interest.
Genome-scale methods have similar depth to the pre-NGS approaches, but reach coverage
at a large portion of the genome, up to covering its complete mappable part (whole-genome
methods).
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High-throughput locus-specific bisulfite sequencing
There are several ways to prepare a bisulte sequencing library for a locus of interest. The most
common one is to design a pair of PCR primers hybridizing to the bisulte converted DNA and
amplify a short fragment (amplicon) containing the target CpG sites. Primer design should be
performed with certain precautions, e.g. the primer sequences should not contain any under-
lying CpGs, and can be aided by specialized tools [Tusnády et al., 2005]. The amplicon-based
approach is single-stranded by design, and when information from both strands is desired they
can be amplied after adding a so called hairpin linker to one of the double stranded fragment
ends [Laird et al., 2004].
Massively parallel pyrosequencing [Margulies et al., 2005], commercially available as Roche
454 platform, was applied to sequence amplicon-based libraries. A pilot study in normal blood
cells and several types of leukemia [Taylor et al., 2007] demonstrated the power of the method,
allowing for simultaneous analysis of 25 CpG-rich regions in over 40 samples. On average over
1600 sequence reads were generated for each case which is two orders of magnitude more com-
pared to the clonal bisulte sequencing. This supplied the researchers with a detailed picture
of methylation pattern heterogeneity in multicellular samples. This approach was further val-
idated and improved in several follow up studies [Gries et al., 2013; Korshunova et al., 2008;
Varley et al., 2009]. Later, Illumina introduced MiSeq thereby increasing the throughput of the
locus-specic studies by an order of magnitude. The numbers of reads are now reaching tens
of thousands per sample-locus pair, challenging the currently available specialized software
packages.
Genome-scale bisulfite sequencing
An umbrella of genome-scale methods covers the protocols in which a sequencing library cov-
ers a signicant portion of the genome, and the included CpGs are from multiple distant loci.
Whole-genome bisulte sequencing (WGBS) is the most generic approach, when a prepared li-
brary is not biased towards any underlying region type. Several other methods decrease the se-
quencing burden by enriching the library for certain kind of regions. Reduced-representation
bisulte sequencing (RRBS) creates preference for the CpG-dense regions, predominantly CpG
islands, by the use of restriction enzymes with a CpG dinucleotide in their cutting motif, e.g.
MspI [Meissner et al., 2005]. More recent capture-based approaches [Li et al., 2015] enrich
the library for target regions using the pools of immobilized oligonucleotides, e.g. bound to
magnetic beads. The hybridized target DNA is pooled out and sequenced.
First full methylome was obtained by WGBS of a plant organism. In 2008 a complete
genome-wide methylation pattern of Arabidopsis thaliana was obtained [Cokus et al., 2008].
As a rst genome-scale eort in mammals, a mouse RRBS library was sequenced on a Genome
Analyzer machine [Meissner et al., 2008]. Shortly thereafter the rst complete and single-base
resolution human methylomes were published by Lister and colleagues [Lister et al., 2009].
This pilot study was followed by numerous other reports delivering the rst complete methy-
lomes for various human cell lines and tissues [Laurent et al., 2010; Ziller et al., 2013]. Mod-
ied bisulte conversion protocols, such as OxBis-Seq and TAB-Seq, were also used in com-
bination with high-throughput sequencing to map oxidative modications on a genome-wide
scale [Booth et al., 2012; Ito et al., 2011; Song et al., 2013].
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Limitations and further progress
Bisulte sequencing methods made an enormous contribution to the current knowledge of
DNA methylation. It is responsible for many breakthroughs in understanding of DNA methy-
lation landscapes and dynamics described in Section 1.1. However, a number of serious draw-
backs limits their wider application keeping the alternative approaches in the feasibility range.
One serious limitation is the cost, with the price of a complete WGBS experiment is still at
the mark of 3000 Euro. This is the main reason why to date WGBS was mainly used in global
epigenomic mapping eorts aiming at reference methylomes such as ENCODE [Bernstein
et al., 2010], Roadmap [Roadmap Epigenomics Consortium et al., 2015], BLUEPRINT [Abbott,
2011] and DEEP (http://www.deutsches-epigenom-programm.de). The price seriously lim-
its the application of WGBS in EWAS using large cohorts of hundreds to thousands individuals.
Due to its high resolution and low error rates, the comparatively cheaper deep locus-specic
sequencing is a gold-standard method for the candidate-gene studies and EWAS verication.
However, even here many studies decide for the obsolete, yet less costly methods.
The second limitation is the minimal amount of input material. Conventional WGBS pro-
tocols still require 105 cells to construct a reasonable library. This underlies the methylome
heterogeneity problem, introduced in the Section 1.3 below. It is also tightly linked to an issue
of over-amplication, inherent to all bisulte sequencing protocols featuring a PCR step. The
fewer cells are submitted to bisulte treatment, the higher should be the rate of post-bisulte
PCR amplication to deliver enough material for the library preparation. As a result, the ma-
jority of generated sequence reads are in fact stemming from the very same original DNA
fragments and are known as PCR duplicates.
Current progress in the development of genome-scale bisulte sequencing methods is
aimed at improving single-molecule resolution and decreasing the amount of the input mate-
rial. Several steps have already been made in this direction. For instance, unique molecular
identiers (UMI), attached to the source DNA fragments prior to bisulte treatment was sug-
gested as a solution for the problem of PCR duplicates. Furthermore, a PCR-free protocol
was suggested that involves post-bisulte adapter tagging (PBAT) [Miura et al., 2012]. The
future development will most probably concentrate upon single-cell methods discussed below
(Section 1.3).
1.2.4 DNA methylation microarrays
DNA methylation microarrays were developed from the earlier low-throughput methods based
on restriction by endonucleases, immunoprecipitation and bisulte treatment [Harrison and
Parle-McDermott, 2011]. The most well-known restriction-based microarrays included HpaII
tiny fragment enrichment by ligation-mediated PCR (HELP) [Khulan et al., 2006] and com-
prehensive high-throughput arrays for relative methylation (CHARM) [Irizarry et al., 2008].
Immunological methods gave rise to methylated DNA immunoprecipitation (MeDIP) [Weber
et al., 2005]. Several related anity-purication methods based on the use of methyl-binding
domain proteins (MBDs) were also suggested [Gebhard et al., 2006; Schilling and Rehli, 2007].
Despite of several successful applications, the anity-based microarrays were outperformed
by the bisulte-based ones due to the limited throughput, the lack of single-CpG resolution,
low sensitivity and a strong CpG density-associated bias of the former [Down et al., 2008;
Rakyan et al., 2008].
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Bisulfite-based bead arrays from Illumina
Illumina’s DNA methylation bead arrays are an adaptation of the previously existing genomic
platforms used for the high-throughput SNP genotyping. In essence, the assays tracking ge-
nomic SNPs were redesigned to identify bisulte-induced SNPs at CpG positions.
GoldenGate was the rst platform of such kind [Bibikova et al., 2006]. Just as its geno-
typing counterpart it was based on measuring the amount of the product after an allele-
specic PCR and enabled simultaneous quantitative proling of methylation state at 1536
CpG sites mapping to 371 genes. GoldenGate was succeeded by a more progressive Innium
technology which became the basis for three DNA methylation microarrays, HumanMethy-
lation27 [Bibikova et al., 2009], HumanMethylation450 [Bibikova et al., 2011] and Methy-
lationEPIC [Moran et al., 2015]. The Innium technology is a highly parallelized primer-
extension assay, in which each extension reaction is targeting a single genomic CpG (Fig-
ure 1.6). The bisulte converted genomic DNA is hybridized to 50-bp long oligonucleotides
attached to nano-sized bead. The oligonucleotides, complementary to the fragments upstream
or downstream of the target CpGs, serve as primers in the primer-extension reaction. Free nu-
cleotides in the solution carry two dierent uorescent labels (C and G are Cy3-labeled while
A and T carry Cy5) allowing to register the incorporation. Currently two variants of the assay
exist, denoted as type I and type II, which dier in the way the methylated and unmethylated
state intensities are obtained.
HumanMethylation27 (Innium 27k) platform contained only type I probes tagging 27,578
CpG sites across the human genome. HumanMethylation450, commonly known as Innium
450k, was a signicant move forward with 482,421 CpGs and 3,091 supposed non-CG methy-
lation sites. The array genome-wise coverage reached 0.5% of the total CpG number. Approx-
imately two third of the probes were of type II. The higher density of the array comprised a
signicant challenge for the oligonucleotide design and placement. Finally, MethylationEPIC
platform succeeds 450k microarray bringing the total number of tagged CpGs to over 850,000
which is an astonishing 3% of the genomic total.
Application scope and approaching obsolescence
Combination of several qualities determined the success of the bead arrays. The cost and
labor-optimized standard procedure favorably diered them from the genome-scale sequenc-
ing approaches. The lack of single-molecule resolution was compensated by a much higher,
molecular support for each intensity measurement. While a methylation call in genome-scale
sequencing methods is often based on a dozen reads, each intensity measurement relies upon
thousands of template molecules hybridizing to a bead, which guarantees a smaller measure-
ment error. Furthermore, unlike many cost-optimized sequencing protocols (RRBS/CapSEQ),
microarrays consistently return high-quality calls for the majority of covered CpGs in most
of the samples. Owing to these benets bead arrays have become the most popular proling
method of EWAS [Michels et al., 2013]. Only the Gene Expression Omnibus (GEO) database
currently contains data series for almost 1,000 studies using Innium 27k, 450k and EPIC com-
bined.
Nevertheless, the remaining shortcomings of the bead arrays, along with the constant im-
provement of the competing approaches, set an applicability horizon for the microarray meth-
ods. The highly optimized Innium procedure has limited potential for further cost reduction,
and the only possible upgrade is the increase of the genomic coverage. Due to the probe-
based design this becomes progressively dicult. Furthermore, the bead array protocol does
not oer an easy way to decrease the amount of the input material, conserving the cell type
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a. Infinium I assay: 2 bead types per CpG locus, both in the same color channel
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Figure 1.6: Principles of the Infinium methylation assays. a. The older type I assay (probe) fea-
tures two dierent oligonucleotides per probed CpG, physically separated on two dier-
ent beads. One of the oligonucleotides is fully complementary to the bisulfite converted
sequence terminating with the target CpG guanine under the assumption that the tar-
get cytosine is methylated. Analogously, the other oligonucleotide is complementary to
the bisulfite converted sequence assuming the target CpG is unmethylated. During the
microarray procedure, the oligonucleotides are extended to incorporate the base directly
upstream – for the top (Watson) strand – or downstream – for the boom (Crick) strand
– of the target CpG site. Since both oligonucleotides of the type I probe are physically
separated and reside on dierent beads, the rate of the primer extension reaction can be
registered in the same color channel. b. In the case of type II probes primer-extension
reaction is incorporating the base right in the position of the target cytosine. Here the
methylated and unmethylated fragments hybridize to the same physical bead and methy-
lation state of the target CpG determines which base gets incorporated in a concrete ex-
tension reaction. A type II bead, thus, produces signal in both color channels which is
registered as methylated (M) and unmethylated (U) signal intensities. The figure was
adapted from [Dedeurwaerder et al., 2011].
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heterogeneity problem introduced later in this text. As a consequence, while the current text
was written the manufacturer announced the upcoming obsolescence of the complete HiScan
platform within the next two years, which concerns all the DNA methylation microarrays (an
e-mail circulation). Their place will probably be occupied by more dynamic and adaptable
sequencing methods.
1.2.5 Challenges of the DNA methylation data analysis
The wet-lab procedures reviewed above make up only a part of respective proling methods.
The other essential component includes the computational operations, from retrieval of the
raw data down to an advanced DNA methylation statistics. This section describes specic
problems associated with processing of data from bisulte sequencing and DNA methyla-
tion microarrays. A general outline of the downstream analysis common to all types of DNA
methylation data is sketched at the end.
Bisulfite sequencing data
Primary sequencing data is platform-specic and the initial data processing steps are per-
formed by the software of an NGS instrument itself. The current consensus output format
for the initially processed sequence reads is FASTQ [Cock et al., 2010] that harbours per-base
quality scores in addition to the sequence information. A typical data processing pipeline in-
cludes demultiplexing of the raw reads, read-level quality control (QC) and ltering, quality-
based and adaptor-aimed trimming, alignment, post-alignment QC and methylation calling
(Figure 1.7).
An important problem of practical applications is demultiplexing. Since the capacity of the
sequencing runs is most often shared between dierent and unrelated sequencing libraries, the
resulting bulk of sequences contains reads from all users, applications and sequenced samples.
The possibility of assigning reads to a specic library is implemented either by utilizing the
lanes which separate the space of a sequencing machine, or by incorporating sample-specic
sequence tags, also known as multiplex identiers (MIDs). Several publicly available tools
enable read assignment based on short sequence matching algorithms [Blankenberg et al.,
2010].
The initial data processing steps are common to all NGS-based bisulte sequencing meth-
ods and involve quality control of the sequencing experiment. FastQC from the Babraham
Institute (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) has proved it-
self as an extremely useful tool for visualization and primary analysis of quality scores. Base
quality usually decreases in terminal parts of the reads. As a rule such low-quality ends are
trimmed [Krueger et al., 2012]. Trimming is also necessary to deal with spurious incorporation
of cytosines, which appear as methylated in subsequent analysis, due to end repair, sequenced
parts of the adaptor etc [Bock, 2012].
High-quality reads are aligned to the existing genomic reference. The alignment tasks are
principally dierent between locus-specic and genome-scale methods. In the former case
most of the reads are originating from a very small part of the genome. A typical problem
of aligning up to 105 reads to a short reference sequence makes the use of globally opti-
mal dynamic programming algorithms [Needleman and Wunsch, 1970; Waterman et al., 1992]
computationally feasible. In the case of genome-scale data, the size of the reference reaches
the orders of 109 base-pairs, which is intractable by the memory-demanding globally optimal
alignment algorithms. This is why heuristic approaches became very popular, the most suc-
cessful of which are based on the fast searches in hashed data structures [Langmead et al.,
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Figure 1.7: General scheme of DNA methylation data processing and analysis. Non-exhaustive lists
of popular methods and bioinformatic tools are given for each case. The red dashed-doed
line is enclosing data analysis steps performed by RnBeads (Chapter 3). The blue dashed
line demarcates the approximate domains of BiQ Analyzer HT (Chapter 4) and BiQ Ana-
lyzer HiMod (Chapter 5).
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2009]. In both cases, special preparation of the reference sequence is necessary to account for
strand diversion and the alphabet changes due to bisulte conversion [Krueger et al., 2012].
Some of the quality control operations can only be performed on the aligned reads. This
concerns bisulte conversion rate, which is usually estimated at non-CpG cytosines. Further-
more, alignment allows ecient detection of reads originating from the very same original
DNA fragment, commonly known as PCR duplicates. In the paired-end sequencing of the
genome scale libraries, out of two or more read pairs having identical starting and ending
positions all except one are discarded.
The generated alignment is further on used for calling methylation states at each CpG po-
sition in each read. The accurate methylation calling is particularly important at low sequenc-
ing depth, and, therefore, the most critical in genome-scale approaches. To tackle this problem
specialized callers were developed, which account for most of the possible problems [Liu et al.,
2012].
Due to a dierent computational load the development of bioinformatic tools took dierent
pathways for locus-specic and genome-scale data. Generally smaller amounts of data in
locus-specic experiments stimulated the development of complete bioinformatic solutions.
These tools are, as a rule, interactive and GUI-based, supporting the complete data processing
pipeline from raw reads to the nal tables and diagrams with methylation data [Kumaki et al.,
2008; Rohde et al., 2010]. Available third-party tools, as well as two software packages that are
a contribution of the present thesis are introduced in more detail in Chapters 4 and 5. For the
genome-scale methods overwhelming amounts of generated read data impedes the creation
of such “turnkey” software. Here custom bioinformatic pipelines are common and consist of
tools supporting one or several related steps [Chen et al., 2010; Krueger and Andrews, 2011;
Liu et al., 2012]. The most reliable pipelines have now largely taken shape [Krueger et al.,
2012]. In due of this, primary processing of the genome-scale sequencing data is not covered
by the bioinformatic solutions presented below and is out the scope of the present thesis.
Data of DNA methylation microarrays
Principles of data processing for DNA methylation microarrays were reviewed in detail multi-
ple times elsewhere [Dedeurwaerder et al., 2014; Marabita et al., 2013; Siegmund, 2011; Wilhelm-
Benartzi et al., 2013]. A typical low-level pipeline includes data loading, quality control of sam-
ples and probes, intensity normalization and background correction, adjustment of the probe
type bias and calculation of the methylation statistics. The main purpose of the short overview
below is to highlight the challenges and unresolved issues in the context of the solutions that
are part of the present thesis.
The primary raw data of the bead arrays are high-resolution images of the microarray
plate made in two color channels. The image processing and analysis part is performed by the
microarray HiScan platform itself, and the summarized intensities per bead type are stored
in a specialized IDAT format [Bock, 2012]. There are several software packages which enable
vendor-independent parsing of IDAT les and their import into popular statistical environ-
ments such as R [Smith et al., 2013].
As any other microarray platform, Innium/EPIC features a complex multi-step wet-lab
protocol and is inevitably aected by a number of technical biases and noise sources [Dedeur-
waerder et al., 2011]. Quality control is facilitated by a panel of specialized control assays
which are present on the bead array platform [Illumina Inc., 2014]. The control assays monitor
the crucial steps of the procedure and report the intensities in an expected range. The biolog-
ical samples which show low quality in the control assays should be removed. Although the
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task may seem trivial, there are no published methods so far to automate the detection and
removal of low-quality samples.
Normalization aims at reduction of technical biases by computational adjustment of the
intensity data. First, beads at which no primer extension took place still produce a certain
level of background intensity. The manufacturer suggested a simple background correction
method making use of the specialized null probes on the bead array [Illumina Inc., 2014].
Later a more advanced method was developed which used the “out-of-band” intensities of
type I probes for a more reliable estimation of background in each color channel [Triche Jr.
et al., 2013]. Although the bead array technology solved the issue of spatial biases within
one array (sample), it was shown that the overall intensity strongly varies between the arrays
on the same microarray plate, as well as between the plates [van Eijk et al., 2012; Wilhelm-
Benartzi et al., 2013]. Due to large variability this can lead to spurious methylation dierences
between samples. The platform contains specialized normalization probes, which are used in
an intensity scaling normalization developed by the manufacturer [Illumina Inc., 2014]. Sub-
sequently, multiple methods were developed to adjust intensities both within and between
the arrays [Fortin et al., 2014; Pidsley et al., 2013; Touleimat and Tost, 2012]. Finally, it was
noticed that methylation calls from type I and II assays have a substantially dierent distri-
bution [Dedeurwaerder et al., 2011]. Although this may stem from the dierences in genomic
distribution of the two probe types, a number of approaches was developed to adjust these
dierences as well [Dedeurwaerder et al., 2011; Makismovic et al., 2012; Teschendor et al.,
2013].
Technical confounding usually arises from a non-uniform processing of the samples and is
commonly known as batch eects [Leek et al., 2010]. The most extreme form of a batch eect
occurs, for instance, when case and control samples in a simple EWAS study are processed
independently in two separate batches. In this case any bias in methylation calls between the
two batches will be interpreted as eects of interest in the subsequent association analysis and
will render the detection of any true dierences impossible. More subtle forms of technical
confounding arise, for example, in the bead array-based studies. Bead arrays are known to
be aected by an intensity bias systematically spreading across a microarray plate [van Eijk
et al., 2012]. Some of such eects can be solved by normalization methods. The remaining
confounding can be corrected using the specialized methods, such as ComBat [Sun et al., 2011],
or the linear mixed models [Bareld et al., 2012].
The normalized and corrected intensities can be used to generate the methylation calls.
The bead array manufacturer recommended calculating methylation ratios, also known as a
β-value by relating the methylated probe intensity to the total intensity of the methylated and
unmethylated probes [Bibikova et al., 2006]. Alternatively, a log-ratio of the methylated and
unmethylated probe intensities can be used as a quantitative readout, known as M-value [Du
et al., 2010].
In summary, numerous bioinformatic tools exist, enabling one of the above data handling
steps, as well as the complete streamlined analysis of the Innium/EPIC data (reviewed in more
detail in Chapter 3). One of the biggest challenges in primary processing of the bead array data
is the absence of consensus about the preferred method or combination of methods [Dedeur-
waerder et al., 2014]. Multiple comparison meta-studies [Dedeurwaerder et al., 2014; Marabita
et al., 2013] apply various benchmarking criteria which results in divided nal conclusions.
Furthermore, most of the meta-studies are published by one of the method developing groups
which inevitably leads to a biased reporting. In this situation a pipeline allowing for a seamless
and rapid comparison of the existing methods would greatly simplify the real life applications
and facilitate an unbiased benchmarking analysis. This was the main motivation behind the
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modules for processing of bead array data in RnBeads presented in Chapter 3.
Challenges of the platform-independent downstream analysis
Regardless of any specic proling method, high-level DNA methylation data are at certain
point represented as data matrices of methylation calls for each CpG in each proled sample.
Downstream high-level analysis of such data is generally similar to that of other genomic
data types. The multitude of the analysis strategies can be roughly split into a hypothesis-
driven association analysis, hypothesis-free exploratory analysis of the proles and functional
annotation [Wilhelm-Benartzi et al., 2013].
Association analysis, also known as analysis of dierential methylation, is central for the
comparative studies such as EWAS. The goal is to test a family of hypotheses whether a certain
xed or observed factor is signicantly associated with DNA methylation changes at partic-
ular CpGs or loci. The analysis is usually performed by tting linear models to the data of
each CpG [Bock, 2012]. The model coecients of the target phenotype variable are tested for
signicance which results in a set of P -values. The details of the association analysis were
surveyed in numerous publications [Siegmund, 2011; Wilhelm-Benartzi et al., 2013].
Another group of analyses aims predominantly at investigating the observed methylation
proles in their entirety and includes such popular techniques as clustering, dimensionality
reduction and factor analysis. The most popular clustering approach is hierarchical cluster-
ing, although more advanced methods exist specically tailored to DNA methylation data,
e.g. recursively partitioning mixture model [Houseman et al., 2008]. Dimensionality reduc-
tion techniques allow for improved data visualization and discovery of variability components.
Principal Component Analysis (PCA) is an exceptionally powerful generic method extensively
applied to DNA methylation proles. Alternative approaches for lower dimensional represen-
tation include, among other, Multidimensional Scaling (MDS), and a more recent t-Distributed
Stochastic Neighbor Embedding (t-SNE) [van der Maaten and Hinton, 2008].
Both kinds of analysis intersect at the issue of confounding. Confounding occurs when
strong factors that aect DNA methylation at a large portion of CpGs are biasing the associa-
tion analysis and lead to ination of signicance testing. When information about these factors
is known in advance, e.g. for an EWAS cohort age and gender of the individuals, microarray
plate, processing batch, they can be included into linear modeling. When the confounding
factors are not known in full, they can be discovered using the prole analysis methods such
as PCA or clustering. Furthermore, Surrogate Variable Analysis (SVA) [Leek and Storey, 2007]
and its extension independent SVA (iSVA) [Teschendor et al., 2011] are two specialized sta-
tistical methods specically developed for deconfounding an association analysis. Finally, one
specic confounding problem stemming from the cell type-specicity of DNA methylation
proles is in focus of the present thesis. This problem as well as the experimental and compu-
tational methods used to address it are introduced in the concluding Section 1.3.
The high-level analysis of DNA methylation data is remarkably versatile, since it heavily
depends on such factors as study goal and design, presence or absence of specic batch eects
and confounders, availability of additional data e.g. expression proles etc. Consequently, it is
often performed in a general-purpose statistical or spreadsheet environment such as R, SAS,
SPSS or Excel in a highly customized way. Nevertheless, there are a number of computational
tools which implement the complete analysis pipeline. One such bioinformatic solution, the
R package RnBeads is in part contributed by the current thesis and described in Chapter 3.
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1.3 Tackling heterogeneity of the DNA methylomes
1.3.1 Problem definition
The common feature of the mainstream DNA methylation proling methods reviewed in Sec-
tion 1.2 is that they are applied to macroscopic samples containing thousands to millions cells.
Given the possibility of the same genomic CpG being methylated dierently between the pro-
led cells, the resulting readout will be a superposition of the underlying single-cell CpG states
yielding a quantitative signal.
As outlined in Section 1.1 cell methylomes can be dierent due to multiple reasons. In a
healthy organism the largest determinant of the methylation landscape is cell type, aecting
the methylation level at numerous CpG positions across the genome [Lam et al., 2012]. In
case a sample of a heterogeneous tissue is submitted to any of the analysis methods above,
the resulting prole will strongly depend on the proportions of dierent cell types present in
this tissue sample. This notion can be propagated further down to smaller levels. Even if a
relatively homogeneous sample is proled, believed to contain cells of only one well dened
cell type, the abundance of stable cell populations will have a major inuence upon methyla-
tion values of the remaining variable CpGs. More generally, the proportions at which stable
methylation signatures, e.g. the cell type methylomes, are present in a proled cell sample
are always convoluted into the average methylome. This is what is usually understood under
the cell type (cell population) heterogeneity of DNA methylation proles. The latter has to be
discriminated from other types of heterogeneity. For instance, temporal heterogeneity arises
during transition between two stable methylation signatures. If the cells in proled samples
are caught at dierent stages of this transition, this will result in a quantitative signal at the
aected CpGs.
The question whether to dene the cell type heterogeneity as a problem depends on the
goal of the DNA methylation proling. Indeed, when the primary objective is to detect cell
populations carrying a characteristic methylome, the cell population-attributed heterogeneity
is precisely the cause of the sought DNA methylation dierences and cannot be seen as a
purely deteriorating eect. In this context one can rather speak about characterizing and
understanding the methylome heterogeneity. This point of view motivates the methylome
deconvolution results presented in Chapter 6 and will be introduced in detail at the end of the
current section.
The widespread negative connotation was introduced by the association studies where the
cell type composition is usually not the primary analysis target. On the contrary, due to its
uncontrolled dierences in the compared samples, it comes with a risk of losing DNA methy-
lation eects of interest. Such confounding can be particularly harmful in EWAS, where the
statistically justied increase of the cohort sizes imposes limits on sampling unication [Adal-
steinsson et al., 2012; Heijmans and Mill, 2012; Liang and Cookson, 2014].
A comprehensive theory of the heterogeneity eects in EWAS was proposed by House-
man et al. [Houseman et al., 2012, 2015] (thoroughly reviewed in Ref. [Houseman, 2015]). It was
suggested that the association between phenotypic and technical covariates and the observed
methylation measurements could be modeled as a sum of “direct” and cell type-mediated ef-
fects. The “direct” eects are assumed to inuence the methylome in cell type-independent
manner, causing changes in all cell types. In contrast, the cell type-mediated eects are con-
sidered to be primarily associated with the changes in cell type composition. Due to large
dierences between the cell type-specic methylomes the changes in composition are trans-
lating into the phenotype-associated variability of the measured mixture methylomes. Delin-
eating the direct and cell-type mediated eects is one of the primary goals in DNA methylation
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EWAS.
There are several fundamentally dierent strategies for dealing with heterogeneity in DNA
methylation data. First, when standard proling methods have to be used, one can decrease
heterogeneity by cell enrichment or isolation. Second, heterogeneity can be translated into
dierences between methylomes by proling very small cell samples or even single cells. Fi-
nally, one can try to delineate heterogeneity eects computationally. The remainder of the
current section outlines the current state-of-the-art for each of the three approaches.
1.3.2 Cell separation
Most of the cell types are well dened by their morphological or biochemical properties. The
cellular dimensions, volume, shape, nuclear morphology are tightly linked to the cell function,
and are, therefore, intrinsic characteristics of cell types which can be used for their identica-
tion [Gautam and Bhadauria, 2014]. Moreover, cell types are characterized by unique constel-
lation of surface marker proteins, such as the cluster of dierentiation (CD) antigens [Engel
et al., 2015]. These properties can be used to enrich the samples for certain cell type prior to
a DNA methylation analysis, and thereby increase the homogeneity of the resulting methy-
lomes. Cell separation and isolation methods based upon adherence, density and antibody
labeling are designed to fulll this aim [Tomlinson et al., 2013]. While the adherence-based
methods are very rough and generally not aimed at the isolation of pure cell subpopulations,
the density- and, especially, antibody-based ones are of particular importance for DNA methy-
lation proling.
Density-based methods have developed from earlier sedimentation approaches, separating
cells by dierence of their deposition speed in a solution. The most common instance is cen-
trifugation in a density gradient widely applied to separate whole blood into fraction of gran-
ulocytes and peripheral blood mononuclear cells (PBMCs) including monocytes, macrophages
and lymphocytes. This can be exploited by DNA methylation studies using blood which are
not interested in one of the two fractions [Lam et al., 2012]. In most of the cases, however,
density centrifugation is used as a pre-enrichment step for the downstream methods for cell
isolation [Tomlinson et al., 2013].
In case surface proteins are well dened for the target cell type or population, antibod-
ies can be used to selectively label such cells. Antibodies usually carry additional functional
groups enabling subsequent isolation steps. In uorescence-activated cell sorting (FACS) [Bon-
ner et al., 1972], the antibodies carry a uorescent dye. The labeled cells are passing through
a thin stream and get electrically charged depending on their uorescence. An electrostatic
deection system is then used to deviate cell-containing droplets into one or another direction
and this way collects the labeled cells. In magnetic-assisted cell sorting (MACS) the antibod-
ies are attached to magnetic beads which enable the pullout of bound cells with the magnetic
eld [Miltenyi et al., 1990; Rembaum et al., 1982].
Other methods exist for cell separation such as laser-capture micro-dissection [Emmert-
Buck et al., 1996]. The most modern lab-on-chip approaches utilize microuidic devices for
ne cell sorting based on additional physical properties, such as volume and shape. They are,
however, still in early development stages [Tomlinson et al., 2013], and are hardly applicable
for large-scale DNA methylation proling.
The cell separation methods have been successfully used in combination with DNA methy-
lation proling. It was a method of choice for large epigenome consortia, allowing to prole
methylation in a wide range of cell types [Abbott, 2011; Bernstein et al., 2012; Roadmap Epige-
nomics Consortium et al., 2015]. MACS separation allowed generation of high quality ref-
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erence methylomes of various blood cell types [Calvanese et al., 2012; Reinius et al., 2012].
FACS-based sorting of brain cell nuclei antibody-labeled for RBFOX3 (NeuN) nuclear surface
protein was used to separate neuronal and glial fractions, signicantly increasing the resolu-
tion of the DNA methylation studies in brain [Guintivano et al., 2013; Lister et al., 2013].
The potential of cell separation for the future epigenome studies is limited by several pit-
falls [Tomlinson et al., 2013]. The immunolabeling relies upon the existence of a well dened
cellular markers, which may not exist or, what is more often, may not be exclusive. In due of
this diculty the purity achievable by the labelling-based methods is always a relative notion
being limited to the characteristic of carrying a specic surface marker. The purity is fur-
ther undermined by formation of cell clusters containing both labeled and non-labeled cells,
and non-specic antibody binding. Furthermore, the amounts of cells recovered by FACS and
MACS might not be sucient to perform a DNA methylation analysis. Although, DNA methy-
lation is a comparatively stable epigenetic mark, one cannot completely exclude the possibility
that the prolonged times out of the natural environment, sample handling as well as interac-
tions during the isolation procedure, for instance, the antibody binding to an receptor, might
cause certain methylome alterations. Finally, the methods are often still too laborious and
costly to be used in the context of large-scale studies such as EWAS.
1.3.3 Single-cell methods
One possibility to increase the homogeneity of a cell sample is to decrease the sample itself.
This involves the downscaling of the DNA methylation proling method to much smaller
amounts of input materials down to a single cell. Comparative stability of the DNA methy-
lation mark is very favorable and makes it easier to prole methylomes in low amounts of
cells [Schwartzman and Tanay, 2015].
In certain cases the standard proling methods can be applied to low amounts of input
without major adaptation. This is, for example, the case when targeted bisulte sequencing
is performed on repetitive elements, which was successfully applied to study DNA methy-
lation dynamics in early development stages, such as zygote or even pro-nuclei prior to the
fusion [Arand et al., 2012]. Furthermore, any bisulte sequencing protocol is in essence a
single-molecule procedure and a picture for a selected locus reects the distribution in the ana-
lyzed pool of cells. Computational methods were used to draw more insights about methylome
dynamics based on this information [Landan et al., 2012; Siegmund et al., 2009].
The truly single-cell methods extend this approach to the complete genome. So far, three
single-cell DNA methylation assays were published, all being adaptations of the existing bisul-
te sequencing protocols [Schwartzman and Tanay, 2015]. First, a single-tube RRBS protocol
was described that allowed proling of early mouse embryos and ES cells at single-cell reso-
lution [Guo et al., 2013]. Next, PBAT protocol was adapted to single cells [Smallwood et al.,
2014]. As the latest development, another bisulte sequencing protocol was used for low-depth
methylome proling of developmental and drug-induced eects [Farlik et al., 2015].
While having achieved a signicant progress in recent years, low-input and single-cell
methods are in early development stage. A major drawback of the maps obtained by all the
above methods is their sparsity. In the best cases total genomic coverage reaches at most 20% of
all CpGs with mean being around 10% [Schwartzman and Tanay, 2015]. This seriously compli-
cates a comparative analysis since, depending on the number of sequenced cells, there might
be only a few ones having a call for a particular CpG. Scaling of the protocols to more cells
is also dicult in this case, as 20 million reads are typically required to achieve the above ge-
nomic coverage, meaning that only around 80 cells can be proled in one typical two-owcell
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Table 1.1: Computational methods for the correction of cell type heterogeneity
Name Source Predecessor Implementation
Reference-based
Constrained projection [Houseman et al., 2012] R scripts
CETS [Guintivano et al., 2013] R package
Reference-free
RefFreeEWAS [Houseman et al., 2014] SVA R package
FaST-LMM EWASHER [Zou et al., 2014] FaST-LMM R package, python
ReFACTor [Rahmani et al., 2016] PCA R package, python
HiSeq 2500 run. At the moment this is prohibitively expensive to be used for large studies such
as EWAS. The future development will, most likely, come from the novel (third-generation)
sequencing technologies. The latter will enable proling of large, potentially chromosome-
sized DNA fragments and will natively discriminate the modied bases [Munroe and Harris,
2010].
1.3.4 Computational inference and deconvolution
The advantages of cell separation-based and single-cell methods for decreasing and delineat-
ing heterogeneity of the methylomes are doubtless. They are, however, outweighed by in-
herent drawbacks limiting their utility in many application scenarios. In the same time, an
average methylome of a cell sample with a decent depth of support carries information about
all cell populations which contributed to it. As a convenient, cost-ecient and time-saving
alternative, it was suggested that computational methods can be used to detect and measure
tissue heterogeneity of complex samples [Baron et al., 2006; Sehouli et al., 2011]. Earlier this
has been successfully demonstrated for the gene expression data [Kuhn et al., 2011; Shen-Orr
et al., 2010].
The later developed computational methods for methylome heterogeneity analysis are usu-
ally classied in two large groups depending on whether or not they are using any prior
information. Reference-based methods utilize the existing, usually genome-scale proles of
puried cell populations. Reference-free methods attempt to infer the heterogeneity eects
without any prior information. Existing reference-free and reference-based approaches are
summarized in Table 1.1.
Methods for reference-based estimation and adjustment
Houseman et al. suggested a regression calibration-like approach to estimate the contribution
of each of the two eects for every tested covariate [Houseman et al., 2012]. Their model relies
upon reference methylome measurements which were directly used to nd cell type-specic
quantitative markers and to model the target data using the values for the markers observed
in the reference data set. In addition, they devised a systematic quadratic optimization-based
procedure, under the name of constrained projection, that allowed estimation of leukocyte
proportions in genome-scale DNA methylation proles of whole blood samples. The esti-
mated proportions could then be considered as covariates in a subsequent association analy-
sis [Houseman et al., 2012]. The approach by Houseman et al. was validated in several follow-
up studies [Accomando et al., 2014; Koestler et al., 2013].
Similar reference-based approaches were developed focusing at heterogeneity in the brain
tissue. Cell epigenotype-specic (CETS) model is using DNA methylation proles of neuronal-
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enriched and depleted fractions for quantifying the proportion of neuronal and non-neuronal
(glial) cells in bulk samples of various regions in brain cortex [Guintivano et al., 2013]. CETS
mixes measured proles of NeuN+ and NeuN− enrichment fractions in silico with an incre-
mental range of possible mixing proportions to simulate brain tissue methylomes for each
neurons to glia ratio. The observed brain prole is then compared to all simulated mixtures,
and the mixing proportions of the best tting one are considered to represent the proportions
of the observed prole. Another study extended the blood-based constrained projection to
support the brain tissue data and showed how accurate estimates can be obtained using data
from dierent brain regions instead of the NeuN-sorted references [Montaño et al., 2013].
An important aspect of the reference-based methods is the selection of cell type-specic
quantitative marker CpGs. The pilot study in blood applied per-CpG linear modeling of refer-
ence data with cell type as an independent variable and selected the top 500 CpGs showing the
best F-statistic [Houseman et al., 2012]. Later implementation of the constrained projection in
the minfi R-package used a slightly dierent approach, selecting 100 best markers for each
cell type [Aryee et al., 2014]. Finally, a recent paper presents an in-depth systematic method
IDOL for addressing this problem, and demonstrates its superiority [Koestler et al., 2016].
At the moment, most of the available reference-based methods use the reference data also
in their estimation steps. This hinges upon two signicant assumptions. First, it is expected
that technical dierences between the target and the reference data sets are not aecting the
analysis substantially. Second, they assume that the cell type methylomes of the reference in-
dividuals are, on average, equivalent to those of the target cohort. While the rst requirement
can, at least in part, be solved by joint preprocessing of both data sets, the second assump-
tion is very hard to verify in practice. This is why it appears more reliable to use reference
data set to select ctDMRs, and use the methylation values observed at these loci or CpGs as a
basis for estimation or adjustment. An ad hoc implementation of such approach for the cor-
rection of cell type heterogeneity in saliva samples [Souren et al., 2013] is presented as a part
of Chapter 2.
Reference-free correction methods
Reference-based methods showed good performance in multiple data sets [Koestler et al., 2013;
Liu et al., 2013]. However, they largely rely upon the availability of reference DNA methylation
proles of puried cell types which are not always at hand. In addition, the complete set of
contributing epigenome varieties is not known a priori. This stimulated the search for methods
that would be independent of such reference measurements.
First two such methods appeared simultaneously [Houseman et al., 2014; Zou et al., 2014].
RefFreeEWAS [Houseman et al., 2014], from the authors of the constrained projection method
[Houseman et al., 2012], is essentially an adaptation of the more general Surrogate Variable
Analysis (SVA) [Leek and Storey, 2007]. The SVA-inspired assumption behind RefFreeEWAS
is that the cell type methylomes and proportions are convoluted into both coecients and
residuals of the phenotype-based model of the observed data. Although not obtainable explic-
itly, due to orthogonality with other covariates, one can recover the cell type methylomes and
proportions in a convoluted form using joint Singular Value Decomposition of the coecients
and residuals. This also allows for respective correction of the phenotype model coecients
to capture only the “direct” methylation eects.
The second method, FaST-LMM-EWASHER [Zou et al., 2014] is a descendant of the Fast-
LMM algorithm for the signicance analysis in genomic association studies. In a thorough
mathematical analysis the authors expose limitations of the standard linear mixed models
(LMMs) accounting for covariance structure in capturing the confounding caused by the cell
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type variability, as well as of a simple principal component-based correction. The EWASHER
model is based on augmenting the full covariance-aware LMM with correction for top princi-
pal components of the CpG marker matrix. The tting algorithm proceeds in iterative fash-
ion re-selecting the features for the covariance matrix after addition of each new principal
component. The authors demonstrate that EWASHER successfully eliminates the signicance
ination in the statistical analysis of DNA methylation data severely aected by the cell type
heterogeneity.
Finally, the most recent reference-free approach ReFACTor [Rahmani et al., 2016] is apply-
ing sparse PCA for the same purpose of correcting an association analysis for the phenotype
of interest. The idea behind ReFACTor is to nd a small number t of cell type-specic markers
as CpGs which have the lowest distance between their actual observed data and a low-rank
approximation of the observed data based on k principal components, where k is the assumed
number of underlying cell types. The PCA of the data subset on t CpGs is then supposed
to yield scores correlated to the cell type proportions. The PCA scores can subsequently be
used as covariates for the adjustment. In the original publication the authors demonstrate the
slight superiority of ReFACTor as compared to the earlier published methods RefFreeEWAS
and EWASHER.
The available reference-free methods are provably helpful for the analysis of EWAS data
aected by strong cell type heterogeneity eects. Purely from the end user perspective the
methods return heterogeneity-corrected P -values for signicance of association with the tar-
get phenotypic variable of interest at each CpG position. Although, this is often a desired
analysis outcome, DNA methylation data sets tend to be increasingly more complex and, as
a rule, do not meet all prior expectations about the tested hypothesis and the confounding
factors. The internal structure of the sampled methylomes often provides for more interesting
ndings than the starting hypothesis itself. Routine application of such correction methods
may impede an unconstrained data exploration and important insights about the analysed data
set might be missed. Furthermore, from the technical perspective most of the reference-free
methods are explicitly or implicitly based on PCA. PCA is a general-purpose method and the
variability components it captures are not guaranteed to exclusively reect the variability cell
type composition. As a result the above methods are at risk of over-correcting the data for
other unknown, yet potentially interesting factors.
Methylome deconvolution
The reference-based and reference-free methods above, apart from their specic advantages
and disadvantages, were developed with the primary goal of correcting the statistical analysis
in DNA methylation association studies. In general, computational methods for heterogeneity
analysis signicantly improve tractability of the data obtained on multi-cellular specimens.
They require no additional costs and minimal labor overhead while providing for very useful
inference results. However, if one abstracts oneself from the specic issue of confounding, and
looks at methylome heterogeneity from a more general perspective, one can dene a related
deconvolution problem. The latter can be formulated as follows: given a set of cell sample
average methylomes nd all unique underlying methylation signatures as well as their mixing
proportions.
This deconvolution problem is closely related to the goals pursued by the methods for DNA
methylation prole analysis, i.e. the clustering and dimensionality reduction methods briey
reviewed at the end of Section 1.2. An ideal method for solving it should be able to delineate the
observed variability into “biological”, i.e. corresponding to the real DNA methylation changes,
and “technical”, i.e. caused by other eects of non-biological nature, such as batch eects in
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sample handling and calling procedure, measurement noise etc.
Full deconvolution was earlier attempted on gene expression data [Gaujoux and Seoighe,
2012, 2013; Repsilber et al., 2010]. The promising results obtained with linear methods, such
as standard non-negative matrix factorization (NMF), in gene expression are, at the very least,
surprising. Unlike DNA methylation, the expression level is a quantitative signal already at
the level of a single cell meaning that the mixing of the expression signals in a multi-cellular
sample does not have to obey a linear (proportional) mode. An analogous problem in DNA
methylation should be much easier to solve due to its discreteness at the single-cell level and
consecutive mixing linearity.
In Chapter 6 we present a computational method which attempts to solve this problem
in an unsupervised, reference-free manner. We show that, although this problem is compu-
tational hard and resides on the verge of mathematical tractability, the main deconvolution
goals can nevertheless be achieved.
1.4 Outline
The sections above give a rough overview of DNA methylation, the major dimensions of its
variability, the most powerful experimental methods for mapping the latter, and introduce
some of the data analysis problems, specically the problem of heterogeneous methylome
measurements. There are deep mutual relations between each of these fundamental and prac-
tical aspects. The high non-uniformity of the DNA methylation landscape is characterized
by drastic changes of methylation states between neighboring CpG at transitions from an
island-overlapping promoter into a gene body, through the CpG-sparse intergenic regions
to lowly methylated regulatory elements. This non-uniformity makes it necessary to study
DNA methylation at single-CpG resolution. The variability of the landscapes across dier-
ent cell types within one organism compromises the bulk DNA methylation measurements
in large cell samples, especially those coming from heterogeneous tissues, and calls either for
cell isolation-based and low-input proling strategies or for proper statistical correction and
interpretation of average methylomes. Variability of the methylomes across human popula-
tions is an access point for studying the involvement of DNA methylation into pathological
conditions and xation of various environmental inuences, but it also confounds such stud-
ies due to the large inuence of such factors as genetic information, gender and ageing. This
confounding together with technical issues of particular proling technologies necessitate the
creation of powerful yet comprehensive data processing and analysis tools. The contributions
presented in the remainder of the present thesis aim to satisfy these needs with bioinformatic
tools and novel computational methods.
Chapter 2 sets the stage for the subsequent bioinformatic results, and provides an example
of a typical genome-scale DNA methylation study. The chapter presents an EWAS in monozy-
gotic twins discordant for intra-uterine growth. Out of performance and cost considerations
the study embarked upon the Innium 450k arrays to generate high quality average methy-
lomes for 17 female twin pairs. The EWAS demonstrates that even highly controlled settings,
such as monozygotic twin-based study design which the genetic, age, gender and many other
types of confounding reduces to an absolute minimum, is not insured against other types of un-
desired variability eects. In this case a seemingly homogeneous DNA source, the neutrophil-
containing saliva, was nevertheless contaminated with uncontrolled amounts of epithelium.
A simple yet ecient method we developed for the adjustment of the consequent cell type
heterogeneity eects is an important result for the current thesis also presented in Chapter 2.
The negative result of the study was conrmed by a locus-specic analysis of the potential
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candidates and the cell type-specic markers. Taken together, the experience collected while
working on the EWAS formed a basis for bioinformatic and computational results of the sub-
sequent chapters.
Chapter 3 presents RnBeads, a pipeline for processing and analysis of genome-scale DNA
methylation proles similar to those of the twin-based EWAS. RnBeads supports both the bead
array and WGBS/RRBS data and leads the user from minimally preprocessed input les to a
holistic representation of the study data. RnBeads integrates and simplies application of the
state-of-the-art computational methods for dealing with the data analysis problems including
but not limited to those presented in Chapter 2.
Chapters 4 and Chapter 5 is devoted to locus-specic analysis of 5-methylcytosine using
high-throughput bisulte sequencing. These approaches sacrice genomic coverage to obtain
very good representation of the variability between cells, and are usually applied in candidate
gene studies as well as for the verication analyses of the genome-scale studies, the way it
was done in the twin-based EWAS described in Chapter 2. Chapter 4 describes an interactive
software package BiQ Analyzer HT specically developed to handle such data. As pointed
out in the introduction, one limitation of the bisulte method is its inability to discriminate
the oxidative methylation varieties. In Chapter 5 the software is extended to support the 5-
methylcytosine derivatives: 5-hydroxy-, 5-formyl- and 5-carboxylcytosine.
After facing the cell type heterogeneity problem for the rst time, a lot of thinking was
invested to understand it better from many dierent angles. Chapter 6 presents the core result
for the DNA methylation heterogeneity problem: a methylome deconvolution method MeDe-
Com. The concept behind MeDeCom extends beyond the level of statistical correction and
tries to approach the heterogeneity from a constructive data-driven perspective. The pilot re-
sults of MeDeCom in synthetic and real DNA methylation data sets presented in Chapter 6 are
demonstrating the power of such an approach and provide clues for overcoming the current
limitations.
The thesis is concluded by an overarching discussion and outlook in Chapter 7. The discus-
sion rst puts all the bioinformatic results in a common context of a large-scale DNA methyla-
tion study, and then gives in-depth considerations about the methylome deconvolution prob-
lem. The outlook sketches a broader picture of the anticipated developments in the eld and
the author’s opinion about the respective role of bioinformatics researchers in making them
possible.
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Abstract
Background: Low birth weight is associated with an increased adult metabolic
disease risk. It is widely discussed that poor intra-uterine conditions could induce
long-lasting epigenetic modications, leading to systemic changes in regulation of
metabolic genes. To address this, we acquire genome-wide DNA methylation proles
from saliva DNA in a unique cohort of 17 monozygotic monochorionic female twins
very discordant for birth weight. We examine if adverse prenatal growth conditions
experienced by the smaller co-twins lead to long-lasting DNA methylation changes.
Results: Overall,co-twins show very similar genome-wide DNA methylation pro-
les. Since observed dierences are almost exclusively caused by variable cellular
composition, an original marker-based adjustment strategy was developed to elim-
inate such variation at aected CpGs. Among adjusted and unchanged CpGs 3,153
are dierentially methylated between the heavy and light co-twins at nominal signif-
icance, of which 45 show sensible absolute mean β-value dierences. Deep bisulte
sequencing of eight such loci reveals that dierences remain in the range of technical
variation, arguing against a reproducible biological eect. Analysis of methylation
in repetitive elements using methylation-dependent primer extension assays also in-
dicates no signicant intra-pair dierences.
Conclusions: Severe intra-uterine growth dierences observed within these monozy-
gotic twins are not associated with long-lasting DNA methylation dierences in cells
composing saliva, detectable with up-to-date technologies. Additionally, our results
indicate that uneven cell type composition can lead to spurious results and should
be addressed in epigenomic studies.
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saliva, intra-uterine growth restriction, Innium HumanMethylation450 BeadChip
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2.1 Background
Both observational human and experimental animal studies have conrmed that low birth
weight is associated with an increased risk of metabolic diseases, like Type 2 Diabetes (T2D)
[Barker, 2006; McMillen and Robinson, 2005; Newsome et al., 2003]. Although genetic factors
are likely to contribute [Lindsay et al., 2000; Wannamethee et al., 2004], studies assessing the
association between low birth weight and T2D precursors in monozygotic (MZ) twins showed
that the twin who was lighter at birth had a more adverse metabolic prole in adulthood
compared to its genetically identical co-twin, who was heavier at birth [Bo et al., 2000; Grunnet
et al., 2007; Iliadou et al., 2004; Monrad et al., 2009; Poulsen et al., 1997]. This suggests that the
association between low birth weight and increased T2D risk is at least partly independent of
genetic factors.
One of the possible molecular mechanisms explaining this non-genetic association sug-
gests that poor prenatal conditions induce epigenetic modications [Gluckman et al., 2008].
These epigenetic modications are believed to cause a “thrifty” metabolic state, which is ben-
ecial for survival under circumstances of insucient nutrient supply, but unfavorable when
nutrient supply is abundant in postnatal life. An important epigenetic phenomenon is DNA
methylation that almost exclusively occurs at cytosines within CpG dinucleotides and corre-
lates with transcriptional repression, while loss of methylation can result in transcriptional
activation [Bird, 2002].
The notion that poor intra-uterine conditions cause epigenetic modications during prena-
tal development is supported by data from animal studies, where dietary restriction or surgical
interventions are used to induce fetal growth restriction, resulting in epigenetic modications
on metabolic disease-related genes (reviewed by [Seki et al., 2012]). The number of stud-
ies assessing the relation between an adverse fetal environment and epigenetic alterations
in humans is gradually growing as well. For instance, humans who were periconceptionally
exposed to famine during the Dutch Hunger Winter (1944-1945) were reported to show sig-
nicant methylation dierences at several imprinted and non-imprinted genes in comparison
to their unexposed siblings in peripheral blood cells [Heijmans et al., 2008; Tobi et al., 2009].
A genome-wide DNA methylation study performed on CD34+ hematopoietic stem cells from
cord blood of ve intra-uterine growth restricted (IUGR) neonates and ve gestational age and
gender-matched controls [Einstein et al., 2010], identied among others signicant methyla-
tion dierences at the HNF4A gene, which is involved in monogenic diabetes.
However, epigenetic association studies using population or family-based designs suer
from confounding caused by DNA sequence variation. Specically, since birth weight is partly
controlled by genetic factors [Yaghootkar and Freathy, 2012], a study with genetically un-
matched cases and controls cannot dissect whether a small size at birth is due to a poor pre-
natal environment or genetic predisposition. On the other hand, epigenetic variation is often
a result of genetic variation, e.g. allele-specic methylation where the methylation pattern of
a DNA molecule is determined by a cis- or trans-acting genetic variant [Meaburn et al., 2010].
Since MZ twins originate from one zygote, they are almost absolutely genetically identical,
which makes them ideal to search for epigenetic phenomena associated with phenotypic dis-
cordancy. In addition, MZ twins are matched for gender, (gestational) age, maternal factors
(e.g. parity, age) and a broad range of environmental factors.
Depending on whether the embryo splits during an early or later developmental stage, MZ
twins can be dichorionic (DC) or monochorionic (MC), respectively. MZ DC twins have two
separate placentas, while MZ MC twins share a single placenta [Derom et al., 2006]. It has been
shown that the degree of DNA methylation dissimilarity varies between MZ MC and MZ DC
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twins [Kaminsky et al., 2009], indicating that for epigenetic purposes one should either study
MZ MC or MZ DC twins. Due to placental blood vessel connections and unequal sharing of
the placenta, imbalanced blood and nutrient supply is more common in MZ MC compared to
MZ DC twins [Lewi et al., 2010]. Poor prenatal conditions experienced by only one co-twin
often result in large intra-pair birth weight dierences within MZ MC pairs [Loos et al., 2001],
turning them into a “natural experiment” to study the fetal programming origins of late onset
human diseases.
We hypothesized that if poor prenatal conditions induce changes in DNA methylation pat-
terns that remain throughout life, these changes should be visible in MZ MC twins discordant
for birth weight, irrespective of their health status (degree of insulin resistance, obesity etc)
in adulthood. To identify loci that are dierentially methylated due to poor prenatal con-
ditions, we performed an epigenome-wide association study (EWAS) in 17 adult female MZ
MC twin pairs with a relative birth weight dierence greater than 20%. The twins were re-
cruited from the East Flanders Prospective Twin Survey (EFPTS), which started in 1964 and is
unique due to its long term extensive collection of perinatal (e.g. birth weight, gestational age,
parity) and placental data (e.g. chorionicity) of nearly 8800 twin pairs [Derom et al., 2006].
DNA was isolated from saliva, a bio-uid that is easily accessible via a totally non-invasive
method and therefore widely used in large cohort studies and perfect for diagnostic purposes.
Genome-wide DNA methylation proles were determined using the Innium HumanMethy-
lation450 BeadChip and validated using targeted deep coverage bisulte sequencing. Addi-
tionally, repetitive element methylation levels were determined using methylation-dependent
primer extension assays. Our thorough DNA methylation analyses in saliva of birth weight
discordant MZ MC twins show that the adverse prenatal growth conditions experienced by
the smaller co-twins do not lead to long-lasting DNA methylation changes in cells composing
saliva (i.e. buccal epithelium and leukocytes), detectable with up-to-date technologies. In ad-
dition, we observe that EWAS studies can be hampered by variation in cellular composition,
which can lead to spurious results. We present an adjustment method to normalize the DNA
methylation data with respect to variable cell-type content.
2.2 Material and methods
2.2.1 Participants
For this study, 17 spontaneously conceived MZ MC female twin pairs discordant for birth
weight were recruited from the EFPTS [Derom et al., 2006], which is a population-based twin
register that started in 1964 and recorded all multiple births in the Belgian Province of East
Flanders until the present. Discordancy was dened as relative birth weight dierence ≥20%
([highest birth weight – lowest birth weight]/highest birth weight), with the lightest twin
having a birth weight below the 10th percentile and the heavier twin having a birth weight
between the 10th and 90th percentile for that gestational age, gender, parity and chorion type
(based on twin-specic growth charts [Gielen et al., 2008]). To minimize variation due to
gender-specic methylation dierences [Liu et al., 2010], only female twins were included. In
addition, to assure that the DNA methylation changes remain throughout life, only adult (≥18
years) discordant MZ MC female twins were included (in total 61 pairs satisfy these selection
criteria). Of the 17 twin pairs, 15 pairs were newly recruited for this study, while two pairs
were previously recruited for another study [Souren et al., 2011]. None of the participants
suered from severe postnatal complications. The Ethics Committee of the Faculty of Medicine
of the Katholieke Universiteit Leuven approved the project and all participants gave written
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informed consent. The study was conducted according to the principles of the Declaration of
Helsinki.
2.2.2 Phenotypes
Information on birth weight and parity was obtained from obstetric records within 24 hours
after delivery. Gestational age was reported by the obstetrician and was calculated as the
number of completed weeks of pregnancy based on the last menstrual period. The obstetri-
cians and the pediatricians answered a structured questionnaire that provided among other
items information on the mode of conception, abnormalities of the children and the health
status of the children for the period they stayed in the neonatal unit. A trained midwife ex-
amined the placentas within 24 hours of delivery and assessed chorionicity macroscopically
following a standardized protocol [Derom et al., 1995]. Adult phenotypic data were retrieved
from a mailed questionnaire, which included self-reported items on current body weight, body
height, physical activity level, medical history, smoking behavior and alcohol consumption.
Body mass index was calculated as self-reported body weight divided by the square of height
(kg/m2).
2.2.3 Genomic DNA extraction
Saliva samples were collected using the Oragene DNA Self-collection Kit (DNA Genotek, Ot-
tawa, Canada). Genomic DNA was extracted from saliva using the GenElute Mammalian
Genomic DNA Miniprep Kit (Sigma-Aldrich, St. Louis, MO, USA) according to the manu-
facturer’s instructions. DNA was quantied using the Qubit uorometer (Invitrogen GmbH,
Karlsruhe, Germany) and qualied using the Nanodrop 2000C spectrophotometer (Thermo
Scientic, Wilmington, DE, USA). Per DNA extraction batch, only one member per twin pair
was processed.
2.2.4 Zygosity confirmation
Although all twins were monochorionic and thus assumed to be monozygotic, zygosity was
conrmed by genotyping 17 highly polymorphic microsatellite markers using the PowerPlex
ESI 17 system (Promega Corporation, Madison, WI, USA), with an average certainty exceeding
99.99%.
2.2.5 Genome-wide DNA methylation analysis
To avoid dierences in methylation levels within twins due to bisulte treatment or PCR bias,
both members of a twin pair were always processed in the same batch.
Bisulte treatment. For the genome-wide study, per sample 1 ug (2x 500 ng) of genomic
DNA (OD260/280>1.8) extracted from saliva was treated with bisulte using the EZ DNA
Methylation-Gold Kit (D5005, Zymo Research, Orange, CA, USA). In brief, 700 µl water, 300
µl M-Dilution Buer and 50 µl M-Dissolving Buer was added to the CT Conversion Reagent
tube. After mixing, 110 µl of the CT Conversion Reagent was added to 40 µl of DNA, which
was then incubated for 10 min at 98°C followed by 3 hours on 64°C. Afterwards, bisulte-
converted DNA samples were puried by loading, desulfonating and washing on the pro-
vided Zymo-Spin™ IC columns (following the manufacturer’s instructions), eluted in 12 µl
M-Elution Buer and stored at-20°C prior to processing.
47
CHAPTER 2. BIRTH-WEIGHT EWAS IN TWINS
Innium HumanMethylation450 BeadChip. Genome-wide DNA methylation proles were
generated using Illumina’s Innium HumanMethylation450 Beadchip assay (Illumina, San
Diego, CA, USA) at the Department of Psychiatry and Psychotherapy of the Saarland Uni-
versity Hospital. The assay allows determination of DNA methylation levels at >450,000 CpG
sites covering all designable RefSeq genes, including promoter, 5’, and 3’ regions; it captures
CpG islands and shores, non-CpG methylated sites, miRNA promoter regions and disease-
associated regions identied through GWAS [Bibikova et al., 2011]. The Innium Methylation
Assay was performed according to manufacturer’s instructions. In brief, 4 µl of denatured
bisulte-treated DNA was isothermally amplied overnight at 37°C, followed by an enzymatic
fragmentation step using end-point fragmentation. The fragmented DNA was then precipi-
tated, resuspended and loaded on the 12-sample BeadChip (see for the distribution of the sam-
ples across the beadchips Additonal le 1, Table 2.S4). The chips were incubated overnight at
48°C, allowing the fragmented DNA to hybridize to the locus-specic 50-mers on the chip. Un-
hybridized and non-specically hybridized DNA was washed away, followed by a single-base
extension reaction using DNP- and Biotin-labeled ddNTPs.
Subsequently, the hybridized DNA was washed away and a multi-layer staining process
was carried out to attach uorescent dyes to the labeled extended primers. The uorescently
stained chips were imaged using an Illumina HiScanSQ scanner and the Illumina’s GenomeS-
tudio software (Methylation Module v1.8) was used to extract the data, subtract the back-
ground and to normalize the data using internal controls present on the chip (see for de-
tails Supplemental methods). The overall performance of the normalization procedure is il-
lustrated in Figure 2.S13. Subsequently, for each CpG site a β-value was calculated, which
represents the fraction of methylated cytosines at that particular CpG site (0=unmethylated,
1=fully methylated). Only CpGs with a detection P-value <0.001 in all samples were included
(see Table 2.S4). In total, 4325 out of 482,421 CpGs were excluded, of which 351 were located
on the Y-chromosome.
2.2.6 Deep bisulfite sequencing (DBS) analysis
Selected MVPs were validated using DBS. As long as the stocks lasted, the bisulte DNA used
for the genome-wide scan was used for validation analysis or a new bisulte treatment was
performed using standard protocols. In brief, 2 M sodium bisulte and 0.6 M NaOH was added
to 300 ng genomic DNA, which was then incubated for 15 min at 99°C and 30 min at 50°C,
followed by 2 cycles of 5 min at 99°C and 90 min at 50°C. Afterwards, bisulte-treated DNA
was sequentially desulfonated (with 0.3 M NaOH), washed with 1xTE and recovered in 50 µl
0.5xTE using centrifugal lter units YM-30 (Millipore, Schwalbach, Germany).
Amplicons were generated using region-specic primers having on their 5-ends the recom-
mended GS-FLX A and B adaptors sequences (Lib-L) and multiplex identiers (MID) (Roche,
Mannheim, Germany). Bisulte PCRs were carried out in 30 µl mixes, including 1-3 µl bisulte-
treated DNA, 0.2 mM of each dNTP, 3 U HOT FIREPol DNA polymerase (Solis BioDyne, Tartu,
Estonia), 1x reaction buer B (Solis BioDyne), 2.5 mM MgCl2, or 1.5 U HotStarTaq DNA poly-
merase (Qiagen, Hilden, Germany) and 1x PCR buer (Qiagen). Primer sequences, concentra-
tions and PCR conditions are summarized in Table 2.S5.
PCR products were visualized on 1.2% agarose gels, puried using the Gel/PCR DNA Frag-
ments extraction kit (AVEGENE, Taipei, Taiwan) and measured by intercalating uorescence
dye using the Qubit Fluorometer (Qubit HS-Kit, Invitrogen, Darmstadt, Germany). After
equimolar amplicon pooling, emulsion PCR was performed using Lib-L emPCR protocols.
DNA containing beads were recovered, enriched and sequenced on a XLR70 Titanium Pi-
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coTiterPlate (Roche) separated into 8 regions, according to the manufacturer’s protocols. Reads
were extracted from primary s-les and assigned to the reference sequence. Afterwards, the
reads were imported into BiQ Analyzer HT [Lutsik et al., 2011], to lter out low quality reads
and analyze the methylation levels and patterns. In total, 340 amplicons were sequenced and
331,768 high quality sequences were obtained with an average conversion rate >99%.
2.2.7 DNA methylation analysis of repetitive elements
DNA methylation levels in the repetitive DNA elements HERVK and LINE1 (not covered by
the Illumina Beadchip) were determined using methylation-dependent primer extension as-
says (SIRPH). The bisulte PCRs were performed as described in the previous section (see
Table 2.S5, for primer sequences, concentrations and PCR conditions). The degree of methyla-
tion was determined using single-nucleotide primer extension (SNuPE) assays in combination
with ion-pair reversed-phase high-performance liquid chromatography (IP-RP-HPLC) sepa-
ration techniques (SIRPH) as previously described [El-Maarri et al., 2002]. In brief, after am-
plication, unincorporated dNTPs and primers were removed by treating 5 µl PCR product
with Exonuclease I/SAP mix (1U each, USB) for 30 min at 37°C, followed by an inactivation
step of 15 min at 80°C. Afterwards, 14 µl primer extension mastermix (2.0 mM MgCl2, 0.05
mM ddCTP, 0.05 mM ddTTP, 3.6 µM SNuPE primer, 5 U TERMIPol DNA Polymerase (Solis
BioDyne, Tartu, Estonia) and 1x reaction buer C (Solis BioDyne)) were added to the Exonu-
clease 1/SAP treated PCR product. A primer extension reaction was performed with a primer
annealing next to a CpG (in the context of the original genomic sequence) being extended by
either a ddCTP or a ddTTP, depending on whether the site was methylated prior the bisulte
treatment and PCR or not. SNuPE reaction conditions and primer sequences are described in
Table 2.S6. Obtained SNuPE products were loaded directly on a DNASepTM (Transgenomic,
Omaha, USA) column and separated on the WAVETM system (Transgenomic) using acetonitril
gradient elution. The elution gradient parameters were adjusted specically for each SNuPE
primer. Methylation indices (MIs) were obtained by calculating the ratio AC/(AC+AT), where
AC and AT is the area under the peak corresponding to the ddCTP and the ddTTP-extended
primer, respectively, as calculated by Wave Maker v4.1 (Transgenomic). Two CpG sites per
amplicon were analyzed. The assays were validated using DBS of 8 DNA samples (4 chorion
and 4 decidua). Correlation coecients (r) between the SIRPH and the DBS data were for CpG1
and CpG2 of HERVK and LINE1, 0.98, 0.96, 0.73 and 0.82, respectively.
2.2.8 Whole blood and buccal genome-wide reference methylation
data
To generate reference datasets for whole blood and buccal DNA, genome-wide DNA methy-
lation data were obtained from Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih
.gov/geo/) (Table 2.S1). As there are currently no directly comparable 450k datasets avail-
able, we used data obtained with the Illumina HumanMethylation27 BeadChip (shares 25978
CpGs with the 450k chip). Whole blood DNA methylation data were obtained from 274 post-
menopausal female controls (GEO accession number: [GSE19711]) [Teschendor et al., 2010].
Buccal DNA methylation data were obtained from 60 female samples (mean age ± SD, 15.1
± 0.5) (GEO accession number: [GSE25892]) [Essex et al., 2013]. Subsequently, genome-wide
DNA methylation reference datasets for whole-blood and buccal were generated by averaging
the DNA methylation data.
49
CHAPTER 2. BIRTH-WEIGHT EWAS IN TWINS
2.2.9 Data analysis
To determine whether the phenotypic characteristics diered signicantly between the heav-
ier and lighter co-twins, a paired t-test for continuous data and Fisher’s exact test for categori-
cal data were carried out using the statistical package SAS (version 9.2, SAS Institute Inc., Cary,
NC, USA). Using the Bioconductormethylumi library, the genome-wide methylation data were
loaded into R statistical environment for analysis [Gentleman et al., 2004]. Quality control of
the Innium methylation data were assessed using the HumMeth27QCReport library. For all
dierent types of methylation data (i.e. Innium, DBS and SIRPH), DNA methylation dier-
ences between the heavy and light co-twins were tested using the non-parametric Wilcoxon
signed-rank test, which tests the null hypothesis that the mean DNA methylation dierences
are equal to zero (see for details Supplemental methods).
2.2.10 Power calculation
Power analysis of the Wilcoxon signed rank test is complicated, because its power function is
dicult to express [Shieh et al., 2007]. Therefore to estimate the power of our analysis we did
the calculation for its closest parametric equivalent (paired T-test). With a sample size of 16
discordant twin pairs, 99% power is achieved to detect a mean β-value dierence of 0.05 using
a two-sided paired T-Test assuming a standard deviation of 0.025 (which is the true standard
deviation observed in our data) and a signicance threshold of 0.01. The details of this power
calculation and calculations using lower signicance thresholds are presented in Table 2.S7.
2.3 Results
2.3.1 Phenotypic characteristics of the discordant MZ MC twins
Perinatal, maternal and adult phenotypic characteristics of the 17 spontaneously conceived MZ
MC female twins discordant for birth weight are presented in Table 2.1. Compared to the heav-
ier co-twins, the birth weight of the lighter co-twins was on average 698 gram (26.7%) lower
(P<0.0001), with absolute and relative intra-pair birth weight dierences ranging from 500 to
1000 gram and from 21.3 to 35.7%, respectively. In addition, the frequency of a (para)central
umbilical cord insertion was signicantly higher in the heavier co-twins (P=0.008). The mean
age of the twins when the saliva samples were taken was 34.4 years, the youngest twin pair
was 22 years old and the oldest 45 years. The adult phenotypic characteristics body height,
body weight and body mass index did not dier between the discordant twins (P>0.05). In the
questionnaires, none of the twins reported that they experienced diabetes, cancer, cardiovas-
cular or cerebrovascular disease events.
2.3.2 Exploratory analysis of the Infinium methylation profiles
Genome-wide DNA methylation proles of the 17 MZ MC twins were established using the
Innium HumanMethylation450 BeadChip assay. After quality control and ltering, methy-
lation data of 478,096 CpG sites were available. In order to identify global DNA methylation
changes across the samples, the Innium methylation data were used to calculate pair-wise
array-wide Pearson correlations coecients for each pair of samples. As depicted in Figure 2.1
and in Figure 2.S1, twin pair 1 showed severe genome-wide DNA methylation changes com-
pared to all other samples, resulting in a relatively low correlation to other samples (r=0.846-
0.930) while the intra-pair correlation of this twin pair was high (r=0.996). In addition, the
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Table 2.1: Perinatal, maternal and adult phenotypic characteristics of the female MZ twins discordant
for birth weight.
Characteristic Heavier co-twins Lighter
co-twins
Range Pa
N 17 17
Perinatal
Gestational age
(wks)b
37.9 ± 2.4 37.9 ± 2.4 (34 - 42)
Birth weight (g) 2619 ± 319 1921 ± 278 (1440 - 3100) <0.0001
Umbilical cord
insertionb
(Para)central 12 (75%) 4 (25%)
(Para)marginal 4 (25%) 9 (56%)
Velamentous 0 (0%) 3 (19%) 0.008
Maternal
Maternal age (yrs) 26.9 ± 5.4 26.9 ± 5.4 (18 - 43)
Parity 1.8 ± 1.0 1.8 ± 1.0 (1 - 4)
Adult
Age (yrs) 34.4 ± 7.1 34.4 ± 7.1 (22 - 45)
Body height (cm) 166.9 ± 6.1 165.5 ± 6.7 (155 - 177) 0.13
Body weight (kg) 62.7 ± 12.3 61.2 ± 14.2 (47.5 - 102) 0.18
Body mass index
(kg/m2)
22.5 ± 3.8 22.3 ± 4.5 (16.7 - 33.7) 0.60
Continuous data expressed as mean ± SD. Categorical data expressed as: number of observations (%).
aHeavy vs. light calculated using a paired T-test for continuous data and Fisher’s exact test for categorical data.
bMissing for one twin pair.
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overall methylation proles of samples 6_H, 10_H and 12_H deviated such that intra-pair cor-
relation coecients (r=0.975-0.989) for the pairs 6, 10 and 12 were low compared to otherwise
constantly high intra-pair correlation coecients for all other twin pairs (r=0.992-0.997). Care-
ful analysis of the sample independent and sample dependent Innium methylation control
probes present on the BeadChip (see Figure 2.S2 and 2.S3) revealed that the aberrant methy-
lation proles observed for some of the samples are unlikely the result of technical failure.
2.3.3 Cellular composition of saliva as a cause of aberrant
methylation profiles
Since saliva DNA is derived from leukocytes and epithelial cells [Aps et al., 2002; Thiede et al.,
2000], we hypothesized that the deviating DNA methylation proles observed for some sam-
ples were at least partially attributed to inter-sample dierences in cell type proportions. We
therefore compared our data to genome-wide DNA methylation reference datasets obtained
from whole blood and buccal epithelial cells (HumanMethylation27 BeadChip), respectively.
Indeed, in contrast to all other samples, the ve samples with the most deviating proles
(1_H, 1_L, 6_H, 10_H and 12_H) showed lower array-wide correlation coecients to the ref-
erence dataset for whole blood (rnorm=0.943-0.951 vs. rdeviant=0.812-0.939), than to the buccal
epithelium reference dataset (rnorm=0.875-0.915 vs. rdeviant=0.926-0.975) (see Figure 2.1 and Fig-
ure 2.S4). This suggests that the deviating methylation proles observed for these samples
were a consequence of cellular composition dierences, i.e. a higher amount of buccal epithe-
lial cells in the respective saliva samples.
Based on this nding we assumed that individual DNA methylation markers specic for
buccal epithelium (or conversely for whole blood) can be used to determine the relative amount
of buccal epithelium-derived DNA present in the samples. To illustrate that this is a valid as-
sumption we performed an experiment with in vitro generated series of two cell type mixtures
proled on the Innium HumanMethylation450 BeadChip. The results showed that the methy-
lation values of CpGs that are dierentially methylated between the two cell types provided a
good estimate of the mixed proportions (see Figure 2.S5).
Subsequently, we screened for CpGs that were highly discriminatively methylated between
blood and buccal (see for details Supplemental methods) and selected the top 10 most discrim-
inatively methylated CpGs. One of them was cg18384097 in PTPN7 (protein tyrosine phos-
phatase non-receptor type 7; β-valueBuccal =0.82 and β-valueBlood = 0.05), a gene preferentially
expressed in hematopoietic cells (Entrez Gene ID: 5778). When correlating the methylation
values of every CpG with the methylation levels of the PTPN7 CpG, we observed that 58,987
CpGs were strongly correlated with the PTPN7 CpG (|r|>0.8) and 134,265 CpGs were moder-
ately correlated (|r|=0.4-0.8) (see Figure 2.S6). This indicates that for a large number of CpGs
a great amount of the observed variation in DNA methylation levels could be explained by
variation in cellular composition of the saliva samples.
2.3.4 Adjustment for cell type heterogeneity
Following this observation, we decided to diminish the confounding eect of the saliva cell
type composition using linear regression. The detailed procedure is described in Additional
le 1. In brief, rst a model tting approach was used to select, out of the top ten most discrim-
inatively methylated CpGs, a marker CpG of which the methylation measurements behave the
most linear with respect to the changing cell proportions. In our data the PTPN7-associated
CpG (cg18384097) gave the best linear t to the biggest number of CpG positions, and was
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Figure 2.1: Heatmap representing the pair-wise correlations for each pair of samples plus the refer-
ence data set for whole-blood and buccal (27K), calculated from ≈25,978 CpGs. H = high
birth weight, L = low birth weight
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therefore selected as the quantitative marker measuring the proportion of buccal epithelium.
Subsequently, this CpG was used to adjust the Innium data so that the methylation level at
each probe becomes linearly independent of the cellular composition in the studied sample.
Noteworthy, this procedure adjusted only those CpGs that were signicantly aected by the
saliva composition (based on the marker model t), while the methylation levels of the other
CpGs (45%) remained unchanged. Due to the extremely high buccal epithelium content in the
saliva samples of pair 1, some CpGs showed extreme values which could not be approximated
by the linear model and greatly aected the regression slopes. Therefore we excluded pair
1 from the analysis. Interestingly, pair 1 were the only current smokers in the sample and
the only individuals with an intensive and long smoking history (>10 cigarettes/day for 25
years). This most probably caused the highly dierent cell composition in their saliva. The
methylation data of the remaining 32 samples got adjusted for the buccal epithelium content
and in Figure 2.S7, the pair-wise correlations for each pair of samples of the adjusted data are
graphically shown, conrming the robustness of our approach.
2.3.5 Birth weight associated methylation variable positions
Next we tested the hypothesis that poor prenatal conditions lead to signicant DNA methyla-
tion dierences between the heavy and light co-twins for each CpG site independently using
the non-parametric Wilcoxon signed-rank test. Figure 2.2 gives the volcano plots, that is, dis-
tributions of the resulting P-values versus the corresponding mean β-value dierence for each
CpG position, for both the unadjusted data (a) and the data adjusted for buccal epithelium con-
tent (b). The plot documents that large signicant DNA methylation dierences could not be
detected between the heavy and light co-twins (upper corners of both plots are void of data
points). In addition, one can also notice that the uneven cellular composition resulted in a
considerable amount of CpGs that had relatively big eect sizes but high (non-signicant) P-
values. This conrms that the vast majority of the changes were not associated with birth
weight, but were the result of within-pair variation in cellular composition. We therefore pro-
ceeded with the results of the data where the aected CpG positions were adjusted for buccal
epithelium content variation.
Given the small number of signicant changes, we selected a non-stringent signicance
threshold (uncorrected P-value <0.01). In addition, to identify CpG sites likely to be validat-
able using other methods [Rakyan et al., 2011], we focused on CpG positions that showed an
absolute mean β-value dierence >0.05. 7859 CpGs out of 478,096 sites had a P-value <0.01
with absolute mean β-value dierences ranging from 0.0012 to 0.1049 and P-values ranging
from 0.0092 to 3.05x10-5. Only 131 of these CpGs showed an absolute mean β-value dierence
>0.05. To exclude the potential inuence of other blood-derived cells present in saliva [Vidovic
et al., 2012], we extended the adjustment model to include markers of leukocyte subtypes (i.e.
neutrophils, B-lymphocytes, CD4+ T-lymphocytes, CD8+ T-lymphocytes and natural killers)
(see for details Supplemental methods, Table 2.S1 and 2.S2). In total, 3153 CpGs remained sig-
nicant (P<0.01) in both analyses of which only 45 CpGs showed an absolute mean β-value
dierence >0.05 (ranging from 0.05-0.08). We treated this set of 45 CpGs, further denoted
as “birth weight associated methylation variable positions” (BW-MVPs), as being most likely
dierentially methylated between the discordant MZ twins, regardless of the cellular composi-
tion (see for details Table 2.S3). Subsequently, we tested these BW-MVPs using state-of-the-art
technical validation to prove or disprove them being true biological eects.
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Figure 2.2: Volcano plots of the distributions of the P-values resulting from the Wilcoxon signed-
rank test versus the corresponding mean β-value dierence for each CpG position. a.
Unadjusted data (72 CpG sites had a P-value <0.01 and mean β-value dierence >0.05). b.
Data adjusted for buccal epithelium content using the PTPN7 CpG (131 CpG sites had a
P-value <0.01 and mean β-value dierence >0.05) (pair 1 was excluded).
2.3.6 BW-MVP validation using deep bisulfite sequencing (DBS)
The 45 BW-MVPs were prioritized for independent DNA methylation validation either based
on their biological signicance, regulatory relevance and/or whether neighboring probes were
also dierentially methylated. In total, eight BW-MVPs were validated using DBS and their
functional characteristics are summarized in Table 2.2. Some of the prioritized BW-MVPs were
situated in genes strongly involved in glucose and/or lipid metabolism or have been implicated
in T2D or obesity risk (e.g. APPL2, IGF2BP2, PHKG2 and PPARGC1B), which is in line with the
observation that low birth weight is associated with increased metabolic disease risk. Of the
eight selected loci only three were aected (IGF2BP2, PAPOLA and PPARGC1B) by buccal con-
tent, so the methylation values of the other ve remained unchanged. Moreover, in the unad-
justed data the IGF2BP2 and PPARGC1B CpGs were also signicantly dierentially methylated
between the discordant twins. To be able to adjust the DBS data of the IGF2BP2, PAPOLA and
PPARGC1B CpGs for buccal epithelium content, the PTPN7 CpG (buccal epithelium marker)
was also analyzed using DBS and simultaneously served as a positive control. High quality
DBS data were obtained for all amplicons, with an average sequencing coverage of 988 reads
(i.e. individual chromosomal patterns) per amplicon per sample. Examples of the methylation
proles obtained by DBS are given in Figure 2.S8.
Technical performance of both methods was rst analyzed by comparing the (unadjusted)
DBS data of the validated CpGs with the (unadjusted) Innium data for every analyzed sample
separately. The individual correlation plots are presented in Figure 2.S9, and the correlation
coecients calculated for each sample are summarized in a box plot in Figure 2.S10. Overall,
the Innium data correlates very well with the DBS data, with a median correlation coe-
cient of 0.97. From both gures it becomes also clear that sample 12_H is an outlier with a
correlation coecient of only 0.70. When we correlate the (unadjusted) Innium data with the
(unadjusted) DBS data for each validated CpG site separately (see Table 2.3 and Additional data
le 1, Figure 2.S11 and 2.S12), then the DBS data of the CpG sites in APBA1, APPL2, PHKG2,
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PPARGC1B and RUNX2 correlate poorly with the Innium data (r≤0.60). For the other four
CpG sites (Chr10q23.3, IGF2BP2, PAPOLA and PTPN7 ) the correlation coecients were higher
(r=0.73-0.91) and, as expected, the highest correlation was observed for the buccal epithelium
marker (PTPN7 ).
Subsequently, we tested whether the signicant DNA methylation dierences between
the heavy and light co-twins at these BW-MVPs obtained using the Innium data, could be
conrmed with the DBS data. We again performed a Wilcoxon signed-rank test and the results
of both technologies are presented in Table 2.4. Unfortunately, in the DBS data no signicant
DNA methylation dierences were observed between the heavy and light co-twins (p>0.01).
Moreover, in the DBS data we can also include CpGs neighboring the selected MVPs and also
for those CpGs no signicant methylation dierences between the heavy and light co-twins
were observed (data not shown). Since the correlation analysis revealed that sample 12_H
suers from technical problems (Figure 2.S9), we repeated the analysis without pair 12. Still,
in the DBS data no signicant dierences between the heavy and light co-twins were observed,
while the dierences in the Innium data remained signicant.
2.3.7 HNF4A methylation
In addition we analyzed the hepatocyte nuclear factor 4 alpha (HNF4A) promoter, which has
previously been identied as dierentially methylated between IUGR neonates and controls in
a genome-wide scan [Einstein et al., 2010]. Since the signicant region was not covered by the
Innium chip, we analyzed it using DBS with a mean sequence coverage of 865 reads ranging
from 176 to 1324 reads per sample. The HNF4A methylation levels correlated signicantly with
the buccal epithelium marker PTPN7, and therefore the HNF4A methylation data were adjusted
for PTPN7 methylation as described earlier. Following such an adjustment none of the 10 CpG
sites within the HNF4A amplicon retained signicant methylation dierences between the
discordant twins (p>0.01, data not shown).
2.3.8 Global DNA methylation analysis on repetitive elements
Finally, the DNA methylation levels of the genome dispersed repetitive elements human en-
dogenous retrovirus type K (HERVK) and long interspersed nuclear element-1 (LINE1) were
evaluated using methylation-dependent primer extension assays. For every CpG analyzed,
mean methylation indices (MIs, similar to Illumina’s β-values) were very similar among the
heavy and light co-twins and no signicant dierences were observed (p>0.05) (Table 2.5).
Some CpGs strongly correlated with PTPN7 methylation (HERVK CpG1 r=-0.89, LINE1 CpG1
r=-0.49), indicating that global methylation levels are lower in buccal epithelium. Accord-
ingly, when we repeated the analysis following PTPN7 methylation adjustment, no signicant
associations could be detected (data not shown).
2.4 Discussion
We aimed to identify loci that remain dierentially methylated in adult body uid cells as
a consequence of a poor prenatal environment. Our hypothesis was that DNA methylation
changes induced by adverse intra-uterine conditions are detectable in adult MZ MC twins with
large intra-pair weight dierences at birth, irrespective of their health status in adulthood. We
used Innium HumanMethylation450 BeadChip to prole DNA methylation changes genome-
wide, and applied 454 GSFLX-based single-molecule deep bisulte sequencing (DBS) to vali-
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Table 2.5: Methylation analysis of HERVK and LINE1 in the 16 discordant MZ twins (pair 1 excluded).
Element CpGa Mean MI
Heavy Co-twins
Mean MI
Light Co-twins
Mean MI
dierence
pb
HERVK 1 0.61 ± 0.05 0.63 ± 0.02 -0.02 ± 0.06 0.38
2 0.36 ± 0.01 0.36 ± 0.01 0.0008 ± 0.006 0.86
LINE1 1 0.58 ± 0.02 0.58 ± 0.02 -0.0007 ± 0.01 0.86
2 0.37 ± 0.02 0.38 ± 0.02 -0.004 ± 0.02 0.50
All procedures (including bisulfite treatment, PCR and SIRPH assay) were performed in duplicate; the mean
values were used for the statistical analysis. Data are expressed as mean MI ± SD. MI = methylation index, MI
dierence = MI heavy co-twin – MI light co-twin. aCpG 1 and 2 corresponds to the CpG tagged by SNuPE
primer 1 and 2, respectively. bHeavy vs. light calculated using a Wilcoxon signed-rank test.
date potential methylation variable positions (MVPs). To assess possible changes in repetitive
element methylation, we applied bisulte-based primer extension HPLC assays (SIRPH). De-
spite cellular composition dierences, our thorough DNA methylation analyses show that the
methylomes in saliva of birth weight discordant MZ MC twins are very similar.
All analyses were performed on DNA isolated from saliva, a bio-uid that contains ade-
quate amounts of DNA and is easy accessible via a totally non-invasive method. Assuming
that MVPs are maintained in a systemic way, saliva DNA should be suitable for diagnostic
and prognostic purposes, like any other accessible body uid such as blood. However, we
observed that the composition of saliva can be highly variable, possibly causing confound-
ing eects since DNA methylation signatures are cell type-specic. Such hardly controllable
eects should be accounted for, when studying the association of DNA methylation to the
phenotype of interest. This can either be done by separating cells prior to the methylation
analysis, which is usually a challenging experimental task, or by using methods that allow
a post-sampling adjustment for cellular composition. Indeed, here we show that cell type-
specic epigenetic signatures of cells can be used for such post-sampling adjustment.
When (young) MZ twins are used for epigenetic studies, tissues other than blood are pre-
ferred (often buccal epithelium). This is because MZ twins often have a shared blood supply
during intra-uterine development, and therefore epigenetically discordant MZ twins can dis-
play the same epigenetic defect in blood while for instance in broblasts the epigenetic defect is
restricted to the aected twin only [Tierling et al., 2011; Weksberg et al., 2002]. Interestingly,
Kaminsky et al. [Kaminsky et al., 2009] observed that methylation proles of buccal swab
DNA are signicantly more variable within MZ MC twins compared to MZ DC twins. They
suggested that this epigenetic dissimilarity may reect dierences in epigenetic divergence
among embryonic cells at the time of splitting. Since buccal swabs also contain saliva [Thiede
et al., 2000], our results indicate that the previously reported epigenetic dierences within MZ
MC twins observed by Kaminsky et al. [Kaminsky et al., 2009] might be caused by sample
composition-attributed variation of e.g. leukocytes and epithelial cells [Thiede et al., 2000],
rather than a real developmental dierence.
Our results show that MZ twins have very similar genome-wide DNA methylation pro-
les. After controlling for sample composition-attributable variation, we obtained 3153 CpGs
that were dierentially methylated between the heavy and light co-twins with nominal sig-
nicance (p<0.01) of which only 45 CpGs showed an absolute mean β-value dierence >0.05.
To verify whether these loci were true BW-MVPs, eight of these 45 loci were validated us-
ing state-of-the-art targeted DBS. When correlating the Innium with the DBS data for each
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individual separately, the two technologies gave consistent results and the correlations were
high. However, the DBS data did not replicate the DNA methylation dierences between the
heavy and light co-twins. Nevertheless, when correlating the Innium with the DBS data
for each validated CpG site separately, we observed a wide range of Pearson correlation co-
ecient values. The highest correlation was observed for the CpG in the buccal epithelium
marker PTPN7 (r=0.91), which served as a positive control, and the buccal content-aected
PAPOLA and IGF2BP2 CpGs (r=0.87 and r=0.80, respectively) (Table 2.3). This indicates that
true biological variation, linked to the variation of the cell type proportions in saliva samples,
is conrmed by DBS. On the other hand, the decreasingly signicant correlation values ob-
served for the remaining CpGs indicates low or absent true biologically-meaningful variation
in the measured DNA methylation levels. The fact that DBS did not replicate the dierences
between heavy and light co-twins, might thus indicate that the few BW-MVPs identied using
the HumanMethylation450 assay are the result of technical noise, that is, false positives. This
is coherent with the fact that in case a more stringent signicance criteria would have been
used to correct for multiple testing, none of the BW-MVPs would have been called signicant.
In addition, DAVID tool did not identify enrichments in any of the numerous functional an-
notation categories for the genes underlying the BW-MVPs [Huang et al., 2009], indicating
that there was no evidence of coordinated DNA methylation changes at BW-MVPs that would
reect potential regulation events in groups of loci.
Compared to other widely used genome-wide methylation proling technologies that are
based on methylation-sensitive restriction digestion (HELP, CHARM) or anity-based enrich-
ment (MeDIP, MethylCap), the Innium assay has ahigher resolution (single base pair) and
therefore expected to have a higher sensitivity [Rakyan et al., 2011]. However, whether the
Innium assay is sensitive enough to distinguish between an absolute mean β-value dierence
0.05-0.07 is unclear. Bibikova et al. [Bibikova et al., 2009] estimated that with the Innium Hu-
manMethylation27 BeadChip on average β-value dierences of 0.14 or larger can be detected,
with a higher sensitivity at unmethylated and fully methylated sites (e.g. at unmethylated
promoters on average β-value changes of 0.07 were detectable). We made an attempt to esti-
mate the technical noise level by examining the 64 SNP probes that are present on the chip.
For the twin samples that were heterozygous, the SNP probes showed an absolute intra-pair
mean β-value dierence of 0.00-0.03. Hence, trying to replicate absolute mean β-value dif-
ferences of 0.05-0.07 can be a realistic goal, assuming that all probes on the chip perform as
good as these SNP probes. Nonetheless, this is a strong assumption and a number of technical
issues are likely to undermine the performance of the HumanMethylation450 BeadChip, e.g.
dierences between the Innium I and II technologies, multiple CpGs in the probe sequences,
cross-hybridization of (repetitive) sequences (e.g. PPARGC1B contains Alu element) [Chen
et al., 2013; Dedeurwaerder et al., 2011]. On the other hand, whether DBS, which is currently
considered as the gold standard, is sensitive enough to replicate a 5% methylation dierence
is also questionable. On average we obtained 988 high quality reads per sample per amplicon,
thus the lack of replication is unlikely to be the result of low quality DBS data. Still, in three
of the sequenced amplicons informative SNPs were present and for the heterozygous twins a
mean absolute intra-pair allele frequency dierence of 0.05-0.08 was observed. This indicates
that DBS also suers from technical variation, which is probably the result of random bias
induced by PCR amplication. Since all currently used diagnostic methods are PCR-based,
focusing on small methylation dierences might currently not be worthwhile. These aspects
should be more carefully considered in EWAS. Taken together, we cannot exclude the possi-
bility that the BW-MVPs identied in this study are false positives. The fact that the detected
dierences are on the border of technical variation, makes it unlikely that they can be regarded
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as biologically signicant.
The rst EWAS for birth weight was performed on CD34+ hematopoietic stem cells from
cord blood of ve IUGR neonates and ve controls using the HELP assay and identied moder-
ate changes at 56 loci [Einstein et al., 2010]. The authors validated only one locus, the HNF4A
promoter, using another technology (bisulte MassArray). We also analyzed this locus using
DBS, but observed no signicant dierences between the discordant twins. Since the authors
studied CD34+ hematopoietic stem cells from cord blood, our negative results might indicate
that the changes they observed are not maintained until adulthood or that they are specic for
CD34+ hematopoietic stem cells. On the other hand, they only observed a 6% methylation dif-
ference between IUGR neonates and controls [Einstein et al., 2010], which remains according
to our technical observations dicult to replicate.
Currently, six genome-wide DNA methylation studies for birth weight have been published
of which the details are presented in Table 2.6 [Adkins et al., 2012; Banister et al., 2011; Einstein
et al., 2010; Fryer et al., 2011; Gordon et al., 2012; Turan et al., 2012]. All of them studied
fetal tissues i.e. umbilical cord blood, umbilical vascular endothelial cells and/or placenta.
One study used the HELP assay [Einstein et al., 2010], while the other ve studies used the
HumanMethylation27 BeadChip. In addition, one of the studies [Gordon et al., 2012] also
used a twin design (18 MZ and 10 DZ), however the authors did not select the twins based
on birth weight discordancy and therefore the mean relative intra-pair birth weight dierence
of the MZ twins included in their study was only 10.1%. All these EWAS studies for birth
weight reported a number of dierentially methylated loci. However, only one gene (PRSS3)
was reported by more than one study [Einstein et al., 2010; Fryer et al., 2011] and none of
the loci identied in these studies was signicant in our analysis. Moreover, none of these
studies performed an intense technical validation comparable to the one made in our study
or controlled for sample composition-attributed variation. In summary, while the number
of potential candidate loci that become dierentially methylated due to an adverse prenatal
environment is rapidly growing, the validity of these eects, perhaps with the exception of
PRSS3 that was reported by two studies, is questionable since there is no overlap between the
reported loci.
Some studies also examined the relation between birth weight and global DNA methyla-
tion levels by assessing repetitive elements. Fryer et al. [Fryer et al., 2011] observed in 12
cord blood samples that LINE1 methylation was higher among the heavier newborns. How-
ever, Michels et al. [Michels et al., 2011] observed in cord blood of 319 newborns a signi-
cant correlation between low birth weight, high birth weight and preterm birth with reduced
LINE1 methylation, while in placental tissue they observed that low birth weight individu-
als had higher LINE1 methylation compared to normal birth weight individuals. In addition,
Wilhelm-Benartzi et al. [Wilhelm-Benartzi et al., 2012] observed in 184 placenta samples a pos-
itive association between LINE1 and AluYb8 methylation and birth weight. We did not observe
any signicant dierences in LINE1 and HERVK methylation between the heavy and light co-
twins, but we observed dierences in LINE1 and HERVK methylation between leukocytes and
epithelial cells. Further studies should consider such sample composition-attributed variation
as it might be responsible for the inconsistent reports concerning global DNA methylation and
intra-uterine growth.
The majority of the genome-wide methylation studies for birth weight published thus far
used a population based design [Adkins et al., 2012; Banister et al., 2011; Einstein et al., 2010;
Fryer et al., 2011; Turan et al., 2012], thus their outcome variable birth weight suers from vari-
ation induced by gestational age, gender, maternal factors (e.g. maternal weight, age, parity)
and, most importantly, genetic dierences. For all these factors our twin study is controlled
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and hence methylation variations associated with them should be eliminated. Since we fail
to identify any major methylation change, the contribution of such variable factors in data
interpretation should be considered more carefully. One might argue that our negative out-
come is the result of the shared intra-uterine blood supply of MZ MC twins, which “diluted”
any dierential methylation signals. Nevertheless we are aware of this problem and focused
on adult twins, since we earlier observed that epigenetic discordance in MZ MC twins, that
even suered from twin-to-twin transfusion syndrome (TTTS), becomes measurable in saliva
when they grow older [Tierling et al., 2011]. Moreover, for twin pair 2 it was recorded that
they suered from TTTS in utero. In case the severely unbalanced intra-uterine blood ow
would still have an impact on their leukocyte populations, then for this pair one would expect
to see a higher intra-pair correlation, which was not higher than expected on average (see
Figure 2.S7).
Since none of the twins reported in the questionnaire to suer from acute diabetes, cancer,
cardiovascular or cerebrovascular diseases, one might reason that our approach enriched for
healthy individuals. However, the twins were only recruited based on being very discordant
for birth weight and adult health status was never used as an inclusion criteria. In addition,
the EFPTS is a prospective and population-based twin registry [Derom et al., 2006]. Therefore
neither our selection strategy nor the EFPTS ever enriched for healthy individuals. In addition,
a medical examination was not conducted for this study, therefore the actual adult health status
of the twins is unknown. Our twin sample is also relatively young and clear symptoms are
expected to appear at later age. Moreover, manifestation of metabolic disorders is strongly
related to lifestyle factors.
Finally, through the post-hoc power calculation presented in Table 2.S7, we demonstrate
that our approach has sucient power to detect an absolute mean β-value dierence of at least
0.05. To exclude that our negative study outcome is the result of a high false negative rate,
we applied a nominal signicance threshold of 0.01 (gives approximately 99% power). Note
that the statistical analyses show that our design can also easily detect smaller methylation
dierences, since 3108 out of the 3153 CpGs having a p<0.01 in the nal analysis showed
an absolute mean β-value dierence below 0.05. However, these small dierences are not
reproducible using DBS and thus remain in the range of technical inaccuracy.
2.5 Conclusions
Our study is based on the assumption that methylation changes caused by a poor prenatal en-
vironment remain throughout life in many cell types (systemic). The fact that we used saliva
instead of whole blood, is in this respect an advantage since saliva contains ectoderm- and
mesoderm derived cells, while blood only contains mesoderm-derived cells. Nevertheless, our
negative results might indicate that the methylation dierences are restricted to biologically
relevant metabolic tissues (e.g. pancreas, liver, muscle, adipose tissue) and thus absent in cells
composing saliva. It is also possible that the methylation dierences are temporary and do not
maintain until adulthood. Due to placental blood vessel connections, blood of young MZ MC
birth weight discordant twins is not suitable for epigenetic studies. Studying young MZ DC
twins would be an alternative as they do not experience intra-uterine vascular connections,
but they are more rare (33% of all MZ twins) and have smaller intra-pair birth weight dier-
ences. On the other hand, the HumanMethylation450 BeadChip covers just approximately 2%
of all CpGs in the genome and gene bodies and regulatory intergenic regions are underrep-
resented on the chip. In addition, birth weight discordancy in MZ MC twins can arise from
dierent pathologies and in this respect our group is certainly not homogeneous (e.g. dier-
64
CHAPTER 2. BIRTH-WEIGHT EWAS IN TWINS
ent locations of umbilical cord insertion). Despite of these limitations, we can conclude that
genome-wide and locus specic DNA methylation perturbations are small and not abundant in
cells composing saliva (i.e. epithelium and leukocytes) of individuals that experienced severe
intra-uterine growth restriction.
2.6 Accession codes
HumanMethylation450 proles of the twin samples are available in GEO under accession no.
[GSE39560]. The DBS data is available in the Sequence Read Archive under accession no.
[SRA075928].
2.7 Supplementary Data
Supplemental Methods
Infinium HumanMethylation450 data pre-processing
The raw data from the Illumina scanner after the internal image processing stage were loaded
for initial analysis into Genome Studio software (Illumina, San Diego, CA, USA). The back-
ground level – dened as the 5th percentile of the negative control probe signal distribution –
was subtracted from the intensities at each probe in each channel separately, setting the neg-
ative values to 0. The intensities were then normalized by multiplying the intensity at each
probe by the scaling factor. The latter was dened for each sample as the ratio of the mean
intensity of (positive) normalization control probes in this sample to same mean intensity in
an arbitrary-selected reference sample ("normalization to internal controls"). The data was ex-
ported as Genome Studio analysis report, and loaded into R using themethylumi library (http:
//bioconductor.org/packages/2.5/bioc/html/methylumi.html). The sample-dependent
and sample-independent quality control probes were visualized using the HumMethQC27 li-
brary (see Figure 2.S2 and 2.S3). Low-quality probes were dened as those having a detection
p-value (one minus quantile of the negative probe intensity distribution into which the in-
tensity of the given probe falls) greater than or equal to 0.001 in one of the samples, and
were excluded. The methylation level for each probe was estimated as β-value and M-value
[Du et al., 2010] using methylumi routines. We set the oset α, added to the intensities of
methylated and unmethylated probes in order to decrease the inuence of the extremely low
intensities on the resulting methylation levels, to be equal 25.
Adjustment for cell type heterogeneity
Since the uneven cellular composition could undermine the downstream statistical analysis,
we decided to normalize the Innium data so that the methylation level at each probe becomes
linearly independent of the cellular composition in the studied sample. In order to do this,
we rst selected quantitative cell type-specic markers using reference data sets of puried
cell types, supposedly present in saliva [Vidovic et al., 2012]. We composed the reference
data set of publicly available DNA methylation proles obtained with the Illumina Innium
HumanMethylation27 BeadChip (Table S1). The buccal epithelium data was obtained from 60
female samples generated by Essex et al. [Essex et al., 2013]. Leukocyte data was obtained from
Calvanese et al. [Calvanese et al., 2012], who generated HumanMethylation27 proles from
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puried leukocyte-subtypes (e.g. neutrophils, B-lymphocytes, CD4+ T-lymphocytes, CD8+ T-
lymphocytes and natural killers) that were isolated from the same blood pool. Selection of
cell type-specic markers was performed on the set of probes, which is shared between the
HumanMethylation27 and HumanMethylation450 BeadChip.
Our method is based on the assumption that the methylation level of CpGs that are highly
discriminatively methylated between buccal epithelium and leukocytes provide an estimate of
the amount of buccal epithelial cell derived DNA present in the saliva samples. As a conse-
quence, such marker CpGs can be used to adjust the methylation data for the varying cell type
composition of the saliva samples. We are aware that alternative approaches can be used to es-
timate the proportion of buccal derived DNA present in the samples (e.g Principal Component
Analysis). However, we prefer to adjust using a “physical” marker (a real CpG). which has the
advantage that in the validation phase the marker can be measured using another technology
(e.g. deep bisulte sequencing) and thus also in samples of which no array data (so no PCA
estimated cell type proportion) is available.
Although in theory, the relation between the β-value of the marker CpG and the proportion
of buccal derived DNA should be linear, in reality due to technical reasons the precise behavior
of the Innium methylation data with changing cell type composition can be quite dierent.
This is illustrated by a mixing experiment with KG1a and K562 cells, of which the mixed
proportions were proled on the Innium HumanMethylation450 BeadChip. In Figure 2.S12,
the β-values of marker CpGs that were hypermethylated in K562 (and thus hypomethylated
in KG1a) are plotted against the corresponding mixing proportions. Figure 2.S12 indicates that
the methylation values of the marker CpGs provide a good estimate of the mixed proportions,
but it also shows that many probes do not behave linear. Besides, we observed that marker
CpGs often have a dierent range of variation, e.g. β-value Buccal/ β-value Blood Marker_1 =
0.80/0.20, Marker_2 = 0.90/0.05. Accordingly, an intuitive approach like averaging methylation
data of dierent marker CpGs will not reduce noise and therefore not result in a good cell
composition surrogate for adjustment. Instead we used a model tting approach to identify
that single marker CpG of which the methylation measurements behave the most linear with
respect to the changing cell proportions.
The identication of the marker CpGs was performed as follows:
1. For each cell type c from the reference data set, all marker CpGs were ranked by the ab-
solute dierence between the methylation level in c (Mc) and the average of methylation
levels in all other contributing cell types (M¯a):
M¯a =
1
m− 1
∑
i
Mi (2.1)
where Mi is the methylation value of the CpG in the contributing cell type i of all cell
types except c, and m is the number of contributing cell types in the sample.
2. For every considered cell type the top 10 highest ranking CpGs were selected as quan-
titative marker candidates.
3. The optimal quantitative marker was determined as the one giving the best linear t to
the majority of measured CpGs in the saliva data set. For all the 450k probes, 11 one-
parameter linear models were tted, one for each candidate marker and the intercept-
only ("zero") model. Then the t of the 11 models, measured by Akaike information
criterion (AIC), was compared and the model with the lowest AIC was considered to
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give the best linear t. The candidate marker CpG which was most often generating the
best tting model, was considered as the most linear quantitative marker.
We realize that the marker CpGs could potentially be aected by genetic dierences be-
tween the samples of Essex et al. [Essex et al., 2013] and the pooled sample of Calvanese
et al. [Calvanese et al., 2012], i.e. due to SNPs in the probes or allele specic methylation
(meth-QTLs). In order to exclude this, we carefully examined the methylation levels of the
nal marker CpGs in the twin data, in which such eects can easily be detected through the
small intra-pair and large inter-pair beta-value dierences that are observed in case of a SNP
or meth-QTL. In addition, we also examined large whole blood DNA methylation (n=274) and
buccal DNA methylation (n=60) data sets of Teschendor et al. [Teschendor et al., 2010] and
Essex et al. [Essex et al., 2013], respectively. Moreover, we did an extensive annotation search
for potential presence of polymorphisms and/or other genetic variability features in the Hu-
manMethylation450 probe of the marker CpG. The results allowed to be condent that the
selected marker CpGs are not aected by genetic variation.
In case the methylation levels of the marker CpGs are correlated (confounded) with the
phenotype (low birth weight vs. high birth weight), the adjustment procedure will also remove
the DNA methylation changes induced by the intra-uterine growth restriction. However, we
veried this and none of the marker CpGs is associated with the phenotype (ppaired t-test>0.10,
pWilcoxon signed rank>0.10).
Finally, the genome-wide DNA methylation data, expressed as M-values, was adjusted for
variation introduced by cellular composition dierences using standard linear regression. The
selected cell type-specic markers (Table 2.S2) were used as explanatory variables in the linear
regression model, with the methylation levels measured at each probe as the response variable.
First the adjustment was performed using the buccal epithelium marker only. For a given probe
the levels were only adjusted if the AIC of the one-parameter model was lower than the AIC
of the intercept-only, "zero" model (i.e. CpGs not aected by saliva composition do not get
adjusted by this procedure). The residuals of the tted adjustment model incremented with
the intercept term were treated as the adjusted methylation levels. The second adjustment was
done using all selected quantitative markers (Table 2.S2) as predictors and the best adjustment
model for each probe was selected from the set of all possible one- and two-parameter models
plus the “zero” model. The adjusted methylation levels were transformed into β-values via the
logit-transformation.
Association analysis and candidate selection
The hypothesis that poor prenatal conditions lead to signicant DNA methylation dierences
between the heavy and light co-twins was tested using the non-parametric Wilcoxon signed
rank test on the intra-pair β-value dierences obtained for each CpG site independently. The
intra-pair dierence was dened as β-value observed for the heavier co-twin minus the β-
value of the lighter co-twin, and the two-sided null was tested for the symmetry of the sam-
ple distribution around zero. The calculations were performed using the standard R function
wilcox.test. First the Wilcoxon signed rank test was performed on the dataset that was only
adjusted for the buccal marker. Subsequently, the analysis was repeated on a dataset that was
adjusted for additional blood derived cellular subtypes. CpGs that were signicant in both
analysis (p<0.01) and showed an absolute mean β-value dierence >0.05 in both analyses were
considered as being stably dierentially methylated between the discordant MZ twins. The
non-stringent nominal signicance threshold of 0.01 was chosen to limit the number of false
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negatives. To compensate for the substantially increased false positive rate due to multiple
testing, we carried out an extensive technical validation.
Supplemental Figures
Figure 2.S1: Pair-wise correlations for each pair of samples, calculated from ≈480,000 CpGs. Sample
labels are shown on the diagonal. Pearson correlation coeicients are shown in the upper
part of the figure and the dotplots under the diagonal illustrate a visual representation
of the similarity between two samples (H = high birth weight, L = low birth weight)
.
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Figure 2.S2: Sample-independent Infinium methylation controls. Staining controls are used to ex-
amine the eiciency of the staining step in both the red and green channels, and are
independent of the hybridization and extension step. b. Hybridization controls test the
overall performance of the Infinium assay using synthetic targets that are present in the
hybridization buer at three levels (high (5 pM), medium (1 pM) and low concentration
(0.2 pM)) and complement the sequence on the array perfectly, which allows the probe
to extend on the synthetic target as a template. The performance of the hybridization
controls should be monitored only in the green channel. c. Extension controls test the
extension eiciency of A, T, C, and G nucleotides from a hairpin probe, and their perfor-
mance should be monitored in the red (A,T) and green (C,G) channels. d. Target removal
controls test the eiciency of the stripping step aer the extension reaction. Target re-
moval controls are present in the hybridization buer RA1 and these oligos are extended
using the probe sequence as a template. This process generates labelled targets and ex-
tension from the probe does not occur. All target removal controls should result in low
signal compared to the hybridization controls, indicating that the targets were removed
eiciently aer extension. H = high birth weight, L = low birth weight.
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Figure 2.S3: (on the previous page) Sample-dependent Infinium methylation controls. a. Bisulfite
controls I use the Infinium I probe design to monitor the eiciency of the bisulfite con-
version. If the bisulfite conversion was successful, the "C" (converted) probes will match
the converted sequence and get extended. If the sample has unconverted DNA, the "U"
(unconverted) probes will get extended. Performance of bisulfite controls C1, C2 and
C3 should be monitored in the green channel, and controls C4, C5 and C6 should be
monitored in red channel. b. Bisulfite controls II use the Infinium II probe design to
monitor eiciency of bisulfite conversion. If the bisulfite conversion reaction was suc-
cessful, the "A" base will get incorporated and the probe will have intensity in the red
channel. If the sample has unconverted DNA, the "G" base will get incorporated across
the unconverted cytosine, and the probe will have an elevated signal in the green chan-
nel. c. Non-polymorphic controls test the overall performance of the assay, from ampli-
fication to detection, by querying a particular base in a non-polymorphic region of the
genome. They allow comparing assay performance across dierent samples. One non-
polymorphic control has been designed for each of the four nucleotides (A, T, C, and G).
d. Specificity I controls are designed to monitor extension specificity for the Infinium
I probes. G/T mismatch controls check for non-specific detection of methylation sig-
nal over unmethylated background. PM controls correspond to A/T perfect match and
should give a high signal. MM controls correspond to G/T mismatch and should give
a low signal. Performance of GT mismatch controls should be monitored in both green
and red channels. e. Specificity II controls are designed to monitor extension specificity
for the Infinium II probes. Specificity II probes should incorporate the "A" base across
the non-polymorphic T and have intensity in the red channel. In case of nonspecific in-
corporation of the "G" base, the probe will have elevated signal in the green channel.
f. Negative controls target bisulfite-converted sequences that do not contain CpG din-
ucleotides. Assay probes are randomly permuted and should not hybridize to the DNA
template. The mean signal of these probes defines the system background. The perfor-
mance of the negative controls should be monitored in both the green and red channel.
H = high birth weight, L = low birth weight.
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Figure 2.S4: Pair-wise correlations for each pair of samples, including the reference dataset for whole-
blood and buccal (27k), calculated from ≈25,978 CpGs. Sample labels are shown on the
diagonal. Pearson correlation coeicients are shown in the upper part of the figure and
the dotplots under the diagonal illustrate a visual representation of the similarity be-
tween two samples. H = high birth weight, L = low birth weight.
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Figure 2.S5: Mixing experiment with KG1a and K562 cells profiled on the Infinium HumanMethyla-
tion450 BeadChip. β-values of marker CpGs hypermethylated in K562 cells (and thus
hypomethylated in KG1a cells) ploed against the corresponding mixing proportions.
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Figure 2.S6: Distribution of the correlation coeicients of the methylation values of the ≈480,000
CpGs to the methylation values of the PTPN7 CpG (cg18384097).
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Figure 2.S7: Pair-wise correlations for each pair of samples aer adjusting for cell type composition
using the PTPN7 CpG (cg18384097), calculated from ≈480,000 CpGs. Sample labels are
shown on the diagonal. Pearson correlation coeicients are shown in the upper part of
the figure and the dotplots under the diagonal illustrate a visual representation of the
similarity between two samples. H = high birth weight, L = low birth weight.
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Figure 2.S8: Examples of methylation profiles generated using the deep bisulfite sequencing data of
the APPL2, PPARGC1B, PHKG2 and PTPN7 amplicons. The bold CpGs correspond to the
BW-MVPs identified using the Infinium HumanMethylation450 BeadChip.
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Figure 2.S9: Correlation plots in which the (unadjusted) Infinium 450K data of the validated CpGs is
ploed against the (unadjusted) deep bisulfite sequencing (DBS) data for every sample
separately. Infinium data are expressed as β-value. DBS data are expressed as mean
methylation level, in which the methylation level is calculated by dividing the number
of reads in which the particular CpG is methylated by the total number of sequenced
reads. H = high birth weight, L = low birth weight.
Figure 2.S10: Box plot of the correlation coeicients calculated between the Infinium 450K data and
the deep bisulfite sequencing (DBS) data of the validated CpGs for every individual
sample.
77
CHAPTER 2. BIRTH-WEIGHT EWAS IN TWINS
Figure 2.S11: Comparison of the (unadjusted) Infinium data with the (unadjusted) deep bisulfite se-
quencing (DBS) data of the validated BW-MVPs and the buccal marker (PTPN7) of the
17 discordant MZ twin pairs. Infinium data are expressed as β-value. DBS data are ex-
pressed as mean methylation level, where the methylation level is calculated by dividing
the number of reads in which the particular CpG is methylated by the total number of
sequenced reads. H = high birth weight, L = low birth weight.
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Figure 2.S12: Continuation of Figure 2.S11.
Figure 2.S13: Box-plot of the intra-pair dierences in Beta-values of the 64 SNPs present on the In-
finium HumanMethylation450 BeadChip before (a) and aer (b) normalisation using
internal controls and background subtraction by the GenomeStudio soware (Methy-
lation Module v1.8).
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Supplemental Tables
Table 2.S1: DNA methylation profiles used to create the cell-type reference data set.
Cell type/Tissue Accession #samples Reference Comments
Tissues
Whole blood GEO: GSE19711 274a [Teschendor et al., 2010]
Buccal epithelium GEO: GSE25892 66a [Essex et al., 2013] Mouth scrabs
Purified cell types
Neutrophils (granulo-
cytes)
GEO: GSE30090 1b [Calvanese et al., 2012] Centrifugation, neg-
ative selection while
sorting for other cell
types
B-lymphocytes GEO: GSE30090 1b [Calvanese et al., 2012] Centrifugation,
CD19+ staining and
sorting
CD4+
T-lymphocytes
GEO: GSE30090 1b [Calvanese et al., 2012] Magnetic bead isola-
tion
CD8+
T-lymphocytes
GEO: GSE30090 1b [Calvanese et al., 2012] Magnetic bead isola-
tion
NK cells GEO: GSE30090 1b [Calvanese et al., 2012] Centrifugation,
CD56+ staining and
sorting
aThe reference profiles were obtained by averaging of the profiles of individual samples. bThe reference profiles
were obtained by methylation profiling of the pooled samples (5 individuals). GEO = Gene Expression Omnibus.
Table 2.S2: Cell type-specific quantitative markers used as explanatory variables in heterogeneity ad-
justment.
Probe IDa Cell-type Buccal ep-
ithelium
Neutro-
phils
B-cells CD4+
T-cells
CD8+
T-cells
NK-
cells
Chr. Position Gene
cg18384097 Buccal 0.82 0.04 0.06 0.04 0.04 0.09 1 202129566 PTPN7
cg20748065 Neutrophils 0.79 0.02 0.78 0.92 0.85 0.69 7 75583421 POR
cg00226923 B-cells 0.82 0.96 0.01 0.85 0.78 0.80 6 36972027 FGD2
cg22858308 CD4+
T-cells
0.93 0.94 0.95 0.19 0.68 0.75 6 143095613 HIVEP2
cg10163825 CD8+
T-cells
0.07 0.10 0.15 0.18 0.74 0.15 16 776685 -
cg06900776 NK-cells 0.28 0.02 0.01 0.10 0.12 0.78 X 100878107ARMCX3
aOicial Illumina Infinium probe identifier, valid both for Illumina HumanMethylation27 and HumanMethyla-
tion450 BeadChips.
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Table 2.S3: Characteristics of the 45 CpG sites that are significantly dierentially methylated between
the heavy and light co-twins (BW-MVPs) identified using the Infinium HumanMethyla-
tion450 BeadChip.
CpG
Number
Mean
β-
value
dierence
P-
value
Chromosomal
position
Gene
name
Gene region Relation
to
CpG
island
Enh. AbB
1 cg16826055 0.06 0.00003 Chr 7: 41087207 Yes Yes
2 cg02409150 -0.06 0.00003 Chr 16: 30764007 PHKG2 Body S_Shelf
3 cg12170649 -0.06 0.00006 Chr 12: 105622107 APPL2 Body Yes
4 cg26404226 -0.05 0.00006 Chr 10: 90686467 Yes
5 cg18699337 -0.07 0.00009 Chr 17: 44159144 KANSL1 Body Yes Yes
6 cg05518778 -0.08 0.00031 Chr 7: 148730143 S_Shelf Yes
7 cg07574216 -0.08 0.00043 Chr 3: 156394398 5’UTR, TSS1500 S_Shore Yes
8 cg21234955 -0.07 0.00043 Chr 9: 97713896 C9orf3 Body Yes Yes
9 cg12149795 -0.05 0.00043 Chr 21: 47882121 DIP2A Body S_Shelf Yes
10 cg14696311 -0.07 0.00058 Chr 13: 114855198 RASA3 Body S_Shelf Yes Yes
11 cg09683440 0.06 0.00058 Chr 16: 83869927 Yes Yes
12 cg02350090 -0.06 0.00058 Chr 5: 1951736 S_Shore
13 cg14123607 0.07 0.00076 Chr 9: 72164709 APBA1 5’UTR
14 cg05680237 0.06 0.00101 Chr 6: 27103185 N_Shelf Yes
15 cg13071869 -0.06 0.00101 Chr 3: 112948716 BOC 5’UTR Yes Yes
16 cg03839714 -0.07 0.00131 Chr 10: 31361534 Yes Yes
17 cg22979546 -0.05 0.00131 Chr 15: 28389947 HERC2 Body Yes
18 cg15049370 -0.07 0.00168 Chr 5: 149186389 PPARGC1Body Yes Yes
19 cg04416414 0.07 0.00168 Chr 19: 14260587 LPHN1 3’UTR N_Shore Yes
20 cg10984962 -0.07 0.00168 Chr 2: 236462202 AGAP1 Body Yes Yes
21 cg14868128 -0.06 0.00168 Chr 6: 22367352 Yes Yes
22 cg08846459 -0.06 0.00168 Chr 5: 2176047
23 cg15487251 -0.05 0.00168 Chr 3: 185544216 IGF2BP2 TSS1500 S_Shore Yes
24 cg25064052 -0.05 0.00168 Chr 4: 166216151 KLHL2 Body Yes Yes
25 cg21450228 -0.05 0.00214 Chr 3: 23727711 Yes Yes
26 cg10773972 -0.07 0.00269 Chr 15: 81035670 FAM108C1Body Yes Yes
27 cg20438460 -0.05 0.00269 Chr 2: 146580994 Yes Yes
28 cg15940337 -0.05 0.00269 Chr 8: 142456489 FLJ43860 Body S_Shelf Yes Yes
29 cg08561071 0.06 0.00336 Chr 19: 41627236 CYP2F1 Body N_Shelf Yes
30 cg10156499 -0.05 0.00336 Chr 11: 112161291 S_Shore Yes Yes
31 cg02832477 -0.06 0.00418 Chr 2: 121501895 S_Shelf
32 cg13181022 0.05 0.00418 Chr 12: 69247976 CPM 3’UTR
33 cg00587523 0.06 0.00516 Chr 17: 46212998 SKAP1 3’UTR
34 cg24994002 0.06 0.00516 Chr 5: 14118611 Yes
35 cg04416247 -0.05 0.00516 Chr 3: 85213671 CADM2 Body Yes Yes
36 cg24049629 0.07 0.00763 Chr 3: 50376475 RASSF1 TSS1500, Body N_Shore Yes
37 cg25828093 0.07 0.00763 Chr 8: 26041003 Yes Yes
38 cg22768222 0.06 0.00763 Chr 6: 45383690 RUNX2 Body N_Shelf
39 cg12394706 0.06 0.00763 Chr 8: 99988676 S_Shore Yes
40 cg10362113 0.06 0.00763 Chr 14: 96978537 PAPOLA Body Yes Yes
41 cg20540235 -0.08 0.00919 Chr 8: 91683243 Yes Yes
42 cg13035743 0.06 0.00919 Chr 6: 32119685 PRRT1 1st Exon, 5’UTR S_Shore Yes Yes
43 cg26544458 -0.06 0.00919 Chr 12: 109045006 CORO1C Body Yes
44 cg12222588 0.05 0.00919 Chr 18: 34823808 CELF4 3’UTR Island Yes
45 cg07965300 0.05 0.00919 Chr 12: 56368138 RAB5B 5’UTR Island Yes
Bold and underlined CpG sites were validated using deep bisulfite sequencing. β-value dierence = β-value
heavy co-twin – β-value light co-twin, Chr = chromosome, NA = not applicable, Shelves = 2-4 kb from CpG
island, Shores = 0-2 kb from CpG island, TSS200 = within 200 bp from transcription start site, TSS1500 = within
1500 bases from transcription start site, UTR = untranslated region, Enh.= Enhancer, AbB = Aected by buccal.
Table 2.S4: Distribution of the samples across the beadchips, detected CpGs (detection p-value<0.001)
and the corresponding call rate per sample.
Pair Twin Array Row Column Detected
CpGsa
Call rateb
1 H 1 1 1 481967 99.9
L 1 2 1 481792 99.9
2 H 1 3 1 481942 99.9
L 1 4 1 481839 99.9
3 H 1 5 1 481902 99.9
L 1 6 1 481826 99.9
4 H 1 1 2 481937 99.9
L 1 2 2 481923 99.9
5 H 1 3 2 481876 99.9
L 1 4 2 481968 99.9
6 H 1 5 2 480062 99.5
L 1 6 2 481727 99.8
7 H 2 1 1 482018 99.9
L 2 2 1 481996 99.9
8 H 2 3 1 481949 99.9
L 2 4 1 481913 99.9
9 H 2 5 1 481880 99.9
L 2 6 1 481048 99.7
10 H 2 1 2 481644 99.8
L 2 2 2 481941 99.9
11 H 2 3 2 481934 99.9
L 2 4 2 481941 99.9
12 L 2 5 2 481800 99.9
H 2 6 2 481775 99.9
13 H 3 2 2 481873 99.9
L 3 3 2 481843 99.9
14 H 3 4 2 481300 99.8
L 3 5 2 481767 99.9
15 L 3 6 2 481663 99.8
H 4 1 1 481806 99.9
16 H 4 2 1 481839 99.9
L 4 3 1 481845 99.9
17 L 5 5 2 481888 99.9
H 5 6 2 481772 99.9
aNumber of CpGs with a detection p-value<0.001. bCall rate (%), based on a detection p-value <0.001. Total
number of CpGs are 482421. H = high birth weight, L = low birth weight.
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CHAPTER 2. BIRTH-WEIGHT EWAS IN TWINS
Table 2.S6: Reaction conditions and primer sequences of the SIRPH analysis.
Gene/
element
Region SNuPE primer 1 SNuPE primer 2 Acetonitril
Gradient
Oven
Tem-
pera-
ture
HERVK LTR 5’-TAGGGATATAAAAATTG-3’ 5’-GGAAAGATTTGAT-3’ 15 min:
5%-7.5%
50°C
LINE1a 5’ UTR
CpG
island
5’-CCTAACTCCTTAC-3’ 5’-CCCCTTTCTTTAACTC-3’ 13 min:
4.75%-7.25%
50°C
SNuPE reactions were performed starting with 2 min denaturation at 96°C followed by 50 cycles of 96°C for 20 s,
50°C for 30 sec and 60°C for 30 sec. Products are loaded directly onto the DNASepTM column (Transgenomic) and
separated applying the respective acetonitril gradient. aExtended with ddATP and ddGTP. LTR = long terminal
repeat.
Table 2.S7: Statistical power of the twin study.
Magnitude of the correlation Power at
alpha = 0.01
Power at
alpha = 1 · 10−4
Power at
alpha = 1 · 10−6
0.0 0.99 0.65 0.11
0.2 1.00 0.80 0.21
0.4 1.00 0.94 0.40
0.6 1.00 1.00 0.75
0.8 1.00 1.00 1.00
1.0 1.00 1.00 1.00
The table shows the statistical power to detect a mean β-value dierence of 0.05 with a sample size of 16 twin
pairs based on a standard deviation of 0.025 (which is the true median standard deviation observed in the data)
using a two-sided paired T-test.
Abbreviations
APBA1 = Amyloid beta A4 precursor protein-binding family A member 1
APPL2 = Adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper con-
taining 2
BW-MVP = Birth weight associated methylation variable positions
DBS = Deep bisulte sequencing
DC = Dichorionic
DZ = Dizygotic
EFPTS = East Flanders Prospective Twin Survey
EWAS = Epigenome-wide association study
GEO = Gene Expression Omnibus
GWAS = Genome-wide association study
HELP = HpaII tiny fragment enrichment by ligation-mediated PCR
HERVK = Human endogenous retrovirus type K
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HNF4α = Hepatocyte nuclear factor 4 alpha
IGF2BP2 = Insulin-like growth factor 2 mRNA-binding protein 2
IP-RP-HPLC = Ion-pair reversed-phase high-performance liquid chromatography
IUGR = Intra-uterine growth restriction
LINE1 = Long interspersed nuclear element-1
MC = Monochorionic
MI = Methylation index
MVP = Methylation variable positions
MZ = Monozygotic
PAPOLA = Poly(A) polymerase alpha
PHKG2 = Phosphorylase kinase, gamma 2 (testis)
PPARGC1B = Peroxisome proliferator-activated receptor gamma coactivator 1-beta
PTPN7 = Protein tyrosine phosphatase non-receptor type 7
RUNX2 = Runt-related transcription factor 2
SIRPH = Single-nucleotide primer extension assays in combination with ion-pair reversed-
phase high-performance liquid chromatography separation techniques
SNP = Single nucleotide polymorphism
SNuPE = Single nucleotide primer extension
TTTS = Twin-to-twin transfusion syndrome
T2D = Type 2 Diabetes
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Abstract
We present RnBeads, a software tool for large-scale analysis and interpretation of
DNA methylation data. A user-friendly, automated and customizable analysis work-
ow gives rise to detailed hypertext reports. Supported assays include whole genome
bisulte sequencing, reduced representation bisulte sequencing, Innium microar-
rays, and any other protocol that yields high-resolution DNA methylation data. Rn-
Beads facilitates reproducible analysis of epigenome-wide association studies, cancer
epigenome proling and many other applications of DNA methylation mapping.
Keywords: DNA methylation analysis, computational epigenetics, whole genome
bisulte sequencing, reduced representation bisulte sequencing, epigenotyping mi-
croarrays, Illumina Innium HumanMethylation450 assay, bioinformatics software,
epigenome-wide association studies, medical epigenomics
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3.1 Main text
DNA methylation is an important epigenetic mark and widely studied in the context of biolog-
ical processes and diseases. Several assays are now available for mapping DNA methylation
genome-wide, at high resolution and in a large number of samples. Whole genome bisulte se-
quencing (WGBS) provides comprehensive genome-wide coverage (approximately 28 million
CpGs in the human genome) at the cost of resequencing the whole genome [Lister et al., 2009].
Reduced representation bisulte sequencing (RRBS) focuses the sequencing on a dened sub-
set of DNA fragments that contain at least one CpG each, thereby covering approximately two
million individual CpGs in the human genome [Gu et al., 2010]. The Innium HumanMethy-
lation450 (“450k”) assay uses an adapted genotyping microarray to measure DNA methylation
at approximately 0.5 million CpGs [Bibikova et al., 2011]. In addition, enrichment-based assays
such as MeDIP-seq [Down et al., 2008] and restriction-enzyme based MRE-seq [Harris et al.,
2010] can be combined with bioinformatic algorithms to infer high-resolution DNA methy-
lation data for a large proportion of CpGs [Stevens et al., 2013]. The technical accuracy and
reproducibility of these assays is generally high [Bock et al., 2010; Harris et al., 2010], but bioin-
formatic analysis of the resulting datasets remains a complex task with many pitfalls [Bock,
2012].
We developed the RnBeads software with the goal of establishing a user-friendly work-
ow for the analysis and interpretation of large-scale DNA methylation data. RnBeads builds
upon extensive prior research on bioinformatic and statistical methods for DNA methylation
analysis. We have reviewed the features of 22 related software tools (Table 3.S1), and based
on our assessment of existing algorithms and software we dened the following key elements
of RnBeads: (i) Support for all genome-scale and genome-wide DNA methylation assays that
provide single-basepair resolution; (ii) extensive functionality for high-level DNA methyla-
tion analysis, including data visualization, quality control, exploratory analysis, handling of
batch eects, correction for tissue heterogeneity, and dierential DNA methylation analysis;
(iii) generation of interactive reports that allow users to select results and adjust parameters
without having to rerun the analysis; (iv) implementation of a standardized pipeline mode that
is essentially self-conguring, with the additional option to adapt the workow using custom
parameter settings and/or custom scripts; (v) exibility to run RnBeads on a personal com-
puter, on high-performance computing infrastructure, via a web-based service and in a cloud
computing environment, depending on the scale of the analysis; (vi) sucient performance to
process – on a suitable scientic computing cluster – the largest DNA methylation datasets
that are currently available (10s of WGBS proles, 100s of RRBS proles, or 1000s of Innium
450k proles); (vii) reproducibility and easy results sharing through automatic documentation
of parameters and analysis methods in the RnBeads report.
To be able to support all protocols for large-scale DNA methylation mapping, RnBeads
builds upon existing software tools that can convert raw data into high-resolution DNA methy-
lation proles. Sequencing data should be preprocessed prior to running RnBeads using soft-
ware tools such as Bismark [Krueger and Andrews, 2011], BSMAP [Xi et al., 2012] and/or
Bis-SNP [Liu et al., 2012] (for WGBS/RRBS), MEDIPS [Lienhard et al., 2014], MEDUSA [Wil-
son et al., 2012] or BayMeth [Riebler et al., 2014] (for MeDIP-seq), or methylCRF [Stevens
et al., 2013] (for MRE-seq). Raw IDAT les from Innium 450k experiments can be imported
directly into RnBeads, in which case the preprocessing and normalization are performed by
RnBeads using low-level functionality imported from other R/Bioconductor packages (methy-
lumi, min and wateRmelon, cf. Table 3.S1). Alternatively, users can preprocess and normalize
the data prior to importing them into RnBeads, for example using the Illumina GenomeStudio
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Figure 3.1: Comprehensive analysis of DNA methylation data with RnBeads RnBeads provides a
workflow for large-scale DNA methylation analysis. The soware is R-based and can be
run locally on a personal computer (small analyses), on a scientific computing cluster (large
analyses), or in the cloud using the RnBeads web service (small analyses) or a custom in-
stance of Galaxy CloudMan (large analyses). The RnBeads workflow consists of seven
modules and is essentially self-configuring based on a sample annotation table provided
by the user. Each module generates part of the RnBeads hypertext report, which includes
method descriptions, results diagrams and links to data tables. Furthermore, all data and
annotations are stored in RnBSet objects to facilitate custom analysis workflows in R, and
they are exported for visualization using genome browsers and follow-up analyses using
other soware tools.
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software. In addition to data import, the core workow of RnBeads comprises quality control,
preprocessing and ltering, generation of genome browser tracks and data tables, optional in-
ference of confounding covariates (e.g., dierent cell type compositions), exploratory analysis
and dierential DNA methylation analysis. Each step of the workow is performed by a ded-
icated RnBeads module, as illustrated in Figure 3.1 and described in more detail in the Online
Methods.
RnBeads is straightforward to run even for inexperienced users, and the standard pipeline
requires an R installation http://r-project.org but no prior R programming experience. It
can be launched using a single R command: rnb.run.analysis(), which takes a user-provided
sample annotation table as input and extracts relevant information needed to automatically
congure the analysis. For example, annotation columns containing many unique labels are
interpreted as sample identiers, while columns with several dierent labels are regarded as
sample groups that are to be compared against each other. It is also possible to run some or
all steps of the RnBeads workow interactively and to write R scripts that operate directly on
the RnBSet object containing all DNA methylation data and sample annotations of a given
analysis. The main result of the RnBeads pipeline is an interactive hypertext report with
publication-quality gures (box plots, bar charts, heatmaps, dendrograms, histograms, den-
sity plots, quantile-quantile plots, scatter plots, deviation plots, volcano plots, word clouds,
etc.) and tables (DNA methylation proles, ranked lists of dierentially methylated regions,
attribute enrichment scores, etc.) covering a broad spectrum of topics and analyses. These
reports can be viewed from a local directory or over the Internet, and they facilitate data
integration with web-based tools such as the UCSC Genome Browser [Meyer et al., 2013], En-
sembl [Flicek et al., 2013], Galaxy [Giardine et al., 2005], the WashU Epigenome Browser [Zhou
et al., 2011], and EpiExplorer [Halachev et al., 2012].
To illustrate the practical use of RnBeads, we applied the software to two datasets for
which the underlying biology is relatively well understood. The resulting RnBeads reports
are available online (http://rnbeads.mpi-inf.mpg.de/examples.php), and it is straight-
forward to rerun these analyses using the rnb.run.example() function in RnBeads. The rst ex-
ample is based on Innium 450k proles for 124 glioblastoma patients generated by The Cancer
Genome Atlas (TCGA) project [Weisenberger, 2014]. We show how RnBeads can identify and
characterize samples with glioblastoma CpG island methylator phenotype, an epigenetically
dened subtype of brain tumors (Figure 3.S1 and Supplementary Note).
The second example focuses on an RRBS dataset describing the DNA methylation dynam-
ics of blood and skin stem cell dierentiation in mice [Bock, 2012]. This dataset comprises
13 blood and 6 skin cell populations with biological replicates and DNA methylation data for
slightly more than two million CpGs in each sample. The RnBeads analysis report provides an
overview of this dataset (Figure 3.2 and http://rnbeads.mpi-inf.mpg.de/examples.php).
The global distribution of DNA methylation is characteristically bimodal, and discrete peaks
at 33%, 50% and 67% DNA methylation disappear after ltering out CpGs with low sequencing
coverage (Figure 3.2, a). Exploratory analysis conrms that the dierence between blood and
skin cell types dominates the analysis (Figure 3.2, b), and DNA methylation levels are gener-
ally higher in blood cells than in skin cells when taking regional averages over all annotated
genes (Figure 3.2, c). Hierarchical clustering perfectly discriminates between blood and skin
cell types (Figure 3.2, d), conrming that DNA methylation patterns tend to be determined
more strongly by cellular lineage than by other properties such as cell proliferation or dier-
entiation status.
RnBeads also identies dierentially methylated regions (DMRs) that are statistically sig-
nicant and exhibit pronounced DNA methylation dierences between the two lineages. This
93
CHAPTER 3. RNBEADS
analysis is performed for single CpGs and also for sets of pre-dened genomic regions such as
CpG islands, genes, promoters and genome-wide tiling regions. Such region-of-interest based
DMR analyses provide an eective way of increasing the statistical power to detect dier-
ential DNA methylation [Bock, 2012]. The priority-ranked list of DMRs between blood and
skin cell types comprises many genes with established roles in blood and skin biology, such
as members of the homeobox and keratin gene families. Scatterplots provide a convenient
way of visualizing the overall frequency of DMRs for a region type of interest (Figure 3.2, e
shows data for entire gene loci), and volcano plots illustrate the relationship between eect
size and signicance of the DMRs (Figure 3.2, f). In Figure 3.2, the Hoxb3 gene is highlighted
as an example of blood-specic DNA methylation, and we can use the rnb.plot.locus.prole()
function of RnBeads to produce a genomic view of this locus – thus providing an example of
custom R scripting on top of the RnBSet object calculated by the standard pipeline (Figure 3.2,
g).
In addition to these two relatively small examples, we assessed the performance of Rn-
Beads when applied to large-scale datasets from the ENCODE, TCGA, IHEC, Roadmap Epige-
nomics, and BLUEPRINT consortia. All analyses could be completed within reasonable time
on a standard scientic computing cluster (Table 3.S2), and the resulting Methylome Resource
(Figure 3.S2 and http://rnbeads.mpi-inf.mpg.de/methylomes.php) provides comprehen-
sive analysis reports for some of the largest publicly available DNA methylation datasets. On
this website we also provide precongured RnBeads analyses for these large-scale epigenome
collections, which can be run along as reference maps when analyzing custom DNA methy-
lation datasets. Such reference-based analyses are particularly valuable for researchers who
have generated a specialized DNA methylation dataset and who want to assess the data qual-
ity and/or biological relevance in context with a broad range of reference methylomes. The
concept of precongured and re-runnable analyses of reference epigenome data also provides
a means of making data from large-scale epigenome mapping projects more useful for smaller-
scale and mechanism-centered studies, thereby contributing to the broader relevance of large-
scale epigenome mapping projects [Bock, 2014].
In summary, RnBeads combines good practices from prior research into a comprehen-
sive and ecient pipeline, thereby facilitating large-scale analysis and interpretation of DNA
methylation data. The software also fosters standardization, reproducibility and data shar-
ing between labs and across collaborative projects. Detailed documentation and examples of
RnBeads analyses as well as the Methylome Resource with its pre-congured analyses are
available from the RnBeads website http://rnbeads.mpi-inf.mpg.de/.
3.2 Online Methods
3.2.1 RnBeads soware overview
RnBeads is written in the R programming language (http://www.r-project.org). It is avail-
able under the GPLv3 open source license and has been submitted for inclusion in Biocon-
ductor [Gentleman et al., 2004]. RnBeads follows a modular design that supports automated
pipeline workows as well as exible interactive analyses. The default RnBeads workow is
executed by calling the rnb.run.analysis() command, either in an interactive R session or via R’s
support for scripted analyses. Optionally, an XML conguration le can be provided in order
to execute RnBeads analyses with standard parameter sets. RnBeads analyses can also be run
on the Internet using either the RnBeads web service (http://rnbeads.mpi-inf.mpg.de/we
bservice.php, which is restricted to small datasets, or using the Galaxy integration of Rn-
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Figure 3.2: (on the previous page) Analysis of DNA methylation during adult stem cell dierentia-
tion based on RRBS data. DNA methylation data for 19 cell types of the blood and skin
lineages [Bock, 2012] were reanalyzed with RnBeads. The full analysis report is avail-
able online (http://rnbeads.mpi-inf.mpg.de/examples.php). All diagrams in this fig-
ure were calculated by RnBeads but have been simplified and reformaed according to
journal standards. a. Global distribution of DNA methylation levels among retained and
removed CpGs aer the preprocessing step. b. Two-dimensional representation of DNA
methylation profiles calculated using multi-dimensional scaling based on average methy-
lation levels in 5kb tiling regions. Samples are color-coded according to tissue type. c.
Composite plot of DNA methylation levels in blood (green) and skin (orange) cell types
averaged across all genes. Each gene was covered by six equally sized bins and by two
flanking regions of the same size. Smoothing was done using cubic splines. d. Heatmap
with hierarchical clustering of DNA methylation levels among lineage marker genes that
are specifically expressed in the blood lineage. Clustering used average linkage and Man-
haan distance. e. Scaerplot of groupwise mean DNA methylation levels across genes,
with the 1,000 highest ranking dierentially methylated genes highlighted in red. Point
density is shown as blue shading. f. Volcano plot illustrating eect size and statistical
significance across genes, with the 1,000 highest ranking dierentially methylated genes
highlighted in red. Point density is shown as blue shading. g. DNA methylation profile of
the Hoxb3 gene locus. Heatmaps show DNA methylation levels of single CpGs according
to the color scheme in panel d. Smoothing of DNA methylation levels (boom) was done
using cubic splines.
Beads available from Galaxy tool shed (http://toolshed.g2.bx.psu.edu). On a suciently
powerful computing infrastructure, RnBeads can process very large cohorts (Supplementary
Table 2). To exploit the parallelization options of RnBeads and to avoid out-of-memory prob-
lems, users who want to run large analyses should carefully review the corresponding sections
in the RnBeads documentation.
When used with default options on small to medium-scale datasets, RnBeads is essentially
self-conguring: It parses a user-provided sample annotation table, congures the analysis
accordingly and then executes the RnBeads modules as shown in Figure 1. RnBeads work-
ows can also be ne-tuned using global conguration parameters, which are specied using
rnb.options(). During execution of an RnBeads analysis, each step is tracked by extensive log-
ging functionality. Upon successful completion, the modules write their results into an inter-
active report comprising method descriptions, publication-quality diagrams and links to data
tables. The reports generated by RnBeads use client-side scripting and the dynamic features
of XHTML to enable interactive data exploration of pre-calculated results. RnBeads can also
save the analysis options and data objects in binary RData objects, which makes it straight-
forward to rerun an analysis with the same parameters and to comply with the paradigm of
reproducible research [Gentleman et al., 2004]. Finally, custom workows can be designed by
running the analysis modules individually or by using R functions that operate directly on
RnBSet objects (these objects are instances of an R S4 class and constitute the RnBeads repre-
sentation of all DNA methylation and metadata within a given dataset). For instance, Figure 2g
was created using the function rnb.plot.locus.prole() for plotting genome browser like views
of individual genomic loci.
The following paragraphs describe the methodology and functionality behind RnBeads
and its modules in more detail. Further information on RnBeads is also available in the pack-
age vignette (http://rnbeads.mpi-inf.mpg.de/data/RnBeads.pdf), from the example re-
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ports (http://rnbeads.mpi-inf.mpg.de/examples.php), and from the other materials on
the RnBeads website (http://rnbeads.mpi-inf.mpg.de). RnBeads was also compared with
22 related software tools for DNA methylation analysis in terms of supported assays, data and
analysis types, visualizations and other functionalities (Supplementary Table 1). This compar-
ison includes the following software tools: BEAT [Akman et al., 2014], BiSeq [Hebestreit et al.,
2013], Bisulghter [Saito et al., 2014], BSmooth [Hansen et al., 2012], ChAMP [Morris et al.,
2014], COHCAP [Warden et al., 2013], CpGassoc [Bareld et al., 2012], DMEAS [He et al.,
2013], EpiDi (QDMR) [Zhang et al., 2013], Genome Studio (Methylation module)[Illumina
Inc., 2014], FastDMA [Wu et al., 2013], HumMeth27QCReport [Mancuso et al., 2011], IMA [Wang
et al., 2012], LumiWCluster [Kuan et al., 2010], MethLAB [Kilaru et al., 2012], methyAnal-
ysis [Du et al., 2014], methylkit [Akalin et al., 2012], MethylSig [Park et al., 2014], methy-
lumi [Davis et al., 2014], min [Aryee et al., 2014], Shinymethyl [Fortin et al., 2014] and wa-
teRmelon [Pidsley et al., 2013]. For each software tool, the supported features were determined
by manual review of the respective publication, software documentation and supplementary
material.
3.2.2 Data import
RnBeads supports a broad range of DNA methylation assays, comprising the Illumina Innium
microarray platform (in both its 450k and 27k version), various types of bisulte sequencing
(including WGBS and RRBS) and other sequencing-based methods that can be used to bioin-
formatically infer DNA methylation measurements at the level of single CpGs (such as MeDIP,
MDB-seq and MRE-seq). RnBeads analyses are congured by providing a user-generated sam-
ple annotation table that not only identies the input data les but also includes columns with
analysis-relevant information such as tissue types or disease states. RnBeads accepts a broad
range of tab-separated or comma-separated text les, and concrete examples of such sample
annotation tables are available from the RnBeads website. The data import module of RnBeads
parses the annotation table and uses the contained information to congure the analysis, for
example identifying the data les that are to be loaded and inferring which specic compar-
isons may be of interest to the user.
For Innium microarrays, it is recommended to start the analysis from signal intensity
data (IDAT) les and to let RnBeads perform the normalization and DNA methylation calling.
Alternatively, RnBeads can load pre-normalized data from Illumina GenomeStudio report les,
import Innium datasets directly from the Gene Expression Omnibus (GEO) database, or read
preprocessed data in one of several tabular formats. When IDAT les are loaded into RnBeads,
the R/Bioconductor package methylumi [Davis et al., 2014] is internally used for performing
the low-level processing. RnBeads oers several alternative options for signal intensity-based
normalization, which is an important step to reduce probe biases that could interfere with the
analysis. The RnBeads default for Innium data normalization is SWAN [Makismovic et al.,
2012], which is implemented in the min package [Aryee et al., 2014] and which – in our
experience – provides a good balance of accuracy, robustness, runtime performance and soft-
ware stability. In addition, RnBeads supports Illumina’s standard normalization procedure as
implemented in methylumi, the BMIQ normalization method [Teschendor et al., 2013], and
all modular normalization algorithms that are available in the wateRmelon package [Pids-
ley et al., 2013]. RnBeads also supports the background correction techniques implemented
in methylumi [Davis et al., 2014], which can optionally be combined with the normalization
algorithms.
For sequencing-based methods, data preparation requires steps that are highly protocol-
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dependent, including sequence alignment and DNA methylation calling for single CpGs [Bock,
2012]. These steps need to be completed prior to loading the data into RnBeads; and the
RnBeads analysis starts with importing BED les or data tables that provide the number of
methylated and unmethylated observations for each covered CpG. For example, bisulte se-
quencing data can be preprocessed with the Bismark software [Krueger and Andrews, 2011],
whose export format for DNA methylation values is directly supported by RnBeads without
the need for le conversion. Furthermore, the combination of BSMAP [Xi et al., 2012; Xi and
Li, 2009] and Bis-SNP [Liu et al., 2012] is well-suited for preprocessing reduced representation
bisulte sequencing data, and the output format of Bis-SNP is also a supported input format
for RnBeads. Enrichment-based and restriction-enzyme based assays require specialized al-
gorithms for inferring DNA methylation levels at single-basepair resolution. Software tools
such as MEDIPS [Chavez et al., 2010], MEDUSA [Wilson et al., 2012] and methylCRF [Stevens
et al., 2013] give rise to DNA methylation tables that can be imported into RnBeads as BED
les or in one of several other data le formats.
After the DNA methylation data have been loaded from any of the supported input for-
mats, RnBeads combines the data of all samples into a single RnBSet object that constitutes
the basis for all further analysis steps. This object can become very large when perform-
ing genome-wide analyses in large numbers of samples (e.g., up to 100 GB for some of the
benchmarking analyses shown in Supplementary Table 2). RnBeads thus provides the option
to maintain the RnBSet object on hard disk rather than in main memory using the  pack-
age [Adler et al., 2014], which is essential for performing large analyses on computers with
limited memory. The RnBSet object also links the DNA methylation data to genome annota-
tions such as CpG islands, genes and promoters, genome-wide tiling regions and user-dened
genomic region sets. RnBeads currently supports the human, mouse and rat genomes with
auxiliary data packages named RnBeads.hg19, RnBeads.mm9, RnBeads.mm10 and RnBeads.rn5.
The FAQ section on the RnBeads website describes how users can prepare additional genome
assemblies for DNA methylation analysis with RnBeads. The RnBSet object primarily stores
DNA methylation levels as beta values, which are used by most modules; nevertheless, Rn-
Beads also calculates M-values [Du et al., 2010] and uses them for the limma analysis as part
of the dierential DNA methylation module.
ality control
RnBeads helps the user identify certain technical and biological biases that are common in
large-scale DNA methylation datasets, which includes technical assay failures, sample mix-
ups, and batch eects (the latter are addressed by the Exploratory Analysis module and de-
scribed in the corresponding section below). Quality issues are highlighted in the RnBeads
reports, but it is ultimately left to the user to handle them appropriately, e.g. by excluding
samples with low technical data quality, by resolving sample mix-ups using genotyping data,
or by statistically correcting for batch eects. When RnBeads reports signicant quality issues
it is typically advisable to consult with an experienced statistician, in order to assess whether
or not these issues may be symptoms of more severe problems with the study design or the
assay that was used.
The detection of technical failures is assay-specic and diers between sequencing-based
and microarray-based analyses. For Innium data, RnBeads plots the microarray’s quality
control probes to monitor technical parameters such as bisulte conversion eciency and un-
specic probe hybridization. For sequencing-based datasets, the quality assessment is largely
focused on sequencing coverage, given that bisulte conversion and clonal read rates are typ-
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ically dealt with already during alignment and DNA methylation calling.
RnBeads also addresses the relatively common problem of sample mix-ups [Westra et al.,
2011], for example using the genotyping probes that are present on the Innium microarray
to conrm sample identity. As illustrated in Supplementary Figure 1a, clustered heatmaps
based on genotype measurements provide a straightforward graphical approach for identify-
ing sample duplications and mix-ups, genetically related individuals, and other types of genetic
similarity. RnBeads also calculates inter-sample distances based on these genetic data, which
enables users to quantitatively compare sample pairs with respect to their genetic similarity.
In addition, RnBeads uses DNA methylation data to predict which samples were derived from
male and female donors, based on their X-inactivation status and the presence or absence
of measurements on the Y-chromosome. This classier makes it easy to detect discrepancies
between gender information from the sample annotation table and the biological sex of the
analyzed samples, which are often indicative of sample mix-ups.
3.2.3 Preprocessing
To minimize the risk of measurement biases aecting the analysis, RnBeads implements a
framework for rule-based ltering of samples, CpG sites and DNA methylation measurements.
Filtering is performed in two steps, in order to provide exibility and to avoid biasing the nor-
malization procedure of Innium analyses with problematic samples. First, RnBeads removes
low-quality data that could bias an analysis, discarding samples and CpGs that contain a sub-
stantial fraction of measurements with low technical quality (e.g., bad detection p-value for
Innium data or low sequencing coverage in the case of bisulte sequencing data) as well as
CpGs and measurements that may be unreliable for other reasons. For example, RnBeads can
remove Innium probes overlapping SNPs that stand a high chance of inuencing DNA methy-
lation measurements; and the default pipeline implements a previously published heuristic for
identifying such probes [Nordlund et al., 2013]. Users who wish to apply dierent criteria can
also switch o the default ltering in RnBeads and instead provide a custom list of probes or
CpGs that should always be excluded. In a second step, RnBeads discards those samples and
CpGs that should be included in the normalization but not in the analysis. Examples are CpGs
with too many missing values or with zero variability in their methylation values. Further-
more, users can congure additional ltering rules and dene a custom blacklist of CpGs that
should always be excluded and/or a whitelist of CpGs that should always be retained. The
default ltering criteria of RnBeads were chosen relatively conservatively with the goal of re-
ducing the risk of spurious or misleading results. For datasets with signicant quality issues,
it can be worthwhile to change the ltering criteria in order to remove problematic probes and
samples more aggressively, whereas low-coverage bisulte sequencing data may require more
lenient ltering criteria. All ltering is tracked in the RnBeads report, and before-after plots
visualize any changes in the global distribution of DNA methylation levels that may arise from
the ltering.
3.2.4 Tracks and Tables
Before proceeding with detailed data analysis, RnBeads exports the preprocessed and quality-
controlled data in several formats, thus facilitating data visualization with genome browsers
and complementary analyses with other software tools. On the one hand, RnBeads provides
track hubs that that can be loaded into various genome browsers, thus providing a common
reference point for exploring the bigBed and bigWig data tracks that RnBeads generates. On
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the other hand, the software aggregates the preprocessed data in CSV and BED les that can be
loaded and analyzed with custom scripts and with web-based tools such as Galaxy [Giardine
et al., 2005], the Genomic HyperBrowser [Sandve et al., 2013], EpiGRAPH [Bock, 2009], and
EpiExplorer [Halachev et al., 2012]. Furthermore, sample-wise statistics including the number
of assayed CpGs and genomic regions, the number of assayed CpGs per region type, and the
average read coverage (for sequencing data) are summarized in a dedicated table.
3.2.5 Exploratory Analysis
Global changes in DNA methylation can often be identied by visual inspection of the nor-
malized and quality-controlled DNA methylation data, prior to in-depth analysis of dierential
DNA methylation. To facilitate this type of exploratory analysis, RnBeads visualizes sample-
specic DNA methylation proles at the single-CpG level and for genomic regions of interest.
The global distribution of DNA methylation levels is summarized by density plots, which help
identify samples and sample groups that deviate from the characteristic bimodal shape with its
clear-cut distinction between highly methylated loci and essentially unmethylated loci (e.g.,
due to global gain or loss of DNA methylation). RnBeads also provides two types of visual-
ization for DNA methylation variation within and across sample groups, which facilitates the
detection of hypervariable samples (e.g., due to technical issues or biological eects such as
high tissue heterogeneity). The aforementioned DNA methylation proles are computed not
only based on single CpG measurement values, but also based on methylation levels in prede-
ned regions such as gene promoters or enhancer elements. Furthermore, if the user includes
biological or technical replicates in the analysis and identies them as such (as described in
the package vignette), RnBeads calculates pairwise correlations and visualizes them as scatter-
plots, thereby providing a global assessment of the reproducibility between the experiments.
Hierarchically clustered heatmaps provide a global assessment of sample subtypes in the
dataset. This analysis is quantitatively supported by various distance metrics, by the calcula-
tion of silhouette statistics to identify the best tting number of clusters, and by systematic
association testing between the obtained clusters and the user-provided sample annotations.
Dimension reduction using principal component analysis and multi-dimensional scaling is also
available within RnBeads. In combination with interactive sample coloring, this functionality
provides a powerful way of visualizing associations between sample annotations and global
trends in DNA methylation data. Finally, RnBeads generates composite plots of DNA methy-
lation levels around genes and other genomic regions; and these plots can for example help
detect global changes in DNA methylation that aect gene promoters dierently compared to
intragenic or intergenic regions.
The analysis of global trends and associations is also helpful for detecting batch eects,
which can arise from technical confounders such as date and duration of sample processing,
the person running the assay, and the sample origin. Batch eects are not uncommon in
large-scale DNA methylation datasets, in particular among those generated with microarrays
or with enrichment sequencing protocols such as MeDIP and MBD-seq. To systematically de-
tect batch eects, RnBeads runs tests for signicant association between user-provided sample
annotations (we recommend to include at least the sample collection data, the processing date,
and the sample origin) and the directions of largest variance identied in a principal compo-
nent analysis of the DNA methylation dataset. Statistical testing is also performed to identify
signicant associations among the sample annotations (e.g., in order to identify problematic
confounding between collection date and sample type or disease status) and with quality con-
trol indicators such as bisulte conversion rates and non-specic binding (for Innium data).
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In these comparisons, RnBeads automatically selects the appropriate statistical test (Fisher’s
exact test, Wilcoxon rank sum test, Kruskal-Wallis one-way analysis of variance, or Pearson
correlation coupled with a permutation test) based on the type of annotation data. All results
are visualized in the RnBeads report, thus providing a systematic assessment of associations
between trends in the DNA methylation data and sample annotations.
3.2.6 Dierential DNA methylation
DNA methylation dierences can be analyzed not only at the level of individual CpGs, but
also by combining measurements across larger genomic regions, which increases statistical
power and can result in more interpretable sets of dierentially methylated regions [Bock,
2012; Bock and Lengauer, 2008]. In each comparison dened by the sample annotation table,
RnBeads initially computes p-values for all covered CpGs. By default, this analysis is per-
formed with hierarchical linear models as implemented in the limma package [Smyth, 2004]
and using M-values [Du et al., 2010], which exhibit a distribution that is more consistent with
limma’s statistical model assumptions than the beta values that RnBeads uses in most parts of
its analysis. Alternatively, by conguring the dierential.site.test.method option, p-values can
also be calculated using two-sided t-tests or the RefFreeEWAS method [Houseman et al., 2014],
which is described in more detail in the section on covariate inference below. In addition to the
default unpaired analysis, RnBeads also supports paired-samples analysis, which can substan-
tially increase statistical power when analyzing matched pairs such as tumor versus normal or
disease-discordant twins. The CpG-level p-values are corrected for multiple testing using the
false discovery rate (FDR) method. Furthermore, to obtain aggregate p-values at the level of
predened genomic regions, the uncorrected, CpG-specic p-values within a given region are
combined using an extension of Fisher’s method [Makambi, 2003]. This procedure results in a
single aggregate p-value for each region, and the aggregate p-values are subjected to multiple
testing correction using the FDR method.
In order to address the problem that minimal but consistent dierences tend to receive low
p-values that do not reect biological signicance, RnBeads ranks the dierentially methylated
regions according to the combination of statistical signicance and eect size. The eect size
is estimated in two ways, namely as the absolute dierence in DNA methylation and as the
relative ratio of mean DNA methylation levels between sample groups. These two measure-
ments dier in their relevance for regions with low versus high DNA methylation levels and
thus complement each other. In regions of the genome that exhibit DNA methylation values
near 0%, the DNA methylation ratio between sample groups tends to overestimate the eect
size, and the absolute DNA methylation dierence is a more appropriate measure. The oppo-
site is true for high DNA methylation values near 100%, where the relative ratio is the more
stringent and appropriate measure of eect size.
In summary, RnBeads combines statistical testing with a priority ranking scheme that is
based on the absolute and relative eect size of the dierences between sample groups; and
it assigns a combined rank score for dierential DNA methylation to each analyzed CpG site
and genomic region. This combined rank is dened as the maximum (i.e. worst) of three
individual rankings: (i) by absolute dierence in mean DNA methylation levels, (ii) by the
relative dierence in mean DNA methylation levels, which is calculated as the absolute value
of the logarithm of the quotient of mean DNA methylation levels, and (iii) by the CpG-based
or region-based p-value calculated as described above. The priority-ranked lists can be used
directly for downstream analysis, such as manual inspection of the top-ranking regions in a
genome browser or for web-based analysis using tools such as Galaxy and EpiExplorer. In
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addition to the ranking of dierential DNA methylation, RnBeads visualizes the observed dif-
ferences using scatterplots and volcano plots, and it performs enrichment analysis for Gene
Ontology (GO) terms associated with strongly dierentially methylated regions.
3.2.7 Covariate inference
Even well-designed studies performed with accurate DNA methylation assays can include con-
founders and potential sources of batch eects. For example, the samples in an epigenome-
wide association study may be collected using dierent preprocessing steps in dierent coun-
tries or from genetically distinct populations. Furthermore, many large cohort studies are
currently being conducted on whole blood, which is characterized by signicant cellular het-
erogeneity. RnBeads implements a number of methods for data correction that can be used to
help control such biases.
Batch eects arise from variation in the sample origin or sample handling [Leek et al.,
2010], and their eect on the measurements can obscure biologically relevant dierences. As
long as the batch eects are not too strongly confounded with the biological comparisons of
interest, RnBeads together with specialized statistical tools can correct for the resulting bi-
ases. To that end, known sources of batch eects (e.g., sample processing date, the microarray
slide or the sequencing machine, the origin of clinical samples or the person performing the
sample preparation) should be documented by dedicated columns in the sample annotation
table, and these columns can then be specied as known confounders when performing the
limma-based analysis of dierential DNA methylation. RnBeads also integrates the surrogate
variable analysis method as implemented in the sva package [Leek et al., 2012] as an optional
step of the standard workow, which can detect batch eects of unknown origin and anno-
tate them in such a way that they can be controlled for as covariates during limma analysis.
Furthermore, other methods for batch eect detection such as ComBat [Johnson et al., 2007],
ISVA [Teschendor et al., 2011] and RUV-2 [Gagnon-Bartsch and Speed, 2012] can be applied
to RnBSet objects as part of custom RnBeads workows. Any such adjustments should be care-
fully monitored to avoid introducing additional biases, and it is typically advisable to consult
with an experienced statistician when strong batch eects are detected in a dataset.
DNA methylation dierences between heterogeneous samples (such as blood, tumor tis-
sue, and most other types of tissue biopsies) can arise not only from cell-intrinsic dierences
in DNA methylation but also from dierences in the cell composition between cases and con-
trols. It is often important to distinguish between these two causes of DNA methylation dif-
ferences, particularly because they give rise to dierent biological interpretations [Jae and
Irizarry, 2014]. RnBeads supports three alternative methods for handling cell type hetero-
geneity in the context of analyzing dierential DNA methylation. First, for certain sample
types such as whole blood it is possible to purify reference populations of the most preva-
lent cell types in the heterogeneous sample and to use their DNA methylation as reference
for quantifying dierences in cell composition between samples [Houseman et al., 2012]. The
estimated cell composition percentages can then be included as covariates in the limma-based
analysis of dierential DNA methylation. This method is most commonly used for epigenome
wide association studies performed on patient cohorts for which only whole blood samples
are available [Michels et al., 2013]. Suitable reference maps have been generated for the In-
nium 450k assay [Reinius et al., 2012]. Any such reference maps must be generated with the
same assay and processed in the same RnBeads analysis to minimize bias. It is also important
to assess whether there are any strong batch eects between the reference samples and the
samples that are to be analyzed, which can be a major issue when using published reference
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datasets rather than reestablishing the reference populations in-house. Second, the RefFreeE-
WAS method has recently been proposed for inferring global trends indicative of cell type
heterogeneity directly from the data [Houseman et al., 2014]. RnBeads supports this method
as an alternative to limma and t-tests in the dierential DNA methylation module. Third, the
FaST-LMM-EWASher software provides an alternative approach to reference-free analysis of
tissue heterogeneity [Zou et al., 2014], and RnBeads can export preprocessed DNA methyla-
tion data in a format that can be directly loaded into FaST-LMM-EWASher. However, users
should be aware that especially the reference-free methods are still relatively new and sus-
ceptible to various biases in the data, such that the results of these analyses – and in fact of
any analysis that attempts to correct for tissue heterogeneity – should be carefully checked
for statistical as well as biological plausibility.
3.2.8 Implementation details and package design
RnBeads and its companion data packages currently comprise a code base of approximately
32,000 lines of R code, and they export over 200 functions, classes and methods. To struc-
ture all functionality in a exible and easily understandable way, RnBeads utilizes elements of
object-oriented programming available in R, and all DNA methylation data are organized in an
R S4 class hierarchy. Each analysis module is implemented as an independent unit operating
on an RnBSet object, and the modules write their results into a hypertext report that employs
XHTML and JavaScript to enable self-contained interactivity. The RnBeads reports are orga-
nized by gures, which are collections of related plots spanning relevant parts of the parameter
space. This setup allows users to dynamically explore each gure without the need to rerun
the analysis. The ggplot2 package [Wickham, 2009] is used to generate publication-grade plots,
which are incorporated in the reports as bitmaps for quick visualization and as vector graphics
for high-resolution printing and for custom postprocessing using vector graphics software.
Heatmaps are visualized using the heatmap.2 functionality of the gplots package [Warnes,
2012]. Genome browser like views are created using the Gviz package [Hahne et al., 2014].
3.2.9 Scalability and performance
RnBeads has been designed to be scalable to large sample sizes and ecient in its use of com-
putational resources. Parallel computation is implemented using the foreach and doParallel
packages; and large R objects can be maintained directly on hard disk using the  package,
which leads to a massive reduction of the memory required for large analyses. Small RnBeads
analyses can be completed on a standard personal computer, while large analyses should be
run a scientic computing cluster (or on adequately powered cloud computing infrastructure).
For users who prefer a web-based workow, a web server supporting analyses with up to 24
samples is available on the RnBeads website. Furthermore, it is relatively straightforward to
run RnBeads in an academic or commercial cloud computing environment using an instance
of Galaxy CloudMan [Afgan et al., 2010], as described in the FAQ section on the RnBeads
website. RnBeads has been tested successfully on Innium datasets comprising thousands of
samples, on reduced presentation bisulte sequencing datasets with hundreds of samples and
on whole genome bisulte sequencing datasets with dozens of deeply sequenced methylomes.
Nevertheless, analyses of this scale require careful planning and conguration to avoid out-of-
memory problems or excessive runtime. Supplementary Table 2 lists runtime measurements
of RnBeads for several large datasets, and the RnBeads documentation provides additional
instructions on how to set up large analyses.
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3.2.10 Methylome resource
The Methylome Resource on the RnBeads website (http://rnbeads.mpi-inf.mpg.de/meth
ylomes.php) was established by applying RnBeads to the largest public datasets that are cur-
rently available for whole genome bisulte sequencing, for reduced representation bisulte
sequencing, and for the Innium 450k assay. This resource provides a reference of large-scale
DNA methylation analyses that can be used in various ways. For example, researchers can
browse through the reports online, explore biological hypotheses, and investigate relevant
aspects of the data visually or through custom data analysis with R or other software tools.
Furthermore, researchers can download the data and conguration les of the Methylome Re-
source, add their own DNA methylation data, and then run RnBeads in order to analyze their
data in the context of high-quality methylome datasets that span a broad set of tissue types.
For whole genome bisulte sequencing, the Methylome Resource covers DNA methyla-
tion proles of 41 samples with coverage of 28,158,385 CpGs [Ziller et al., 2013]. These methy-
lomes are compiled from several sources, including the activities of the Roadmap Epigenomics
Project and the International Human Epigenome Consortium [Satterlee et al., 2010], and they
span a broad range of human cell types. For reduced representation bisulte sequencing, we
obtained DNA methylation proles for 216 samples with coverage of 2,295,083 CpGs from the
ENCODE project [ENCODE Project Consortium, 2004], which comprises cell lines and pri-
mary samples of various normal and cancerous tissue types [Varley et al., 2013]. Finally, for
the Illumina Innium 450k assay, we downloaded raw intensity les for 4,034 primary tumor
and normal control samples with microarray coverage of 485,577 CpGs, which have been col-
lected by the TGCA consortium [Weisenberger, 2014]. All data were processed according to
a standardized RnBeads workow, and these analyses could be completed in no more than a
few days on a standard scientic computing cluster (Supplementary Table 2).
3.2.11 Availability and website
Additional materials, including the RnBeads download, the package vignette, the source code,
an RnBeads web service, commands and congurations for cloud-based RnBeads analysis,
example analysis reports, the methylome resource, documentation and FAQs are available on
the RnBeads website (http://rnbeads.mpi-inf.mpg.de/).
3.3 Supplementary Material
Supplementary Note
As an example for RnBeads-based analysis of Innium 450k data, we performed a reanalysis
of a publicly available glioblastoma dataset generated by The Cancer Genome Atlas (TCGA)
project [Weisenberger, 2014]. Glioblastoma multiforme is an aggressive type of brain cancer
with a median survival time of little more than a year and substantial variation between pa-
tients [Wen and Kesari, 2008]. In an attempt to stratify patients according to the molecular
characteristics of the tumors, recent research has identied a subtype that is characterized by
elevated levels of DNA methylation, prolonged survival and high frequency of mutations in the
IDH1 gene [Noushmehr et al., 2010]. The discovery of this “glioblastoma CpG island methy-
lator phenotype positive” (G-CIMP+) subtype was based on Illumina’s Innium 27k assay,
prompting us to validate this observation using RnBeads and an extended dataset of Innium
450k proles for 124 glioblastoma patients.
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We downloaded the raw microarray signal intensity les (in IDAT format) from the TCGA
website (http://tcga-data.nci.nih.gov), created a sample annotation le that contains
the available patient data – including IDH1 mutation status – and then launched RnBeads.
The software identies the data directory and input le format from the annotation le and
normalizes the raw intensity data using SWAN [Makismovic et al., 2012] (other normalization
algorithms are supported as well, as described in the Online Methods). CpG-specic DNA
methylation levels are obtained from the normalized data and collected in an RnBSet object
that provides the basis for all subsequent analyses. During quality control, RnBeads performs
clustering of all samples based on genotype ngerprinting probes included on the Innium
microarray (Supplementary Figure 1a), which provides an eective method for identifying
sample mix-ups and duplications. Here, we identied two samples with identical SNP patterns,
in concordance with their TCGA annotation as primary and recurrent tumors from the same
patient. All other samples were taken from genetically unrelated patients. RnBeads provides
exible features for data ltering as part of the preprocessing module (Supplementary Figure
1b), which are useful for excluding measurements that could bias the analysis (e.g., due to low
signal quality, overlap with SNPs, or X-chromosome association in case of dierent sex ratios
between cases and controls).
Based on the ltered and quality-controlled dataset, RnBeads performs hierarchical clus-
tering to facilitate data exploration and outlier detection. In the clustered heatmap, we observe
a small and distinct group of samples with increased promoter hypermethylation suggestive
of the G-CIMP+ subtype (Supplementary Figure 1c). These putative G-CIMP+ samples in-
deed exhibit the characteristic enrichment of IDH1 mutations and a clear separation with re-
spect to their global DNA methylation levels – patterns that are particularly evident from a
low-dimensional projection of the entire dataset that has been annotated with IDH1 muta-
tion status and G-CIMP subtype information (Supplementary Figure 1d). The signicance of
this association is also conrmed by pairwise statistical tests for associations that RnBeads
performs between all sample annotations (Supplementary Figure 1e). Furthermore, RnBeads
calculates groupwise comparisons between the mean DNA methylation levels in the G-CIMP
positive versus negative samples for CpG islands and for genome-wide tiling regions (Supple-
mentary Figure 1f). The resulting scatterplots show that the gain of DNA methylation among
the G-CIMP+ samples is more pronounced in CpG islands than in genomic regions exhibiting
low CpG content.
These automated, exploratory analyses provide a starting point for dissecting the patterns
and mechanisms of epigenetic deregulation that may aect DNA methylation in G-CIMP+
tumors. Follow-up analyses can be performed directly in R, most conveniently by using the
precalculated RnBSet data object that RnBeads prepares as part of the initial analysis. Further-
more, RnBeads makes it easy to export the data and results in a variety of formats and to hand
them over to stand-alone or web-based bioinformatic tools for further analysis.
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Supplementary Figures
Figure 3.S1: (on the next page) Analysis of DNA methylation in a cancer cohort based on Infinium
450k data. RnBeads was used to rediscover a clinically distinct subgroup of glioblastoma
patients characterized by increased DNA methylation levels (termed G-CIMP+), and to
predict the G-CIMP status for a total of 124 patients using Infinium 450k a. Detection
of genetic duplicates among the patient samples (columns) using a clustered heatmap of
intensity values for the genotyping probes that are present on the Infinium microarray
(rows). The inset shows that two samples exhibit a high level of genetic identity, and they
are indeed derived from tumors of the same patient. b. ality control plot summarizing
the outcome of the data filtering. The bar plots on the top le show that the majority of
CpG sites (top) and samples (boom) are of good quality and can be retained. The rel-
atively straight line in the quantile-quantile plot indicates that the probe filtering does
not have a major impact on the distribution of DNA methylation in the dataset. c. Iden-
tification of a small but clearly distinguished cluster of G-CIMP+ glioblastoma samples
with elevated DNA methylation levels especially in CpG-rich genomic regions (dark blue
in the lemost column). In the heatmap, blue colors denote high levels of DNA methy-
lation, red indicates low levels and grey represents intermediate levels. For visualization
purposes, only the 100 gene promoters (rows) with the highest levels of inter-sample
variation in DNA methylation are shown (columns), but the hierarchical clustering is
based on d. Global assessment of the similarity between the DNA methylation profiles,
ploing all glioblastoma samples according to their second and third principal compo-
nents. The samples exhibit strong separation according to the G-CIMP status (denoted
by point shape) and IDH1 mutation status (denoted by point color). e. Analysis of signif-
icant associations between all user-provided right triangle (orange: Pearson correlation
followed by permutation-based estimation of the p-value; green: Fisher’s exact test; blue:
Wilcoxon rank sum test; violet: Kruskal-Wallis one-way analysis of variance). f. Genome-
scale comparison between the DNA methylation levels of G-CIMP positive (y-axis) and
G-CIMP negative (x-axis) tumor samples, focusing on CpG islands (le scaerplot) and
on 5-kilobase tiling regions with a CpG content in the boom quartile (right scaerplot),
respectively. Genomic regions that are dierentially methylated with an FDR below 0.05
are presented as red points. All other regions are displayed in blue, and color brightness
denotes point density.
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Figure 3.S2: RnBeads-based Methylome Resource of reference epigenome datasets. Screenshot of
the Methylome Resource (http://rnbeads.mpi-inf.mpg.de/methylomes.php), which
makes large-scale DNA methylation datasets readily available for follow-up research.
On the one hand, it provides detailed analysis reports for publicly available methylome
datasets that can be explored interactively. On the other hand, the Methylome Resource
website lets RnBeads users download all data and configurations that are needed to re-
run all or part of the DNA methylation analyses in their local or cloud-based comput-
ing environment. These re-runnable analysis configurations make it straightforward for
RnBeads users to analyze their own DNA methylation data in the context of publicly
available reference epigenome maps.
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Supplementary Tables
Table 3.S1: Comparison between soware tools for DNA methylation analysis
The table as an Excel (.xlsx) file is available from:
http://www.nature.com/nmeth/journal/v11/n11/extref/nmeth.3115-S2.xlsx
Table 3.S2: Performance benchmark for large DNA methylation analyses with RnBeads
 
Data type1 No. of Samples2 No. of CpGs3 No. of Annotations4 No. of Comparisons5 Runtime (node)6 Runtime (cluster)7
Infinium 450k 100 485,577 2 2 2h 12min 1h 9min
Infinium 450k 500 485,577 6 6 15h 2min 7h 29min
Infinium 450k 1000 485,577 10 10 1d 13h 51min 20h 15min
Infinium 450k 4034* 485,577 5 18 9d 7h 21min 6d 18h 40min
RRBS 10 1,804,103 2 2 1h 56min 49min
RRBS 50 2,169,859 6 6 5h 32min 1h 54min
RRBS 100 2,221,920 10 10 10h 13min 2h 57min
RRBS 216* 2,295,083 7 11 1d 8h 50min 14h 27min
WGBS 5 28,132,494 2 2 20h 43min 8h 23min
WGBS 10 28,150,344 6 6 2d 10h 23min 20h 5min
WGBS 20 28,154,125 10 10 4d 12h 21min 1d 15h 34min
WGBS 41* 28,158,385 5 6 3d 4h 54min 1d 9h 27min
1 Data from the following sources were included in the analysis: TCGA (Infinium 450k), ENCODE (RRBS), Ziller et al. (WGBS)
2 Subsets of the full datasets were randomly generated in order to assess the effect of sample size on runtime
3 Number of CpG sites present in at least one sample. For RRBS/WGBS, low-coverage sites are removed prior to counting
4 Adding more columns to the sample annotation table increases the complexity and runtime of the analysis
5 Including more pairwise comparisons in the analysis strongly increases runtime but can be parallelized effectively
6 Serial runtime measured on a scientific computing cluster (16 nodes), summing up the runtime of all contributing nodes
7 Parallel runtime / time to completion on a scientific computing cluster (16 nodes) with optimal use of job parallelization 
* The analysis results for the full datasets are available as part of the Methylome Resource on the RnBeads website
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Abstract
Bisulte sequencing is a widely used method for measuring DNA methylation in eu-
karyotic genomes. The assay provides single-basepair resolution and, given sucient
sequencing depth, its quantitative accuracy is excellent. High-throughput sequenc-
ing of bisulte-converted DNA can be applied either genome-wide or targeted to a
dened set of genomic loci (e.g. using locus-specic PCR primers or DNA capture
probes). Here we describe BiQ Analyzer HT (http://biq-analyzer-ht.bioinf.m
pi-inf.mpg.de/), a user-friendly software tool that supports locus-specic analysis
and visualization of high-throughput bisulte sequencing data. The software facili-
tates the shift from time-consuming clonal bisulte sequencing to the more quantita-
tive and cost-ecient use of high-throughput sequencing for studying locus-specic
DNA methylation patterns. In addition, it is useful for locus-specic visualization of
genome-wide bisulte sequencing data.
Availability
http://biq-analyzer-ht.bioinf.mpi-inf.mpg.de (This website/software is free
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4.1 Introduction
DNA methylation is a widely studied epigenetic modication. It is present in all vertebrates
and many invertebrate animals as well as in plants [Suzuki and Bird, 2008]. In mammals,
DNA methylation plays an important role for developmental gene regulation and for germline
repression of repetitive elements [Bird, 2002]. Aberrant DNA methylation patterns are fre-
quently observed in cancer [Esteller, 2008] and may also occur in many other human dis-
eases [Feinberg, 2007]. The link between locus-specic DNA methylation alterations and com-
mon diseases has created signicant interest in using these epigenetic alterations as biomark-
ers in drug discovery and clinical diagnostics [Laird, 2003].
To investigate the many roles of DNA methylation in development and disease, researchers
depend on experimental methods that accurately measure DNA methylation patterns at high
accuracy and aordable cost. Many technologies with dierent advantages and disadvantages
have been developed over the last twenty years, but only bisulte-based methods provide
quantitative DNA methylation data at single-basepair resolution [Laird, 2010]. In bisulte
sequencing the DNA is treated with sodium bisulte, which selectively converts unmethy-
lated cytosines into uracils but leaves methylated cytosines untouched [Frommer et al., 1992].
Hydroxymethylated DNA, which has recently been detected in some mammalian cell types,
is also left unconverted and is indistinguishable from methylated DNA using bisulte-based
methods [Huang et al., 2010].
Bisulte sequencing has recently been used to obtain the rst genome-wide, high-resolution
maps of DNA methylation in the human genome [Laurent et al., 2010; Lister et al., 2009].
Bisulte-based methods also performed well in a benchmarking study of DNA methylation
mapping technologies [Bock et al., 2010]. Along with technologies for DNA methylation map-
ping at a genomic scale, locus-specic bisulte sequencing plays an important role as gold-
standard validation method and promises to become a standard technology in clinical diag-
nostics [Bock, 2009].
Locus-specic bisulte sequencing has traditionally been performed by Sanger sequencing
of a few dozen hand-picked DNA clones, making this method rather time-consuming and
costly. To address these limitations, researchers increasingly use high-throughput sequencing
instead of Sanger sequencing [Korshunova et al., 2008; Taylor et al., 2007; Varley and Mitra,
2010], which has three major advantages: (i) Due to the increased sequencing throughput
it becomes feasible to obtain highly quantitative DNA methylation patterns for the loci of
interest. This is particularly relevant for studying heterogeneous tissue samples and for clinical
diagnostics. (ii) Due to lower per-base costs and the use of multiplexing to sequence many
samples and/or loci in a single machine run, the sequencing costs are substantially reduced.
(iii) The cloning step for isolating DNA populations that carry the DNA sequence of a single
DNA molecule becomes obsolete because current methods for high-throughput sequencing
measure the sequences of individual DNA clones.
A major roadblock for the wider use of high-throughput bisulte sequencing is the lack
of software tools for processing and analyzing the vast number of sequencing reads that are
characteristic of this method. Several software tools have been developed for processing small-
scale bisulte sequencing data obtained by conventional Sanger sequencing. The BiQ Ana-
lyzer [Bock et al., 2005] software from our group has recently been updated to version 2.0 and
continues to be a useful tool for interactive analysis of small-scale bisulte sequencing data.
Alternative tools include the QUMA web service [Kumaki et al., 2008], BISMA [Rohde et al.,
2010], and several more specialized programs [Carr et al., 2007; Grunau et al., 2000; Hetzl et al.,
2007; Xu et al., 2007]. None of these tools can be scaled to the read numbers that are typically
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obtained by high-throughput sequencing. For this reason, recent studies utilized custom data
analysis scripts, none of which are publicly available [Korshunova et al., 2008; Taylor et al.,
2007; Varley and Mitra, 2010].
Here we describe BiQ Analyzer HT, a comprehensive software tool for locus-specic anal-
ysis of high-throughput bisulte sequencing data. BiQ Analyzer HT builds on concepts that
we originally developed for the popular BiQ Analyzer software [Bock et al., 2005], but it was
redesigned and rewritten to meet the challenges arising for the analysis of high-throughput
bisulte sequencing data. All functionality of BiQ Analyzer HT is available through a web-
startable graphical user interface, which guides the user through the data analysis (Figure 4.1).
As an additional option, it is possible to run the computationally intensive parts of the soft-
ware on a remote high-performance computer while maintaining the user-friendliness of a
graphical interface run locally. Finally, BiQ Analyzer HT provides an optional command-line
interface to facilitate integration into automatic data analysis pipelines.
4.2 Program Overview
BiQ Analyzer HT facilitates locus-specic analysis, quality control and visualization of high-
throughput bisulte sequencing data. The tool takes sequencing read data as input, and it
produces quality-controlled output tables and diagrams of the inferred DNA methylation in-
formation for each sample, locus and DNA methylation site.
BiQ Analyzer HT is a Java-based program which can be run on any computer which has
a recent version of the Java Virtual Machine installed. The tool is available as a self-installing
Java Web Start distribution, and as a downloadable installation package for computers that
are not connected to the Internet. BiQ Analyzer HT’s project-based user interface supports
the interactive analysis of bisulte sequencing data for multiple target loci in multiple sam-
ples. A typical analysis consists of three phases: (i) data import, (ii) sequence alignment and
quality control, and (iii) visualization and export of the inferred DNA methylation information
(Figure 4.1).
To prepare high-throughput sequencing data for analysis with BiQ Analyzer HT, the user
rst applies vendor-specic software to perform base-calling, to resolve any sample multiplex-
ing and to convert the data into one of two standard formats, FASTA or BAM. When importing
FASTA les obtained by locus-specic bisulte sequencing, BiQ Analyzer HT expects one le
per sample and locus. We currently provide a custom script that automatizes data prepara-
tion for the Roche 454 sequencing platform (http://biq-analyzer-ht.bioinf.mpi-inf.m
pg.de/), and we will add similar scripts for other platforms based on user demand. Alterna-
tively, genome-scale bisulte sequencing data can be imported as BAM les, which are most
conveniently generated with BSMAP [Xi and Li, 2009].
When a new BiQ Analyzer HT project is initialized, an output directory is created into
which the software writes its analysis results (Table 4.1). The project structure is dened by
the user, adding samples and loading FASTA les containing the single genomic reference
sequences that dene each locus. The resulting tree structure is shown in BiQ Analyzer HT’s
main window. Once the data are loaded, this tree can be ordered either by samples or by loci,
depending on the biological question of interest.
Read alignment and inference of DNA methylation information are controlled by param-
eters that the user selects on the setup screen. While the default values often provide good
results, it is recommended that a user runs a rst analysis with default parameters, inspects the
results and then adjusts the parameters as necessary. Dataset-specic choice of quality-control
parameters can sometimes compensate for quality issues that may be present in the primary
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Figure 4.1: BiQ Analyzer HT workflow. Bisulfite sequencing data are generated either for the en-
tire genome or selectively for a defined set of genomic loci using commercially available
high-throughput sequencers (a). To reduce sequencing cost, bisulfite-converted DNA from
several samples and/or loci is typically barcoded and combined into a single sequencing
run. The multiplexed read data are separated and converted into FASTA or BAM files us-
ing vendor-provided soware and/or custom scripts (b.), before they are loaded into BiQ
Analyzer HT (c). Once loaded, the user sets alignment and quality control parameters
(d), inspects the inferred DNA methylation paerns (e) and adjusts the parameters un-
til satisfactory results are obtained. Finally, the DNA methylation measurements can be
visualized graphically (f) and exported as tab-separated tables (g) for in-depth analysis us-
ing spreadsheets such as Excel, statistical soware such as R/Bioconductor and biomarker
development tools such as MethMarker (h). 117
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data. For example, a decrease in alignment stringency parameters allows for retaining reads
with reduced similarity to the reference, which would be removed by the default ltering cri-
teria. This can be essential to process highly polymorphic sequences such as retrotransposable
elements and DNA repeats.
Once satisfactory results are obtained, the inferred DNA methylation data can be exported
in several formats, including sequence alignments, data tables and DNA methylation plots. Ta-
ble 4.1 summarizessummarizes all output items. The sequence alignments provide a detailed
account of how the DNA methylation levels were inferred. In addition, they can be used to
identify allele-specic single-nucleotide polymorphisms or evidence of structural variation in
the sequence data. The data tables facilitate exploratory data analysis using spreadsheets, in-
depth statistics using statistical software such as R/Bioconductor [Gentleman et al., 2004] and
epigenetic biomarker development using BiQ Analyzer’s companion tool MethMarker [Schuf-
er et al., 2009]. Finally, the DNA methylation plots visualize the results of BiQ Analyzer HT
analyses, for example for use in papers and scientic reports.
The visualization module of BiQ Analyzer HT utilizes the publicly available GSEA li-
brary [Subramanian et al., 2005] for plotting DNA methylation heatmaps. BAM le handling
is implemented using the Picard library (http://picard.sourceforge.net/), and parts of
the sequence processing code are based on the BioJava framework [Holland et al., 2008].
4.3 Data Processing
BiQ Analyzer HT implements a data processing pipeline that is run for each combination of
locus and sample in the project tree. The pipeline aligns all sequencing reads from the cor-
responding input le to the locus-specic genomic reference sequence, and based on these
alignments it infers which cytosines are methylated or unmethylated by comparing the read
sequence with the reference sequence. The key steps of the data processing pipeline are out-
lined in more detail below. All analyses are conveniently accessible via the graphical interface.
They can also be run from the command line, which facilitates integration with automatic data
processing pipelines.
Read alignment. The analysis of bisulte sequencing data crucially depends on accurate
alignments. This is an inherently dicult task when complex genomic regions with repetitive
elements and structural variation are studied and further complicated by the fact that bisulte-
converted DNA has substantially lower information content than genomic DNA. For this rea-
son, speed-optimized seed-based aligners such as BLAT [Kent et al., 2002], MAQ [Li et al., 2008]
and BWA [Li and Durbin, 2009] – which are commonly used for aligning high-throughput se-
quencing data – could undermine the accuracy of BiQ Analyzer HT. After exploring several
alternatives, we chose to use the Needleman-Wunsch algorithm [Needleman and Wunsch,
1970], which is guaranteed to nd the optimal (although not necessarily the correct) alignment
between each sequencing read and the reference sequence. Furthermore, we made several
modications to the algorithm that account for recurrent issues with bisulte-converted DNA
(Supplementary Text S1). To partially compensate for the fact that the Needleman-Wunsch
algorithm is substantially slower than current short-read aligners, we use a highly optimized
implementation of this algorithm. This implementation provides excellent performance for
read numbers in the order of 104 per locus on a standard laptop computer (Table 4.2). Further-
more, the read alignment can be outsourced to a remote high-performance computer, which
makes it feasible to process in the order of one million reads per locus on a standard laptop
computer.
Quality control and read ltering. Based on the pairwise alignment of the sequencing reads
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with their corresponding genomic reference sequence, the data quality of the bisulte sequenc-
ing experiment is estimated. Basic quality measures include the alignment score and sequence
identity with the bisulte-converted reference sequence, the estimated bisulte conversion
rate (fraction of unconverted cytosines outside of the analyzed methylation context, e.g. “CG”)
and the number of DNA methylation sites with missing data. The sequencing read data can
be ltered for each of these quality measures, in order to quickly discard low-quality or oth-
erwise unsuitable reads. The threshold values of each quality measure are set to empirically
chosen defaults, but users may need to adjust these parameters interactively to account for
the characteristics of their specic datasets.
Inference of DNAmethylation patterns. BiQ Analyzer HT focuses by default on CpG methy-
lation, which is the most common modication of eukaryotic DNA. The user can also choose to
include other symmetric and asymmetric methylation contexts in the analysis, such as CpHpG
and CpHpH. A methylation context is dened as a pair of DNA sequence motifs which match
the methylated and unmethylated states of a site. The positions of the potential methylation
sites are detected by nding matches of the rst motif in the aligned reference sequence. The
methylation state is then determined by comparing the sequences at the corresponding posi-
tions of the aligned sequence read, and the site is characterized as methylated, unmethylated
or missing value (“1”, “0” and “x”, respectively). The collection of DNA methylation states
for all sites in a given sequencing read constitute its methylation pattern, and the number of
methylated sites divided by the total number of sites that are not missing values denes the
mean methylation of a sequencing read.
Data visualization and export. The inferred DNA methylation data and quality control
information can be exported for documentation and follow-up analysis using statistical tools
(Table 4.1). The resulting tables list the quality measures, DNA methylation patterns and mean
methylation levels for each sequencing read that has not been ltered out during quality con-
trol. Prior to exporting these tables, they can be sorted by one of the quality measures or by
the inferred DNA methylation information.
4.4 Performance Evaluation
To conrm the practical utility of BiQ Analyzer HT for large datasets and to assess its perfor-
mance relative to existing low-throughput tools, we benchmarked the tools on datasets with
up to one million reads (Table 4.2). These data sets were obtained by multiplexed loci-specic
bisulte sequencing on the Roche 454 sequencing platform. Briey, three classes of repetitive
elements (RE1, RE2 and RE3) were amplied from bisulte-treated mouse DNA, and several
thousand reads were sequenced for these repetitive elements. To evaluate BiQ Analyzer HT’s
performance for one million reads, we further constructed articial test sets from the actual
dataset of region RE3 by reusing sequencing reads multiple times. The results of this bench-
marking show that all existing tools have severe limitations in the number of reads that can
be processed (Table 2). In contrast, with BiQ Analyzer HT we could successfully analyze a
dataset with one million reads mapping to a single locus.
4.5 Conclusions
BiQ Analyzer HT provides comprehensive support for locus-specic analysis, quality con-
trol and visualization of high-throughput bisulte sequencing data. It addresses the bioinfor-
matic challenges of using high-throughput sequencing as a fast and cost-ecient alternative
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Table 4.1: Analysis results generated by BiQ Analyzer HT
Category Title Access Format Description
Tabular
Project summary GUI TSV Basic information summarizing the analysis
Sample summary GUI TSV DNA methylation summary for each locus in
each sample
Results table OD TSV Alignment quality, estimated bisulfite con-
version rate and DNA methylation summary
for each sequencing read
Methylation
paern table
GUI TSV DNA methylation paerns for each sequenc-
ing read. Columns correspond to DNA
methylation sites (typically CpG positions)
Project results ta-
ble
GUI TSV Combined results table for all samples and
loci
Graphical
Methylation
paern map
OD,
GUI
PNG Heatmap-style representation of DNA
methylation paerns for each sequenc-
ing read. Columns correspond to DNA
methylation sites
Methylation
profile
OD,
GUI
PNG,
SVG
Diagram visualizing the frequency of methy-
lated, unmethylated and missing-value ob-
servations for each DNA methylation site
Project methyla-
tion heatmap
GUIi PNG Heatmap of mean DNA methylation levels
for each locus in each sample
Methylation
profile heatmap
GUIi PNG Heatmap of mean DNA methylation levels
for each DNA methylation site at a specific
locus
Sequence
Alignment OD FASTA Multiple alignment of sequencing reads for
each locus in each sample
Filtered reads OD FASTA Sequences of all reads that passed quality fil-
tering
OD (“output directory”) – the item is wrien to the project output directory tree; GUI (“graphical user
interface”) – the item can be exported via “Save as ...” or “Copy to clipboard” in the corresponding context
menu; TSV – tab-separated value table; FASTA – sequencing reads in multiple-sequence FASTA format. i The
data table from which the heatmap is generated can also be exported for follow-up analysis.
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Table 4.2: Performance comparison of soware packages for locus-specific analysis of bisulfite se-
quencing data
Region Read
Count
Performance
BiQ Analyzer
2.0
QUMAa BiQ Analyzer
HT
BiQ Analyzer
HTb
Memory ET Memory ET Memory ET Memory ET
RE1 400 350 300 NAc 10 95 30 1000 6
RE2 1054 500 911 NAc 25 200 50 1000 9
RE3 3150 >1000 3455 NAc 70 200 95 1000 16
RE3d 104 NAf NAc 323 300 285 1500 50
RE3d 105 NAf NAf NAg 3500 440
RE3d 106 NAf NAf NAg 10 000 1940
All tests, except for the cases noted explicitly, were run on a standard laptop with dual-core processor and 2 GB
main memory. The values of peak memory usage are given in MB. ET (“execution time”) denotes the total
duration of the analysis in seconds.
aThe QUMA web-server runs on a high-performance machine (8 dual-core processors, 16 GB main memory).
bBiQ Analyzer HT running on a high-performance machine (8 dual-core processors, 16 GB main memory).
cMemory usage of the web-servers does not aect performance for the end user. dThe dataset was obtained by
concatenating multiple copies of the initial set of reads obtained for RE3. eThe test could not be performed
because the number of reads in the set exceeded the maximum read threshold of the web server. fThe
calculation could not be finished due to an error. gTests with BiQ Analyzer HT for the last two read sets were
performed only on the high-performance computer.
to clonal bisulte sequencing, and it is fully compatible with multiplex analysis of several
loci and samples. The alignment algorithm was specically optimized for bisulte-converted
sequences, and it supports the analysis of both CpG and non-CpG methylation patterns. In
summary, the combination of locus-specic high-throughput sequencing and interactive data
analysis with BiQ Analyzer HT provides a highly practical approach for measuring the DNA
methylation patterns of 10s to 100s of loci in 100s to 1000s of samples, for example in the
context of biomarker validation and clinical diagnostics.
4.6 Supplementary Material
Supplementary Text S1. Bisulfite Sequence Alignment
Wildcard alignment. By selectively converting unmethylated but not methylated cytosines
into uracils (the uracils are subsequent converted into thymines during PCR amplication),
bisulte treatment gives rise to signicant discrepancies between the sequencing reads and
the genomic reference sequence of the corresponding locus. Simply aligning the bisulte se-
quencing reads to the genomic reference sequence therefore results in low-quality alignments.
Several approaches exist to improve the alignment of the bisulte sequence reads. Most com-
monly, all cytosines in both the read sequence and the reference sequence are replaced by
thymines. BiQ Analyzer HT uses a related but slightly more complex method that makes use
of wildcard sequence characters. Prior to the alignment, in the genomic reference sequence
all cytosines within the methylation context (typically “CG”) are converted into Zs, and all
cytosines outside of the methylation context are converted into Ys (Fig. S1). These wild-
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card characters are assigned dierent substitution scores for cytosines and thymines in the
sequencing read (Fig. S2).
Scoring scheme. In the general case, no prior information is available on the length of
the reads obtained in a bisulte sequencing experiment. In other words, the read lengths may
dier substantially from the length of the reference sequence. We therefore use local alignment
following the Needleman-Wunsch algorithm, which assigns zero gap-extension penalties to
all gaps located before the rst and after the last non-gap character in both the sequencing
read and the genomic reference sequence.
Methylation site alignment bonus. Correct alignment of the methylation context (typi-
cally “CG”) is optionally rewarded by an increment of the alignment score, which can improve
the results when aligning low-quality or highly polymorphic reads. This bonus discourages
the alignment algorithm from introducing gaps at the methylation sites that are being ana-
lyzed.
Bisulte conversion rate. Prior information is usually available regarding the expected
methylation context of the analyzed DNA sample. For example, in dierentiated mammalian
cells one expects methylated cytosines to occur almost exclusively at CpG dinucleotides. The
cytosine-to-thymine conversion rate for cytosines outside the expected methylation context
is used by BiQ Analyzer HT to estimate the bisulte conversion rate, providing an important
indicator of the technical success of the experiment.
Supplementary Figures
a) AACCTCTTGAACGAGTTCAGA
b) AATTTCTTGAACGAGTTCAGA
c) AAYYTCTTGAAZGAGTTCAGA
Figure 4.S1: Modifications of the sequence alignment alphabet for aligning bisulfite sequences. a)
Genomic reference sequence. b) In silico bisulfite-converted reference sequence. c) The
BiQ Analyzer HT conversion scheme introduces dierent wildcards for cytosines inside
and outside of the expected methylation context (typically “CG”)
.
A G Y Z T N -
A MS MP MP MP MP MP MP
G MS MS MP MP MP MP MP
C MS MP CCR MS MP MP MP
T MS MP CR MS MS MP MP
N MS MP MP MP MP MP MP
- MS MP MP MP MP MP MP
Figure 4.S2: BiQ Analyzer HT substitution matrix. The columns correspond to the genomic reference
sequence, and the rows correspond to the sequencing read. MP – mismatch penalty,
MS – match score, CR – a negative term proportional to the conversion rate, CCR – a
complement of CR such that CR+CCR=MS+MP.
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Abstract
Recent data suggest an important biological role for oxidative modications of methy-
lated cytosines in DNA, specically hydroxymethylation, formylation and carboxy-
lation. Several assays have been described to prole these modications genome-
wide as well as in targeted, locus-specic settings. So far no comprehensive soft-
ware has been described to aid the analysis of sequencing data from these assays.
Here we present BiQ Analyzer HiMod, an interactive and user-friendly software tool
for low-level processing, quality control and initial analysis of the high-throughput
locus-specic DNA modication sequencing data. The software supports four dif-
ferent proling assays, leading the user from raw sequence reads to summarized
modication measurements and publication-quality plots. The program combines
well-established graphical user interface of its predecessor tool, BiQ Analyzer HT,
with new and extended analysis modes. BiQ Analyzer HiMod also includes updates
of the analysis workspace, an intuitive interface, a custom vector graphics engine,
and support of additional input and output data formats. The tool is freely available
as a stand-alone installation package from http://biq-analyzer-himod.bioinf.
mpi-inf.mpg.de/.
Availability
The BiQ Analyzer HiMod installation package is freely available from
http://biq-analyzer-himod.bioinf.mpi-inf.mpg.de/ .
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5.1 Introduction
DNA methylation is widely recognized as a key epigenetic mechanism playing a crucial role in
development and disease [Bergman and Cedar, 2013; Smith and Meissner, 2013]. Sequencing
of bisulte-treated DNA is the gold standard for base resolution mapping of DNA-methylation
[Bock et al., 2010; Harris et al., 2010]. Recently, oxidized derivatives of 5-methylcytosine (5mC)
were identied that are assumed to have important biological function [Branco et al., 2011].
Like 5-methylcytosine the oxidized derivatives occur predominantly at CpG-dinucleotide cy-
tosines [Kohli and Zhang, 2013]. However, conventional bisulte sequencing does not dis-
criminate between dierent oxidized forms. Sodium bisulte treatment converts unmodi-
ed cytosine, 5-carboxy (5caC) and 5-formylcytosyne (5fC) into deaminated forms, which are
subsequently replaced by thymines during PCR amplication, while methylated and hydrox-
ymethylated (5hmC) cytosines remain unchanged [Huang et al., 2010]. Several new methods
have been suggested recently to overcome these limitations and transform the specic oxida-
tive modications into sequence-based signals. Oxidative bisulte sequencing (oxBS-seq) in-
volves an oxidation reaction to convert 5hmC to 5fC [Booth et al., 2012]. A subsequent bisulte
reaction followed by the amplication step converts 5fC to thymine whereas the original 5mC
is replaced by cytosines in PCR amplicons (Figure 5.1, a). TET-assisted bisulte sequencing
(TAB-seq) utilizes the opposite scheme and applies an enzymatic oxidation by the TET pro-
tein to convert all 5mC to 5hmC and further to 5fC and 5caC, while the initially present 5hmC
is protected by glycosylation prior to the bisulte reaction (Figure 5.S1). The subsequent bisul-
te treatment and PCR converts the initially present 5mC (as well as 5fC and 5caC) to thymine
while the 5hmC is replaced with cytosines [Schüler and Miller, 2012]. Similar methods were
developed for mapping 5fC and 5caC, such as formyl-chemically-assisted bisulte sequencing
(fCAB-seq) [Song et al., 2013] (Figure 5.1, b) and chemical-modication-assisted bisulte se-
quencing (CAB-seq) [Lu et al., 2013] (Figure 5.S1). Following the modied bisulte treatments
of either oxBS-seq, TAB-Seq, CAB-seq or fCAB-Seq the DNA is amplied and sequenced. The
abundance of any modication under inspection is estimated by comparing such sequencing
results to data obtained by conventional bisulte sequencing. Note that all modied bisulte
methods are only partially modication-specic and mostly produce cumulative estimates of
several dierent modications.
While several tools have been developed for the analysis of conventional locus-specic
bisulte sequencing data of various scale [Bock et al., 2005; Kumaki et al., 2008; Lutsik et al.,
2011], no software package currently supports an integrated analysis of data from multiplexed
locus-specic high-throughput DNA modication proling. For the genome-scale data the
MLML tool has been designed to produce accurate DNA methylation and hydroxymethylation
levels from preprocessed oxBS-seq, TAB-seq and other similar data [Quy et al., 2013].
To ll this gap we developed BiQ Analyzer HiMod (or shortly BiQ HiMod), a specialized
interactive software package for the preprocessing, quality control and analysis of various
DNA modications in high-throughput targeted sequencing experiments. BiQ HiMod is an
extension of our previously published BiQ Analyzer HT tool [Lutsik et al., 2011]. It provides
a user-friendly interface, comprehensive and customizable streamlined analysis pipeline, rich
graphical and tabular output. The tool currently supports four experimental assays and can
be easily extended to include the upcoming methods.
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a
b
Figure 5.1: Principal scheme of oxBS-seq and fCAB-seq methods. a. oxBS-seq. Oxidative bisulfite
treatment followed by PCR leads to conversion of the oxidative modifications to thymines
while only 5mC appears as cytosine in the sequencing reads. The cumulative level of 5hmC
can be established for each CpG site by comparing to ordinary bisulfite sequencing. b. In
fCAB-seq 5fC is protected from the conversion and together with 5mC and 5hmC appears
as cytosine aer PCR. The bulk 5fC abundance is calculated by subtracting the cumulative
levels of 5mC + 5hmC pair obtained from ordinary bisulfite sequencing.
Table 5.1: Information that can be extracted from each DNA modification profiling method supported
by BiQ Analyzer HiMod
Method Underlying modification Measurements
Bisulfite treatment Modified treatment
C T C T
oxBS-seq 5mC
5hmC
5fC
5caC
C
5mC (SM)
5hmC (B)
5fC + 5caC + C (B)
TAB-seq
5mC
5hmC
5fC
5caC
C
5hmC
5mC
5fC
5caC
C
5hmC (SM)
5mC (B)
5fC + 5caC + C (B)
fCAB-seq
5mC
5hmC
5fC
5caC
C
5fC (B)
5mC + 5hmC (B)
5caC + C (B)
CAB-seq
5mC
5hmC
5caC
5fC
C
5caC (B)
5mC + 5hmC (B)
5fC + C (B)
SM, single-molecule resolution; B, bulk per-CpG measurement
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5.2 BiQ Analyzer HiMod
5.2.1 Overview
BiQ Analyzer HiMod is a cross-platform interactive Java application, which can run on any
system with properly installed and congured Java Runtime Environment. The package in-
stallation is performed via a simple “click-through” installer. BiQ HiMod facilitates a fully in-
teractive primary processing and analysis of sequencing data from locus-specic DNA modi-
cation proling experiments, and currently supports oxBS-seq, TAB-seq, fCAB-seq and CAB-
seq assays. The comprehensive and ergonomic graphical user interface provides means for
multi-level overview of the complete multiplexed sequencing project, in which a number of
genomic loci of interest are sequenced in several biological samples. The underlying software
architecture uses the fact that most of the basic data processing steps are invariant to the type
of chemical treatment and thus the reads from ordinary and modied bisulte procedure can
be preprocessed independently. During the quality control cycle the user renes the quality
thresholds of the processing pipeline until a satisfactory quality level is reached for each read
batch. After low-level processing, cumulative levels of each DNA modication are summa-
rized based on the results of the individual preprocessing pipeline runs. Final results can be
exported as tables, gures, alignments, and genome browser tracks (see Supplementary text
for a detailed list). Importantly, BiQ HiMod maintains the full functionality of the previous
versions by supporting the analysis of conventional bisulte sequencing data in an indepen-
dent analysis mode.
5.2.2 Data preparation and project setup
BiQ HiMoD is designed to import multiple data sets of individual sequencing reactions and
loci. Today’s data sets are often generated by NGS-based multiplexed locus-specic sequenc-
ing [Holland et al., 2008; Robinson et al., 2011; Rohde et al., 2010]. In NGS approaches sequences
are usually indexed by short sequence tags (using multiplexing library kits), pooled and sub-
mitted to a high-throughput sequencing platform, e.g. Illumina MiSeq or Roche 454. In such a
setting BiQ HiMod requires the direct sequencing output to be demultiplexed using available
third-party tools. We recommend the barcode splitter from Galaxy [Blankenberg et al., 2010;
Giardine et al., 2005; Goecks et al., 2010] as an adequate solution which suits researchers with
minimal bioinformatics experience. Reads ready to be loaded must be in FASTA or FASTQ
format with one le per each sample-locus-treatment combination.
Besides demultiplexing, data preparation usually includes several additional standard steps,
e.g. trimming of low quality parts of the sequence reads (often at the 3-end) and – in case of
paired-end sequencing – joining of overlapping mate reads. In the FAQ section of the BiQ
HiMod web site (http://biq-analyzer-himod.bioinf.mpi-inf.mpg.de/FAQ.php) we de-
scribe an example of such a data preparation workow in a step-by-step way using third-party
tools integrated into the Galaxy framework [Blankenberg et al., 2010; Giardine et al., 2005;
Goecks et al., 2010].
Following data preparation one needs to set up an analysis project and import the data.
For a relatively small project this can be done directly using the GUI controls. For larger data
sets one should prepare a spreadsheet-like text le, (see our example on the program web site).
Samples are dened by deliberate string identiers, while the genomic loci exhibit one-to-one
mapping to their genomic reference sequences, supplied as single- or multi-sequence FASTA
les. We recommend extracting sequence information via the Galaxy “Extract Sequence” tool
starting from a BED le with genomic coordinates of each amplicon, such that the generated
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FASTA records contain genomic location information. This information will be used further
on, in order to bring the analysis into the genomic context and generate genome browser
tracks.
Finally, sequencing reads can be imported directly from the genome-wide sequencing ex-
periment (e.g. whole-genome or reduced-representation bisulte sequencing), if the data are
available as aligned sequencing reads (BAM les). BiQ HiMod facilitates loading the reads of
a corresponding region based on coordinate information and analyzing them in the context
of the corresponding genomic reference. This feature of BiQ HiMod can be extremely useful
for quickly scanning several locus specic read distributions in regions of interest in large
genome-wide WGBS or RRBS datasets provided they are accessible as BAM archives.
5.2.3 Primary processing pipeline
The software backend was subjected to several modications compared to the predecessor
version of the tool. The FASTQ les parsing is now supported using the data import library
of the BioJava project [Holland et al., 2008]. Loaded sequence reads are independently aligned
to the corresponding reference sequence using the bisulte-modied semi-global implemen-
tation of Needleman-Wunsch algorithm, which was further tweaked to improve robustness
of the modication site alignment (see Supplementary Text and [Lutsik et al., 2011] for more
details). The set of ltering criteria was extended to include sequencing quality scores, and
default thresholds are set to ensure that only high quality bases are considered. The full list
of quality metrics and DNA modication statistics are given in the Supplementary Text. All
processing and analysis options remain fully customizable and can be rened after the initial
analysis.
5.2.4 antification of modification levels
The sequencing results obtained with BiQ HiMod after conventional bisulte, oxidative--
bisulte, Tet-assisted bisulte sequencing or fCAB, redBS-seq are at comparably high resolu-
tion. A quantitative assessment of the relative abundances of dierent modications depends
on the comparison of two independent sequencing results. This comparative mode is a core
feature implemented in BiQ HiMod. However, these comparisons have two main limitations:
i) except for one modication type one can obtain estimates of modication dierences at sin-
gle CpG positions only as an average across all sequences and not per sequence ii) in most
comparisons combinations of several modication types are not separable from each other.
For illustration, we consider the results of the oxBS-seq method. Here, the reads from the or-
dinary bisulte treatment contain unconverted cytosines which were methylated or hydrox-
ymethylated in the original DNA molecule. The read cytosines from the oxidative bisulte
treatment can only be mapped to the 5mC of the original DNA. All in all, oxBS-seq yields a
single-molecule resolution map of 5mC, bulk per-CpG average levels of 5hmC and a combi-
nation of 5fC, 5caC and unmodied cytosines. Table 1 summarizes the information which can
be extracted from each of the data types. For every type of analysis BiQ HiMod takes into
account all potential modications and summarizes the information accordingly.
The estimation of bulk modication levels in BiQ HiMod is performed by a simple subtrac-
tion of converted cytosine frequencies. In case of low abundance of the target modication, in
particular 5fC and 5caC, the true biological changes of modication levels may overlap with
the experimental and the technical error range, sometimes leading to negative DNA modica-
tion levels. To overcome such diculties, on the experimental side we recommend gathering
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data from several independent experiments using high and ultra-high sequencing coverage.
Moreover, the statistical signicance of the observed variation should be tested. Summarized
data can be exported in bedGraph format and loaded into downstream statistical software,
e.g. MLML or RnBeads (http://rnbeads.mpi-inf.mpg.de), for correction and proper statistical
evaluation.
5.2.5 Visualization and data export
The frontend of BiQ HiMod provides capabilities for the top-down level-by-level exploration
of a sequencing experiment. On the top level the global overview of the analysis project is
given by the samples vs. loci heat maps visualizing average modication abundances for each
sample-locus pair (Figure 5.2, a). More detailed proles of each studied locus are provided by
the locus-wide bar plots visualizing the modication levels at each CpG position with realistic
relative genomic distances (Figure 5.2, b). On the bottom level, sequence pileup, read-level cy-
tosine pattern map and data tables are available for the most in-depth exploration and quality
control similar to the analysis mode of BiQ Analyzer HT. The newly introduced diagnostic
plots simplify the selection of the quality control thresholds by visualizing read batch-wide
distributions of major analysis metrics, e.g., score and sequence identity of the read-reference
alignment, bisulte conversion rate, number of missing or mutated modication sites etc. (Fig-
ure 5.2, c).
Read-level and summarized modication data can be exported as tab-delimited les for
downstream statistical analysis and visualization in favorite statistical software packages, e.g.,
R/Bioconductor, SPSS, and Excel, or custom bioinformatic pipelines. Furthermore, BiQ HiMod
feeds into large-scale experimental projects by exporting its results as genome browser tracks.
Furthermore, methylation values for each analyzed CpG-site can be saved in bedGraph format
importable into genome viewers and browsers, such as IGV [Robinson et al., 2011] or UCSC
Genome Browser [Kent et al., 2002] (http://genome.ucsc.edu/index.html) (see example
in Figure 5.2, d). This allows for a convenient display of amplicon validation data in the con-
text of genome-wide epigenetic data tracks, such as DNA methylation, histone modication,
chromatin accessibility maps etc.
5.2.6 Soware architecture, GUI improvements and the new
graphics engine
BiQ HiMod builds upon the modular and robust design of its predecessor tool, BiQ Ana-
lyzer HT, with a multistep data processing pipeline, as its backend, combined with an in-
teractive graphical user interface at the frontend. The backend takes raw sequencing reads
and reference sequence information as input, performs a series of preprocessing steps – data
loading, alignment, quality ltering, cytosine conversion calling – and generates the result-
ing tables and graphics for each sample-locus combination. The backend output is written
directly to the hard drive and can be found in the project directory. This results in ecient
use of the operating memory and guards against information loss. The interactive frontend,
implemented in Java standard AWT/Swing framework, enables the setup of a large-scale mul-
tiplexed NGS analysis project for one of the supported proling methods, coordination of the
pipeline runs, and summarization of the results at the sample, locus, and project levels as well
as export of the results.
BiQ HiMod expands the basic form of the GUI design of the predecessor tool, BiQ Analyzer
HT, by introducing several major improvements. First, the project summary view has been
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Gene 1 Gene 2
0.79 0.38 Sample 1
0.79 0.37 Sample 2
0.78 0.33 Sample 3
0.77 0.36 Sample 4
0.72 0.22 Sample 5
0.73 0.24 Sample 6
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5mC + 5hmC
5mC
Figure 2
Figure 5.2: BiQ Analyzer HiMod visualization features. a. Global heat map of average bulk (5mC +
5hmC) modification levels at sequenced loci across the samples. The default color code is
given in the color legend (see Figure 5.S2 for more details). b. Bar chart displaying stacked
levels of two modifications at each CpG position in a single locus (see also Figure 5.S3). c.
Diagnostic histogram visualizing the distribution of a quality control metric – sequence
identity of each read-reference alignment – simplifying the sequence identity cuto se-
lection. d. Integration with the IGV genome browser showing genomic tracks with 5mC
and 5hmC levels of three samples (the value range is much smaller for the 5hmC tracks).
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Table 5.2: Benchmarking of BiQ Analyzer HiMod on artificially generated read batches of variable
size.
Number. of reads in each batcha 1,000 2,000 5,000 10,000 20,000 50,000
Running time, min:s normal 0:15 0:32 1:52 5:20 16:48 155:15
w/o paern mapsb 0:15 0:26 1:06 2:13 4:25 25:14
a Given are numbers of reads in each of two read batches (oxBS and conventional bisulfite) processed in every
benchmarking step. Therefore the actual number of processed reads was twice the given number in each step.
b The high computation time for large read sets is based on the size of the produced single read-resolution
paern maps. The user can decide which graphics to generate and by choosing to disable paern maps the
computation time can be significantly reduced.
turned into an ultimate control panel, aording an exhaustive overview without the need of
frequent panel switching. It includes a project summary table, presenting the most crucial in-
formation about each read batch, the project-level heat maps visualizing average modication
levels, and locus-wide bar charts dynamically generated for each selected read batch. Second,
the detailed views of individual read batches were updated and now include the summary
pages presenting the levels of each modication or group of modications as tables and plots.
BiQ HiMod features a completely new custom graphical engine generating high-quality
vector images in SVG format. Most of the plotting parameters, including the exible color
scheme, are fully user-adjustable. The exported SVG les can be further edited via one of the
popular image packages without any loss of quality or directly incorporated into manuscripts
and reports.
5.3 Validation on artificial and real biological data and
performance assessment
In order to test BiQ HiMod and assess its performance we generated articial read batches for
each supported type of experiment by simulation (see Supplementary Text 1 for details). We
estimated the accuracy and robustness of BiQ HiMod results under dierent conditions.
We then applied BiQ HiMod to reprocess the earlier published oxBS-seq data set obtained
by sequencing of repetitive elements in two types of mouse ES cells [Ficz et al., 2013]. In brief,
serum cultured murine E14 ES cells and 2i-medium cultured ES cells from three dierent time
points – 1, 3 and 7 days of cultivation – were sampled, two replicates of each. After oxidative
and conventional bisulte treatment, hairpin amplicons of regions within two repeat types
– intracisternal. A particle, also known as IAP, and long interspersed elements, also known
as LINE-1 or L1 – were constructed as described in an earlier study [Arand et al., 2012]. The
amplicons were sequenced on the MiSeq platform from Illumina using paired end sequencing
(2 x 150). The BiQ HiMod results document an accumulation of 5hmC at LINE1 but not at IAP
elements during the rst 72 hours of cultivation in 2i-medium (Figure 5.S7).
We also benchmarked the runtime of BiQ Analyzer HiMod by analyzing batches of 1,000
to 50,000 articially generated reads. The tests were carried out on a machine with a 2.4 GHz
Intel Core i5 Haswell dual core processor and 2 GB of RAM. The results of the benchmark,
given in Table 2, show that moderate-sized analyses can be performed in a reasonable amount
of time on an average commodity laptop. For data from large-scale experiments amounting to
several millions or more sequence reads, we recommend running BiQ HiMod on industrial-
level workstations with several multicore CPUs and a few dozen GB of RAM.
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5.4 Conclusions and outlook
BiQ Analyzer HiMod is the rst interactive software package for preprocessing, quality control
and initial analysis of various DNA modications from four dierent experimental methods.
Developed on the basis of BiQ Analyzer HT, it features a thoroughly reworked GUI with a large
number of analysis plots as well as a new customizable vector graphics engine, additional data
import and export formats. The tool enables a full-blown analysis starting from raw sequence
reads up to publication-quality plots and genome browser tracks. BiQ HiMod exploits modu-
lar and exible software design allowing for painless further extensions to support upcoming
experimental assays, such as MAB-Seq [Hu and Tzeng, 2014]. The standardized, comprehen-
sive and user-friendly software paradigm implemented by BiQ HiMod will help the tool nd
numerous applications in basic biology and biomedical research.
5.5 Supplementary Material
Supplementary Text
Artificial test data
In order to have controlled data for sanity checks and testing we developed a simulation frame-
work that generates articial sequencing reads for each of the supported methods. The simu-
lation took the following parameters as input:
• one or more reference sequences in FASTA format
• mean methylation (m), hydroxymethylation (h), formylation (f ) and carboxylation (c)rate
µmod, mod ∈ m,h, f, c,
• standard deviation for each modication rate σmod,
• the average number of reads, µreads and
• standard deviation of the number of reads σreads,
• number of samples to be constructed for each reference.
The number of reads N in each read set was determined by a gaussian distribution with
mean µreads and variance σ2reads to create some more dierence between the data sets.
The modication levels for each of S CpG position in the reference sequence were obtained
by generating random samples from a [0,1]-truncated Gaussian distribution with mean µmod
and variance σ2mod of size C . The sampling was repeated for each of the four modications, to
generate S×4 matrixM of probabilities of each modication occurring at each CpG position.
The input parameter values were chosen such that the sums of the rows did not exceed 1. The
modication levels for CpGs for which
∑
modMj ,mod > 1 were resampled until this criterion
was fullled.
To create a read set rst N simple copies of the reference sequence were generated. Then,
the precise state was dened for each CpG position j ∈ {1 . . . S} by sampling N times from
a uniform distribution on [0,1] and mapping the outcomes to the discrete modication states
for each read k ∈ {1 . . . N} using the following rule:
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modificationj ,k =

5mC, 0 < rk < Mj ,m
5hmC, Mj ,m < rk < Mj ,m +Mj ,h
5fC, Mj ,m +Mj ,h < rk < Mj ,m +Mj ,h +Mj ,f
5caC, Mj ,m +Mj ,h +Mj ,f < rk < Mj ,m +Mj ,h +Mj ,f +Mj ,c
C, Mj ,m +Mj ,h +Mj ,f +Mj ,c < rk < 100
r - a sample of size N from the uniform distribution on [0, 1].
The modied cytosines were nally translated into thymine or cytosine based on their
modication state and the selected experimental method, to simulate the eects of the (mod-
ied) bisulte treatment and subsequent PCR amplication. A uniformly distributed random
value on [0,1] was used to simulate errors in this process. If the random value was smaller
pmod the translation did not take place. To simulate incomplete reads, a gaussian distributed
amount of bases were set to gap characters in the beginning or at the end of each read. This
gaussian distribution had a mean of µedgeGap and a variance of σ2edgeGap. An error probability
pseq was introduced to simulate sequencing errors, and dened the probability with which a
reference sequence base was replaced with a random base. Furthermore a gaussian distributed
conversion probability with a mean of µconv and a variance of σ2conv was used to convert cy-
tosines outside of the modication context to thymine. If the gaussian distributed value was
smaller than a given threshold pconv, the current base was converted.
The specic test sets, distributed with BiQ HiMod, were produced based on real reference
sequences of two repetitive elements, analyzed in Ficz et al. study (see main text for more de-
tails). The variable positions of the reference sequences, which were abundant in the reference
sequences, were mapped to one of their actual possible bases using a uniformly distributed
random number on [0,1] and the same probability for each possibility.
The the following parameter values were used:
• µm = 502s−1
• σm = 10
• µh = 202s−1
• σh = 10
• µf = 52s−1
• σf = 10
• µc = 52s−1
• σc = 10
• pmod = 0.02
• µreads = 1000
• σreads = 10
• µedgeGap = 0
• σedgeGap = l · 0.05
• pseq = 0.05
• µconv = 0
• σconv = 1
• pconv = 0.8
where s is the index of the simulated "biological" sample and l the length of the current
read. The parameter values were chosen with the goal that the simulated data were close to
the expected real biological data.
Alignment
The pairwise alignment of each read to the amplicon reference sequence in BiQ HiMod is
performed by a further modied version of the Needleman-Wunsch algorithm used in BiQ
Analyzer HT. In brief, the alignment algorithm implementation features a semi-global gap
penalty to account for variable read length, and extended alphabet of the reference sequence
to aid the alignment of the potentially modied sites (see [Lutsik et al., 2011] for an in-depth
description). In BiQ HT a new wildcard base was introduced to further improve the alignment
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of the modication sites. Cytosines within a methylation context are converted to X both in
the reference sequence and in the sequence reads (CG cytosines in the reference and [CT]G
cytosines in the reads). Matching Xs return a high score in the alignment to promote the
alignment of methylation context positions.
The default parameters lead to good alignments in most of the cases but can be adjusted
by the user if needed.
M - Cost Matrix =

A G Y T − N Z R S W K M B D H V X
A 5 −5 −5 −5 −5 −5 −5 5 −5 5 −5 5 −5 5 5 5 −5
G −5 5 −5 −5 −5 −5 −5 5 5 −5 5 −5 5 5 −5 5 5
C −5 −5 5 −5 −5 −5 8 −5 5 −5 −5 5 5 −5 5 5 −5
T −5 −5 5 5 −5 −5 8 −5 −5 5 5 −5 5 5 5 −5 −5
− −5 −5 −5 −5 0 0 −5 −5 −5 −5 −5 −5 −5 −5 −5 −5 −5
N −5 −5 −5 −5 0 0 −5 −5 −5 −5 −5 −5 −5 −5 −5 −5 −5
X −5 5 −5 −5 −5 −5 −5 5 5 −5 −5 −5 5 −5 −5 5 8

g - Gap extension penalty = -7.0
b - CpG Alignment Bonus = 0.0
Metrics
Sequencing quality BiQ Analyzer HiMod controls the sequencing quality by permitting at most
5% of the bases in each sequence read to have sequence quality score below a user-specied
threshold. The reads with low quality are discarded. The mean quality of all bases is calculated
by dividing the score of each base by the number of bases of the sequence:
Q =
∑lread
i=1 fi
lread
fi - FastQ score of the base i
lread - The length of the read
Sequence identity
The sequence identity is the fraction of bases which are the same in the reference and the
read sequence including the converted cytosines. Based on the length of the shorter sequence
the corresponding parts of both sequences are compared.
SI =
nconv + nid
min(lref , lread)
nconv - The number of bases converted in one sequence but with the same origin
nid - The number of identical bases
lref - The length of the reference sequence
lread - The length of the read
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Conversion rate
The conversion rate is the ratio is calculated for each read as the number of converted
cytosines outside of the modication sites to the number of not converted cytosines outside
of the modication sites.
CR =
t − tin
cout
t - the number of all converted cytosines
tin - the number of converted cytosines in the modication sites
cout - the total number of cytosines out of modication sites
Modication rates
The modication rate is calculated by dividing the number of converted modication sites
by the total number of the reads in a read batch. This is done for each type of modication
(5mC, 5hmC, 5fC, 5caC):
MR =
nc
n
nc - the number of converted modication sites
n - the total number of the reads
Output
BiQ Analyzer HiMod has rich export capabilities. The results can be saved as tables in tab-
separated value (TSV) format, as vector images in SVG format, as genome-browser tracks etc.
The instant and optional output les are summarized in the Tables 5.S1 to 5.S3.
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Supplementary Figures
Figure 5.S1: Principal scheme of TAB-seq and CAB-seq methods. a TAB-seq applies enzymatic oxi-
dation by Tet1 protein to convert 5mC to 5hmC and further to 5fC and 5caC, while the
initially present 5hmC is protected by glycosylation. The 5mC level is calculated by sub-
traction from conventional bisulfite sequencing. b In CAB-seq 5caC is protected from
the conversion and together with 5mC and 5hmC appears as cytosine aer PCR. The
bulk 5caC abundance is calculated by subtracting the cumulative levels of 5mC + 5hmC
pair obtained from ordinary bisulfite sequencing.
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IAP LINE-1
0.79 0.38 Serum 1
0.79 0.37 Serum 2
0.78 0.33 2i 1day 1
0.77 0.36 2i 1day 2
0.72 0.22 2i 3days 1
0.73 0.24 2i 3days 2
0.62 0.08 2i 7days 1
0.62 0.08 2i 7days 2
0 0.5 1.00.25 0.75
5mC + 5hmC level
negative Values
Sample 5
Sample 6
Sample 8
Sample 7
Sample 4
Sample 3
Sample 2
Sample 1
Gene 2Gene 1
Figure 5.S2: A project heatmap displays a matrix of mean modification level for each analyzed am-
plicon in every sample. In case of an analysis bases on two sequencing approaches, there
are three project heatmaps: one for each sequencing approach and one for the dierence
between the returned values. Each entry is colored according to the mean modification
level of the amplicon. Furthermore the mean modification level is given as a decimal
between 0 and 1. In case of dierence heatmaps, negative values are possible. Large
negative values are, as a rule, indicative of problems with the experimental procedure.
Such cases are marked with an X-crossed cells.
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Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 Site 7 Site 8 Site 9 Site 10 Site 11 Site 12 Site 13 Site 14 Site 15
0.44 0.41 0.52 0.45 0.33 0.17 0.14 0.35 0.34 0.44 0.37 0.47 0.52 0.41 0.41 Serum 1
0.43 0.4 0.5 0.44 0.32 0.16 0.14 0.34 0.35 0.41 0.36 0.47 0.5 0.39 0.4 Serum 2
0.37 0.37 0.45 0.41 0.29 0.14 0.14 0.28 0.29 0.36 0.31 0.42 0.45 0.36 0.35 2i 1day 1
0.4 0.38 0.48 0.43 0.3 0.18 0.12 0.3 0.29 0.4 0.34 0.46 0.5 0.39 0.39 2i 1day 2
0.22 0.24 0.34 0.28 0.17 0.1 0.09 0.19 0.2 0.26 0.2 0.29 0.34 0.24 0.2 2i 3days 1
0.22 0.25 0.36 0.31 0.19 0.1 0.09 0.2 0.21 0.27 0.2 0.31 0.36 0.26 0.21 2i 3days 2
0.07 0.09 0.15 0.09 0.05 0.02 0.04 0.05 0.07 0.07 0.05 0.1 0.16 0.08 0.06 2i 7days 1
0.07 0.08 0.16 0.1 0.05 0.04 0.04 0.06 0.08 0.07 0.06 0.1 0.16 0.06 0.05 2i 7days 2
0 0.3 0.6
5mC + 5hmC level
negative Values
Sample 1
Sample 3
Sample 5
Sample 4
Sample 6
Sample 7
Sample 8
Sample 2
Figure 5.S3: A locus heatmap visualizes a matrix of mean modification levels for every potential mod-
ification site of very sample for one specified amplicon. In case of an analysis bases on
two sequencing approaches, there are three reference heatmaps: one for each sequenc-
ing approach and one for the dierence between the returned values. The graphical code
is the same as for the project heatmap (see Supplementary Fig. 5.S2).
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CG1 CG2 CG3 CG4 CG5 CG6 CG7 CG8 CG9 CG10 CG11 CG12 CG13 CG14 CG15
Figure 5.S4: A DNA modification paern map displays a matrix which shows the conversion state
of every potentially modifiable cytosine in every read of a processed read set. Each col-
umn corresponds to a modification site (e.g., a CpG) while each row represents a single
read. The colors representing converted and unconverted states of the modification site-
cytosines as well as the color for mutated modification sites can be customized.
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100%
80%
60%
40%
20%
0% 66bp 14bp 4bp 20bp 11bp 4bp 15bp 31bp 5bp 15bp 4bp 12bp 21bp 4bp 14bp 84bp
CG1 CG2 CG3 CG4 CG5 CG6 CG7 CG8 CG9 CG10 CG11 CG12 CG13 CG14 CG15
5mC + 5hmC
Figure 5.S5: A locus-wide bar chart shows the modification level for each site in a given locus for one
selected sample. For an analysis project with two given readsets (i.e., for all modified
bisulfite methods) there are two bar charts for each amplicon in every sample. A dif-
ference bar chart shows the calculated dierence of the modification levels of the two
readsets. For instance, in case of an oxidative bisulfite analysis project the dierence be-
tween the modification levels represents the bulk 5hmC level. The values represented by
this bar chart are expected to fall into [0,1] interval, while large negative values point at
technical problems of the assay.
100%
80%
60%
40%
20%
0% 66bp 14bp 4bp 20bp 11bp 4bp 15bp 31bp 5bp 15bp 4bp 12bp 21bp 4bp 14bp 84bp
CG1 CG2 CG3 CG4 CG5 CG6 CG7 CG8 CG9 CG10 CG11 CG12 CG13 CG14 CG15
5mC + 5hmC
5mC
Figure 5.S6: A stacked locus-wide bar chart shows the modification levels for both, modified and con-
ventional bisulfite read sets in one plot. The bars of the readset, in which the modification
level is is expected to be higher, are ploed in the background layer while the bars of the
other readset are ploed on top of them. Therefore one can read out both values as well
as the dierence. In case the front row bars are higher than the background ones, the
laer are displayed by a thin horizontal line.
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CG1+ CG2+ CG3+ CG4+ CG5+ CG6+ CG7+ CG8+ CG8- CG7- CG6- CG5- CG4- CG3-
-0.01 -0.02 -0.03 0.01 0.02 0.03 -0.03 0.01 -0.01 -0.05 -0.01 -0.03 -0.01 0.0 Serum 1
-0.01 -0.02 -0.02 0.02 0.02 0.0 -0.01 0.0 -0.01 -0.01 -0.03 -0.01 0.01 0.03 Serum 2
0.01 0.01 -0.03 0.01 0.04 0.03 -0.02 0.02 0.02 0.02 0.01 0.0 0.02 0.01 2i 1day 1
0.01 -0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.04 0.0 0.01 0.01 0.02 2i 1day 2
0.0 0.01 0.0 0.01 0.02 0.01 -0.01 0.01 0.02 0.04 0.03 0.03 0.02 0.02 2i 3days 1
0.01 0.01 0.0 0.02 0.04 0.03 0.0 0.02 0.02 0.02 0.03 0.02 0.02 0.0 2i 3days 2
0.02 0.02 -0.02 0.05 0.05 0.06 -0.02 0.04 0.01 -0.04 0.02 0.0 0.01 -0.02 2i 7days 1
0.03 0.02 0.01 0.01 0.02 0.01 0.0 0.05 0.02 -0.03 0.04 0.04 0.03 -0.02 2i 7days 2
0 0.1 0.2
5hmC level
negative Values
a
b
CG1+ CG2+ CG3+ CG4+ CG5+ CG6+ CG7+ CG8- CG7- CG6- CG5- CG4- CG3- CG2- CG1-
0.06 0.02 0.01 0.05 0.03 0.0 0.04 0.07 0.06 0.06 0.04 0.04 0.02 0.02 0.04 Serum 1
0.04 0.03 0.06 0.01 0.04 0.0 0.03 0.08 0.06 0.1 0.05 0.03 0.04 0.0 0.02 Serum 2
0.08 0.04 0.04 0.07 0.04 0.0 0.04 0.03 0.06 0.06 0.03 0.05 0.04 0.04 0.05 2i 1day 1
0.11 0.04 0.07 0.08 0.06 0.04 0.01 0.04 0.04 0.08 0.07 0.08 0.09 0.06 0.09 2i 1day 2
0.09 0.06 0.1 0.08 0.06 0.02 0.03 0.07 0.06 0.1 0.07 0.07 0.11 0.07 0.07 2i 3days 1
0.08 0.07 0.09 0.1 0.08 0.02 0.03 0.07 0.07 0.08 0.07 0.08 0.09 0.07 0.07 2i 3days 2
0.03 0.04 0.04 0.03 0.01 0.0 0.01 0.0 0.02 0.02 0.01 0.02 0.04 0.03 0.02 2i 7days 1
0.03 0.02 0.04 0.03 0.01 0.02 0.01 0.01 0.01 0.03 0.03 0.02 0.04 0.0 0.0 2i 7days 2
0 0.1 0.2
5hmC level
negative Values
Figure 5.S7: Reprocessing of Ficz et al. oxBS-seq data [Ficz et al., 2013]. a 5hmC level locus-wide
heatmap for the IAP amplicon. b 5hmC level locus-wide heatmap for the LINE1 amplicon.
Since the sequencing was done on a hairpin-library, most of the covered CpG sites are
called twice: one time for each of the original DNA strands.
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Supplementary Tables
Table 5.S1: Main exported graphics
File Content Type
Project heatmap Mean modification data for each amplicon sample
combination
SVG
Statistic heatmap / table Heatmaps and tables containing mean values of im-
portant statistics as sequence identity, read length,
standard deviation, conversion rate, number of
loaded/filtered/exported reads
SVG
Reference heatmap Mean modification data for each modification con-
text position of every sample
SVG
DNA modification paern map Modification paern for every read of the specified
amplicon sample combination
SVG
Single bar chart Mean modification level for every modification con-
text position
SVG
Dierence bar chart Mean dierence modification level for every modifi-
cation context position
SVG
Comparison bar chart Mean modification level for every modification con-
text position. Contains modification levels for both
readsets
SVG
Table 5.S2: Main exported files
File Content Type
Alignment A pseudo-multiple sequence alignment obtained by
merging the pairwise read-reference alignment
FASTA
Result table for a readset Tab separated information about ID, Alignment
score, sequence identity, modification paern, mean
modification level per read, missing CG number, con-
version rate reference and sample
TSV
Summary result table Tab separated information about Reference Sample,
CG position and the three mean modification levels
TSV
Summary for a readset A summary of the analysis TXT
Comparison Summary A summary of the read set comparison TXT
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Table 5.S3: Optionally exported files
File Content Type
All results table One tab-delimited table for all samples and am-
plicons containing ID, alignment score, sequence
identity, modification paern, mean modifica-
tion, missing sites, conversion rate, reference
name and sample name
TSV
Paern table One tab-delimited table for the selected sample
and amplicon containing ID, tab separated pat-
tern, reference name, sample name and if neces-
sary the readset type
TSV
Paern table for a reference Tab-delimited tables for all sample of the selected
reference containing ID, tab separated paern,
reference name and sample name. One for each
readset type
TSV
GFF file Genome browser track (one per sample) GFF
Bedgraph Genome browser track (one per sample) bedGraph
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Abstract
Background: Large-scale DNA methylation studies on blood or tissue samples are
confronted with sample-specic confounding factors such as heterogeneous cell com-
position and individual genetic variation. An unbiased discovery and exploration of
such confounding factors is very important for epigenetic studies.
Results: Here, we present MeDeCom, a reference-free computational framework
using non-negative matrix factorization to decompose complex methylome data of
cell mixtures. MeDeCom not only generates interpretable latent methylation com-
ponents (LMCs) but also provides estimates of LMC proportions per sample. LMCs
can be used for biological exploration, correlating them to reference epigenomes or
to other annotated cell type-specic molecular signatures. Estimated proportions
can be used to interpret sample-specic variation, disease or age-related phenotypes.
Here we demonstrate the MeDeCom performance on articial cell mixtures and com-
plex biological methylome data sets generated for whole blood, partially puried cell
populations and complex brain tissue.
Conclusions: MeDeCom produces a reference-free deconvolution of complex methy-
lation data across many samples. The latent components dened by MeDeCom can
be used for biological exploration. MeDeCom can be applied to any high-resolution
WGBS or Illumina 450k/EPIC array data set of mixed cell populations that has a suf-
cient technical quality.
Keywords: DNA methylation, DNA methylome, cell heterogeneity, deconvolution,
matrix factorization, epigenetics
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6.1 Background
DNA methylation is one of the most extensively studied epigenetic marks in the human genome.
While it is relatively easy to measure, DNA methylation closely mirrors the functional state
of a cell [Schübeler, 2015]. Each human cell potentially comes with a characteristic methyla-
tion prole (methylome) at roughly 27 million CpG dinucleotides [Pelizzola and Ecker, 2011;
Roadmap Epigenomics Consortium et al., 2015]. Our current understanding of DNA methy-
lomes is that: i) they undergo signicant global and lineage-related changes during develop-
ment [Reik et al., 2001]; ii) consequently, they are remarkably cell type-specic [Baron et al.,
2006; Ji et al., 2010; Roadmap Epigenomics Consortium et al., 2015]; iii) they reect the individ-
ual (genetic) constitution [Shoemaker et al., 2010] but are also subject to environmental inu-
ences [Christiansen et al., 2009; Lee and Pausova, 2013]; iv) they change with aging [Horvath,
2013] and v) they accumulate errors over time and are altered in diseased cells [Baylin, 2005;
Esteller, 2007]. DNA methylation can therefore be used to infer the developmental origin, func-
tional and disease-associated changes of cells. However, our methodological capacity to study
complete single-cell methylomes on a large scale has been rather limited so far [Schwartzman
and Tanay, 2015].
For practical reasons comparative epigenomic studies make use of multi-cellular samples
from tissues, organs or body uids such as blood [Bernstein et al., 2010; Roadmap Epigenomics
Consortium et al., 2015]. All these sources are usually composed of several major and minor
cell types. Brain tissue and whole blood are two examples of complex primary human re-
sources widely used for comparative DNA methylation studies [Michels et al., 2013]. Whole
blood leukocytes, which is the most widely used resource for DNA methylome studies [Michels
et al., 2013], include up to ten major and many more minor cell types. Cell population- or cell
type-attributed heterogeneity was shown to be a major source of variation in comparative
blood-based DNA methylome studies [Lam et al., 2012]. The same holds for studies performed
with brain where dierent neuronal, glial and microglial cell types are present. The composi-
tional change of cells in brain tissues may be due to age, gender and disease state [Kaut et al.,
2012; Lunnon et al., 2014; Zhang et al., 2010, 2011]. Therefore, when comparing the brain-
specic DNA methylome between individuals it is important to consider such confounding
eects [Montaño et al., 2013]. Overall, variable cell composition appears to be one of the
strongest confounders in DNA methylome analysis [Adalsteinsson et al., 2012; Houseman
et al., 2015; Jae and Irizarry, 2014].
In view of these observations DNA methylation studies have been applying cell enrich-
ment or cell separation techniques [Dainiak et al., 2007; Tomlinson et al., 2013] to experimen-
tally homogenize the samples prior to methylation analysis [Bundo et al., 2016; Rakyan et al.,
2011]. These methods certainly enhance the interpretability of results, but also come with
the risk of introducing undenable experimental variation, for instance due to non-specic
labeling, problems with tissue dissociation, insucient depletion of non-target cells etc [Ku-
mar and Bhardwaj, 2008; Tomlinson et al., 2013]. In the worst case, cell separation may even
exclude unknown but informative cell populations. An ideal analysis would, therefore, avoid
cell separation and rather study cell-specic methylomes to understand the complex epige-
netic changes occurring in the tissue. Single-cell methylomes would be the gold standard to
tackle this problem, but they are still dicult and costly to obtain for studies in which large
sample numbers have to be compared [Fang et al., 2012; Kantlehner et al., 2011; Schadt et al.,
2013; Schwartzman and Tanay, 2015]. Moreover, non-uniform cell separation or sampling in
single-cell approaches may even introduce uncontrollable confounding eects since important
changes in rare or dicult-to-recover cell populations may be missed.
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Possible approaches to overcome heterogeneity problems is the use of computational esti-
mation or correction (adjustment) methods [Lowe and Rakyan, 2014]. Houseman et al. were
the rst to develop a systematic approach that used reference DNA methylation proles of
puried cell types to infer the cell type proportions in blood via a constrained projection pro-
cedure [Houseman et al., 2012]. This method is currently applied for DNA methylation com-
parisons in whole blood [Accomando et al., 2014; Koestler et al., 2013; Liu et al., 2013]. Similar
cell separation-based approaches were also used for complex tissues such as brain [Guintivano
et al., 2013; Montaño et al., 2013]. Finally, reference-free methods were developed that adjust
for DNA methylation changes caused by cell heterogeneity allowing for the quantication of
“direct” methylation eects [Houseman and Ince, 2014; Rahmani et al., 2016; Zou et al., 2014].
So far, no method has been described which would be able to infer full DNA methylomes
of cell populations and their mixing proportions in a reference-free manner. Here we present
a computational framework called MeDeCom implementing such an unsupervised decompo-
sition approach. MeDeCom builds upon the discreteness of cellular DNA methylation states.
It uses a novel matrix factorization approach to decompose methylome data into a set of un-
derlying latent DNA methylation components (LMCs) and infers their relative contribution.
LMCs can be used for biological interpretation of complex cell composition and cell states.
We demonstrate the performance of MeDeCom in controlled experimental settings and its ap-
plication in more complex scenarios of cell populations and tissues. MeDeCom allows for an
original representation of the DNA methylation data with great relevance to the interpretation
of complex biological samples.
6.2 Results and discussion
6.2.1 MeDeCom: a computational framework for decomposition of
mixed methylomes
We constructed a novel computational framework MeDeCom to decompose mixed methy-
lomes and recover the hidden signatures of individual cell populations. The concept behind
our method is illustrated in Figure 6.1. DNA methylation is a stable base-specic modication.
It can be seen as a discrete position-specic value in DNA extracted from cells (Figure 6.1, a).
Each cell type has a characteristic pattern of discrete (binary) position-specic methylation
states. Most biological samples are mixtures of cells and hence mixtures of homogeneous
cell type-specic methylomes with sample-specic frequencies (Figure 6.1, b). Patterns and
frequencies are convoluted in DNA methylation data obtained from mixed biological sam-
ples (Figure 6.1, c). The variability of methylation between biological samples directly reects
the underlying mixing proportions and numbers of individual and distinguishable cell methy-
lomes. This information can be extracted from varying "intermediate" methylation values
in mixed samples (Figure 6.1, d). Our method decomposes the mixed methylomes into latent
methylation components (LMCs) approximating the underlying cell type-specic patterns and
estimates their frequencies (Figure 6.1, e).
With these premises MeDeCom consists of three key elements (fully described in the
Method section). First, we postulate a linear mixture model representing a set of mixture
methylomes as a noisy product of matrices of LMCs and mixture proportions (equation (6.1)
in Methods). Second, for tting the model we devise a matrix factorization algorithm which
uses a special quadratic regularisation to impose correspondence between LMCs and the hid-
den (cell-specic) methylomes. Third, we developed a cross-validation heuristic to select the
adjustable parameters of the algorithm. The rst parameter is the hidden dimension k corre-
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sponding to the number of identiable LMCs. The second parameter is a tunable regulariza-
tion constant λ which controls the strength of the regularization and helps to obtain accurate
reconstructions of latent methylation states (see Figure 6.1, e and f).
In what follows we apply MeDeCom to synthetic and real Innium 450k data sets, and
demonstrate its usefulness to decompose and interpret complex tissue- and cell-based methy-
lation data. The results of MeDeCom can be visualized and inspected by FactorViz, a tool
allowing a user to evaluate and interpret results over a range of possible solutions. MeDeCom
as well as the interactive FactorViz web-resource are publicly available at http://public.g
enetik.uni-sb.de/medecom.
6.2.2 Validation on synthetic and artificial data
Decomposition of simulated methylation data
We rst validated MeDeCom on synthetic DNA methylation mixtures generated by simulation
(see Methods for details). The synthetic data sets varied in the numbers of true LMCs, the inter-
LMC similarity, the average distribution and the variability of the mixing proportions (see
Table 6.S1). Our goal was to assess the robustness of MeDeCom with respect to the recovery
of LMCs and mixture proportions.
Figure 6.2, a-f summarizes the results of a single characteristic test case with moderately
variable mixing proportions of ve blood-derived cell type proles (see below). The cross-
validation error (CVE) started leveling out at k ≥ 5, indicating that MeDeCom identied
the correct number of underlying LMCs (Figure 6.2, a). The optimal range for the regulari-
sation parameter λ was found around λ = 0.01. Recovered LMCs unambiguously matched
the source DNA methylation proles (Figure 6.2, b). The individual methylation proles were
reconstructed with root mean squared error (RMSE) of 0.064. MeDeCom also accurately re-
produced the mixing coecients (proportions) with mean absolute error (MAE) of 0.0296 (Fig-
ure 6.2, c-f). We obtained similar results for other cases with various numbers of underlying
components and mixing proportions (see the MeDeCom web-resource).
For extreme mixtures we observed our method approaching its performance limits. The
summary plots of the LMC recovery rate (Figure 6.S1) showed that a low number of discrimi-
nating data points, the choice of the model and the variability level of the mixing proportions
were key factors for the eciency of LMC reconstruction. We noticed that the test cases with
highly non-uniform (“biological”) proportions were much more challenging for MeDeCom as
compared to the test cases with more similar (“uniform”) synthetic cell type composition. De-
composition became impossible when variability of the mixture proportions was very low and,
at the same time, was coupled to elevated noise levels (see an example in Figure 6.S2 and the
MeDeCom web resource).
Decomposition of reconstructed cell mixtures
Next we analysed the performance of MeDeCom on public data sets in which cell mixtures
were experimentally reconstructed, i.e. dened biological samples were mixed in known pro-
portions. A very well analysed and described data set was obtained in a recent study on sorted
brain cells [Guintivano et al., 2013] (data set ArtMixN in Table 6.1). In brief, brain cells were
separated using uorescence activated cell sorting (FACS) for a neuron-specic marker NeuN,
after which the obtained NeuN+ (neuronal) and NeuN− (non-neuronal) fractions were mixed
incrementally (Table 6.S2) and the mixed methylomes were measured on a 450k array. We used
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Figure 6.1: (on the previous page) Computational framework of MeDeCom. a. At the level of a sin-
gle cell each genomic CpG site can aain only several discrete DNA methylation states.
With a good degree of approximation, single-cell methylomes can be represented by bi-
nary vectors. b. In one or more related cell samples, e.g. those from a population cohort,
all unique single-cell methylomes can be summarized in a binary-valued matrix of unique
methylomes C supplemented by a matrix of per-individual paern frequencies F . Simi-
lar single-cell methylomes are expected to form well-separated clusters, corresponding to
epigenetically distinct cell populations, such as cell types and subtypes. c. Full informa-
tion in C and F is usually inaccessible in large-scale studies, and a data matrix D for m
CpGs in n individuals (e.g. Infinium 450k-based or summarized WGBS profiles) arises as
a product of the paern and frequency matrices, distorted by sampling errors and mmea-
surement noise. Inference about the paern and frequency matrices is unrealistic based
only on D. d. MeDeCom aempts to represent D as a product with a smaller internal
dimension k (k  q). This gives rise to a matrix T of k methylome prototypes (LMCs) and
a matrixA of their relative contributions (mixing proportions) to each sample (columns of
A sum up to 1). e. The goal is that each LMC closely approximates a cluster of single-cell
methylomes corresponding to a distinct cell population. This is by penalizing intermediate
methylation values in LMCs by quadratic regularization. Degree of regularization is con-
trolled by means of tunable parameter λ. f. A low-dimensional visualization for 2 CpGs
(n = 30, k = 3) provides a good illustration of the potential ill-posedness of problem (6.2)
(see Methods) and influence of the quadratic regularization term. The three plots depict
the summarized methylome clusters (black squares), a set of given data (blue dots) and
the LMCs returned by Algorithm 1 (red squares) for three dierent choices of the regular-
ization parameter λ. All three solutions yield a perfect fit to the given data. However, only
the solution for λ = 0.1 comes reasonably close to the ground truth.
ArtMixN data set to test how well MeDeCom could recover the source NeuN+/− methylomes
and their mixing ratios.
MeDeCom identied the presence of two major LMCs and detected a sharp CVE mini-
mum close to λ = 1.25 · 10−3 (Figure 6.2, G; Figure 6.S3). Each of the recovered LMCs showed
high CpG-wise correlation to the average prole of either the NeuN+ or NeuN− fractions
(Figure 6.2, h) with high accuracy (RMSE of 0.0273 for the NeuN+-matching, and 0.0269 for
the NeuN−-matching LMC). The mixing proportions were accurately recovered as well (MAE
0.014; Figure 6.2, i). Notably, the accuracy of the proportion recovery became compromised
Figure 6.2: (on the next page) Testing MeDeCom on simulated and artificial cell mixture data. a-f. Re-
sults for the simulated data example with 5 methylation components, moderately variable
mixing proportions and medium noise level. a. Selection of parameters k and λ by cross-
validation. b. Matching of the recovered LMCs to the true underlying profiles. The den-
drogram visualizes agglomerative hierarchical clustering analysis with correlation-based
distance measure and average linkage. c-f. Recovery of the mixing proportions. “Truth”
stands for true mixing proportions, “regression” denotes the reference-based proportion
estimation as described in the Methods. In each line plot the synthetic samples are sorted
by ascending true mixing proportion. g-i. Results for the ArtMixN data set. g. Selec-
tion of parameters k and λ by cross-validation. h. Correlation of recovered LMCs to the
NeuN+/− profiles. i. Recovery of mixing proportions (only NeuN+ is shown). Notation is
the same as in c.-f..
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Table 6.1: Public Infinium 450k data sets used in the study.
ID Source GEO Acc. Brief description n Reference
Blood datasets
PureBC [Reinius et al., 2012] GSE35069 7 MACS-purified blood cell types
from blood of 6 healthy male
donors: Neutrophils, Monocytes,
B-cells, CD4+ and CD8+ T-cells,
NK-cells, and Eosinophils
42
WB1 [Liu et al., 2013] GSE42861 whole blood of healthy controls
from an RA study (technical batch
II)
87 PureBC
WB2 [Palli et al., 2003] GSE51032 whole blood of the EPIC Italy
study participants which remained
cancer-free in 2010
442 PureBC
Neuronal datasets
PureN [Guintivano et al., 2013] GSE15745 cortical NeuN+/− fractions of the
29 healthy controls
58
ArtMixN [Guintivano et al., 2013] GSE15745 9 titration mixtures of the
NeuN+/− fractions
9 PureN
FC1 [Guintivano et al., 2013] GSE15745 frontal cortex of 10 MDD patients
and 10 healthy controls
20 PureN
FC2 [Lunnon et al., 2014] GSE15745 frontal cortex from a large AD
study
114 PureN
GEO – Gene Expression Omnibus; MDD – major depression disorder; RA – rheumatoid arthritis; AD –
Alzheimer’s disese
at lower and higher λ values showing that it is important to determine optimal values for
the regularisation parameter (Figure 6.S4). We also complicated the recovery problem by ex-
cluding certain mixtures, e.g. those with NeuN+ proportion ≥ 0.5. MeDeCom successfully
decomposed such data subsets as well (Figure 6.S5).
6.2.3 Methylome decomposition of blood cell samples
Following the successful testing of MeDeCom on synthetic data and reconstructed cell mix-
tures we applied our method to complex biological samples with unknown composition. Since
blood-based methylome proling is widely used for comparative epigenetic studies we set out
to determine whether MeDeCom can help identify and understand cell composition dier-
ences in blood cell methylomes.
Whole blood methylome
We used publicly available Innium 450k proles of whole blood samples from two indepen-
dent studies (Table 6.1). This allowed us to test the reproducibility and robustness of our
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method in a side-by-side comparison. We rst applied MeDeCom to control samples from
a large rheumatoid arthritis study [Liu et al., 2013]. As reported in the original publication,
the samples grouped into technical batches. This was reected in the cell type proportions
estimated by regression (Figure 6.S6 and 6.S7). To avoid technical variation as a confounding
factor we performed our analysis on 87 samples forming a smaller technically homogeneous
batch (data set WB1).
In our MeDeCom analysis the CVE continued to decline for k = 20, . . . , 30, implying a
potentially large number of distinct LMCs (Figure 6.3, a). We therefore considered factorization
results for increasing values of k to understand the relation to underlying major and minor
cell populations. To match the identied blood LMCs to known blood cell populations we
compared our results to the published reference methylomes of blood cells [Reinius et al.,
2012] (data set PureBC).
At k = 2 the recovered LMC1 and LMC2 represented populations of the myeloid and the
lymphoid lineages, respectively (Figure 6.S8). LMC contributions correlated to the summarized
reference-based proportion estimates of lymphoid and myeloid cell types, although the former
were noticeably biased (Figure 6.S9).
At increasing values of k, LMCs with high similarities to reference proles of puried blood
cells are still present, and for k = 20 and λ = 1.0 · 10−3 the clustering analysis results in two
large clusters corresponding to myeloid and lymphoid lineages (Figure 6.3, b; Figure 6.S10).
The 11 LMCs in the "myeloid" cluster together with Monocytes, Eosinophiles and Neutrophils
are separated from 9 LMCs clustering with CD4+ T-cells, CD8+ T-cells, NK-cells and B-cells.
In the “myeloid” cluster we did not observe direct matches of LMCs to any of the three myeloid
cell types. In contrast, within the “lymphoid” cluster we observed one LMC closely matching
the CD4+ T-cell prole, and one LMC corresponding to the sub-cluster of CD8+ T-cells and
NK-cells, indicating better separability of the T-cell signatures. The analysis also identies a
number of individual-specic LMCs (Figure 6.S11 and 6.S12).
Analysis of the second completely independent whole blood data set from the EPIC Italy
study [Palli et al., 2003] (data set WB2) recovered a very similar pattern of LMCs for k =
20 (Figure 6.3, b and c). The direct comparison of the LMCs from both whole blood data
sets reveals a considerable agreement in terms of recovered components in both data sets
(Figure 6.3, d).
An aggregated comparison of LMCs matching to reference cell types in both blood anal-
yses showed a good correspondence to the regression-based estimations of cell proportions
(Figure 6.S13). For several LMCs in WB1 and WB2 we observed that their proportions corre-
lated with age, e.g. for WB1 the LMC12 related to CD4+ T-cells (Figure 6.3, e). Although the
total number of CD4+ T-cells was reported to change non-signicantly with age [Fahey et al.,
2000] the T-cell-specic immunological senescence is a well known phenomenon character-
ized by depletion of the naive T-cell subpopulations [Cossarizza et al., 1996; Romanyukha and
Yashin, 2003]. This might imply that LMC12 is rather reecting the methylation pattern of the
naive CD4+ T-cells. Indeed, a comparison to reference methylomes of isolated T-cells supports
this suggestion (Figure 6.S14).
Next, we selected the 15,000 marker CpGs with the highest discriminative power between
cell types (highest CpG-wise p = 2.91 · 10−44, ANOVA F-test). Visual comparison of these
CpGs between individual reference populations and whole blood data (Figure 6.S15) shows
substantially lower variation of these CpGs in whole blood. Indeed, only a relatively small
proportions of marker CpGs also shows high variance across whole blood samples (see the row
color code in Figure 6.S15). This means that the signal at the marker CpGs which discriminate
cell types of puried myeloid and lymphoid lineages very well is too low as compared to
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the level of overall variation in whole blood. This might explain why LMCs recovered in
whole blood do not unambiguously match average methylomes of isolated cell populations.
To examine this in greater detail we next applied MeDeCom to isolated cell populations.
Purified blood cell populations
Proles of puried blood cell types used to annotate LMCs in the whole-blood analysis are
eectively average methylomes of the cells carrying certain surface marker. However, the
global DNA methylation pattern in various blood cells might not directly reect the expression
of the surface markers, even if a certain number of highly discriminative CpGs can be selected
for each isolated population. To better understand the complexity of methylation signatures
in the reference methylomes we performed a MeDeCom analysis on the seven puried blood
cell populations derived from 6 donors (data set PureBC) [Reinius et al., 2012].
The CVE suggested a stable solution at k = 16 and λ = 10−3 (Figure 6.3, f; Figure 6.S16
and 6.S17). A matrix of mixing proportions (Figure 6.3, g) shows that the recovered 16 LMCs
could be classied into two distinct groups. In the rst group (LMCs 6, 7, 8, 10, 15 and 16) LMCs
were associated with individual donors, most likely reecting donor-specic genetic variation
at the informative CpG positions underlying these LMCs. In other words, our analysis directly
identied confounding genetic variants. In the second group, LMCs 1, 3, 4, 5, 7, 9 and 11 cor-
responded to the enriched cell type-associated proles: e.g. LMC4 was predominantly present
in CD4+ T-cells, LMC11 in Neutrophils etc. Nevertheless, we also observed that several LMCs
were shared by related cell types. For instance, Eosinophils samples show enrichment of the
Neutrophil-specic LMC11, CD8+ T-cells (LMC9) show overlaps with CD4+ T-cells (LMC5).
Finally, we observed LMCs which were associated with more than one cell type, but which
were not a dominating LMC in any of them. For instance, LMC14 was present at low pro-
portion both in CD8+ T-cells and NK cells. Co-occurrence of two or more LMCs within one
isolated cell population, as well as sharing of LMCs between the populations suggests that
these cell populations could be either mixtures of still not separated distinct cell types, or
that these cell populations share epigenetic features that may indeed co-occur in dierent cell
types.
As a clear-cut example of such within-population heterogeneity, for the CD19+ B-cells we
observed a relatively balanced association with two LMCs, LMC2 and LMC13. This is in line
with the fact that peripheral blood contains two B-cell subpopulations: naive and memory
B-cells with distinct methylomes [Kulis et al., 2015]. We investigated the methylation status
of CpGs associated with the two B-cell-specic LMCs in more detail and selected 401 CpG
positions which showed a methylation dierence of more than 0.33 in LMC2 as compared to
LMC13. Many of such CpGs were indeed located in the vicinity of known B-cell associated
genes (Additional File 1), such as PTPRCAP (Figure 6.S18). We related LMC2- and LMC13-
specic CpGs to reference WGBS methylome proles of memory and naive B-cell samples,
obtained by the BLUEPRINT project [Kulis et al., 2015]. The methylation status of 44 matching
CpGs (Additional File 4) indeed corresponds to relative methylation states found in memory
and naive B-cell subpopulations (Figure 6.3, d). The correspondence remained very stable even
when the dierence threshold for the selection of LMC-specic CpGs was decreased to 0.25
to cover more matching CpG positions (Figure 6.3, d). In addition, LMC2 and and LMC13 have
almost inverse proportions for individual donors indicating that the MeDeCom analysis picks
up dierences in the sample-specic abundance of memory and naive B-cells highlighting
individual- or isolation-attributed variation.
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6.2.4 Decomposition of the brain tissue methylomes
In our nal analysis we applied MeDeCom to understand the heterogeneity of brain tissue
methylome. The human brain is composed of many neuronal and glial cell types. To separate
glial cells and neurons current studies apply FACS-based methods. The RBFOX3 protein local-
ized in the nuclear membrane of most of the neuronal cells (also known as NeuN) is used as a
selection marker. While the NeuN-enriched and depleted cell fractions serve as references in
methylome analysis, the question remains to which extent these separated methylomes indeed
reect a variable composition of whole brain tissue.
We applied MeDeCom to 20 frontal cortex methylomes from a major depression disorder
study [Guintivano et al., 2013] (data set FC1 in Table 6.1). The data set also included NeuN+
and NeuN− cell fractions (data set PureN) which we analysed in comparison to total brain
tissue. In addition, we examined an independent bulk frontal cortex methylome data set from
a recent large-scale Alzheimer’s disease study [Lunnon et al., 2014] (data set FC2).
For both FC1 and FC2 data sets the inspection of CVEs showed a substantial change at
k ≥ 3 strongly suggesting three or more LMCs (Figure 6.4, a and Figure 6.S19). We carefully
examined the factorization results and compared the three LMCs at k = 3 and λ = 5 · 10−3 to
the NeuN+ and NeuN− proles. Clustering analysis (Figure 6.4, b) showed that average NeuN−
reference prole is related to LMC3 while the NeuN+ prole is more similar to LMC2. The third
component LMC1 was truly distinct from both "reference" methylomes retaining a slightly
higher similarity to LMC2 and the NeuN+ methylome. All three LMCs were remarkably well
reproduced in the FC2 data set at k = 3 (Figure 6.4, c).
Our nding suggests that the FACS separation of brain tissues in NeuN+ and NeuN− cells
introduces a new confounding variable and does not fully recover the methylomes of total
brain tissues. In order to get more clues about biological nature of the LMCs we asked which
loci dier in their methylation between the LMCs and examined the biological annotation of
genes associated with LMC-specic CpGs. LMC-specic CpGs were selected to have methy-
lation dierences more than 0.33 between one LMC against the two other ones (Additional
File 2). We then mapped LMC-specic CpG positions to their neighboring genes (Additional
Figure 6.3: (on the next page) Results in blood cell methylomes. a-e: WB1 data set. a. Selection of pa-
rameters k and λ by cross-validation. b. Matching the WB1 LMCs to PureBC methylomes
(k = 20, λ = 0.001). Here and below the dendrogram visualizes agglomerative hierarchi-
cal clustering analysis with correlation-based distance measure and average linkage. c.
Matching the LMCs from the WB2 data set (k = 20, λ = 0.001) to the PureBC methy-
lomes. d. Matching the WB1 and WB2 LMCs to each other. Pairs of reproducible LMCs
also matching to the reference profiles are highlighted by red segments. Green segments
mark reproducible LMCs which are not directly matching to any of the the reference pro-
files. e. Proportion of LMC12 from WB1 correlates with the age of healthy individuals.
f-h. PureBC data. f. Selection of parameters k and λ by cross-validation. g. Heat map of
recovered proportions in PureBC data (k = 15, λ = 0.001). Rows represent LMCs while
columns correspond to individual purified samples. The order of blood donors is the same
within column sets, corresponding to one cell type. h. Methylation dierences in naïve
versus memory B-cells at CpGs dierentially methylated between LMC2 and LMC13 from
PureBC data set. WGBS methylation profiles of naïve and memory B-cells are obtained
from BLUEPRINT. The value in memory B-cells is an average of three WGBS samples.
Wilcoxon ranked sum test was used to test the null that WBGS methylation calls are the
same in naive and memory cells at the respective CpG positions.
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File 5; see Methods) and performed a functional annotation of the associated genes using
GREAT [McLean et al., 2010] (Figure 6.S20). LMC2 (NeuN+)-specic CpGs map to genes with
a clear enrichment for neuronal-related terms, while LMC3 (NeuN−)-specic CpGs were close
to genes associated with non-neuronal, mostly oligodendrocyte-related categories. LMC1-
specic CpGs map close to genes associated with developmental and stem cell-related terms.
Strikingly, among the genes associated with LMC1 we found several markers of the neuronal
stem cell lineage, such as PAX6, ZIC1, ZIC4, NEUROG1 (Additional File 2). Notably, the DNA
methylation patterns at LMC1-specic CpGs showed signicantly higher or lower methylation
levels in crude brain tissue than in NeuN+ and NeuN+ reference methylomes (see PAX6 as an
example in Figure 6.S21). Furthermore, a recent study on neuronal heterogeneity in the mouse
brain [Mo et al., 2015] provided a reference for the ne cellular subtypes possibly present in
the mammalian frontal cortex. We found several of the most signicant LMC1-specic genes
among the DMRs reported in [Mo et al., 2015] (Table 6.S3).
As we earlier observed that proportions tend to be biased when k is signicantly lower than
optimal (see the WB1 analysis with k = 2 above), we explored MeDeCom results at k = 4 and
λ = 0.005 (Figure 6.S22). The analysis revealed that the NeuN+-specic LMC3 rather accu-
rately reproduced a reference-estimated NeuN+ content in most brain samples (Figure 6.4, e;
Figure 6.S22, a). However, samples with the highest deviation from the reference-based pro-
portions had the highest proportion of co-puried cells (and methylomes) characteristic of
LMC2 (equivalent to LMC1 for k = 3; Figure 6.4, f and Figure 6.S22, b). For k = 4 two
LMCs match to NeuN−. For each of them MeDeCom-recovered proportions deviated signif-
icantly from the reference-based estimates for NeuN− (Figure 6.4, h and i). Nevertheless, the
combined proportions largely reected the reference-estimated NeuN− content across all sam-
ples (Figure 6.4, j). Again, we observe that samples with the lowest correspondence had high
contribution of LMC2 (Figure 6.4, g). The proportion analysis shows that using MeDeCom
we can infer realistic LMC proportions for NeuN+, NeuN− in individual samples and a third
separate LMC with a distinct cell composition. The latter LMC is variably convoluted into
the other main NeuN+ and NeuN− cell fractions in the reference-based analysis. We conclude
that reference-independent decomposition helps to explore, identify and quantify heterogene-
ity eects across brain tissue samples.
6.3 Conclusions
DNA methylomes of multicellular tissue or cell samples can be modeled as mixtures of sev-
eral latent variables. Here we present a novel computational framework called MeDeCom
which decomposes complex methylation data into latent components and sample-dependent
proportions based on a mixture model for methylomes. We show that the method performs
reproducibly and with high sensitivity on both synthetic and biological data sets.
MeDeCom provides a few advances compared to all existing methods. First of all, MeDe-
Com does no require predened reference cell type measurements. It can be applied to any
data set to explore the compositions of mixtures. Note that reference methylome data are
not yet available for many cell types, and MeDeCom oers the possibility to explore non-
standard data in a reference-free manner. Second, MeDeCom has conceptual dierences to
other reference-free methods such as the Surrogate Variable Analysis methods (SVA) [Leek
and Storey, 2007] [Teschendor et al., 2011], EWASHER [Zou et al., 2014] or the SVA-inspired
RefFreeEWAS [Houseman et al., 2014] method. All these methods focus on the correction
of signicance analysis for a phenotypic trait of interest by calculating and eliminating con-
founding heterogeneity eects. In contrast, MeDeCom uses a variant of Non-negative Matrix
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Figure 6.4: a,b and e-j: FC1 data set. a. Selection of parameters k and λ by cross-validation. b.
Matching frontal cortex LMCs to the reference NeuN+/− profiles. The dendrogram visu-
alizes agglomerative hierarchical clustering analysis with correlation-based distance mea-
sure and average linkage. c. Matching of LMCs between FC1 and FC2. d. Example of an
LMC1-specific CpG (k = 3) in the PAX6 locus. e-j. LMC contributions in comparison to
the reference-based proportion estimates (k = 4). Notation is the same as in 6.2, D. In i
the proportions are summarized for LMC1 and LMC4.
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Factorization (NMF) specically designed to recover latent DNA methylomes by using suit-
able constraints and regularization. The imposed constraints on the factorization integrate
biological prior knowledge such as non-negativity of the estimated methylation proles and
their proportions. However, we show that these constraints alone are not sucient to get
biologically meaningful methylation proles and accurate estimates of their proportions. A
key element distinguishing MeDeCom from other reference free methods is that we add a reg-
ularizer which encodes the prior expectation that most sites in the methylation proles are
close to zero or one. This prior expectation comes from the fact that at the level of a single
cell, methylation proles are binary and for most CpG sites this is true also at the level of
a population of cells of a homogeneous group such as a particular cell-type. This allows us
to estimate simultaneously methylation proles and their proportions without any reference
proles. MeDeCom generates series of decomposition pattern models which can be used for
supervised biological interpretation and for unsupervised cell compositional corrections.
Our proof-of-concept analysis shows that MeDeCom acts robustly and reliably on com-
plex articial and natural methylome mixtures measured by Innium 450k arrays. MeDeCom
identies key signatures of major cell populations present in complex whole blood methy-
lomes without any prior knowledge of references or data adjustment. However, our analysis
also reveals the limits of a MeDeCom analysis. The method strongly depends on a fair number
of discriminatory methylation positions and a sucient level of sample-to-sample variation
(Figure 6.S15). In complex 450k whole blood methylomes both parameters are aected such
that a clean separation and assignment of LMCs specic for blood cell subtypes becomes chal-
lenging. Two major aspects are the likely causes of this diculty. First, the Innium 450k
platform only covers a limited number of CpGs informative for the minor cell subtypes which
can easily become indistinguishable from the remaining technical "noise" of the 450k arrays.
Second, the proportions of most cell subtypes in blood are too low. MeDeCom factorization re-
quires a certain grade of sample-to-sample variations to identify component (cell type)-specic
CpG signals. We already noticed both of these limitations in our articial mixture analyses. In
the future these problems may be partially overcome by using WGBS/RRBS or extended array
platforms such as the Methylation EPIC array covering additional cell type-specic "variable"
CpG positions. Furthermore, cell enrichment or cell depletion strategies may help to obtain
deeper sample-specic compositional insights.
Since MeDeCom does not require predened references it can be exibly applied to any
level of methylome analysis. We show that MeDeCom can facilitate a deeper insight in cell
composition if the sample complexity is experimentally reduced. As one example we investi-
gate the composition of methylomes generated after cell pre-selection e.g. by surface marker-
based separation [Reinius et al., 2012]. Our results on pre-sorted CD4+ (T-cell) or CD19+
(B-cell) blood cells clearly show that their methylomes still maintain a substantial level of
heterogeneity. We identify a number of additional separable DNA methylation components
some of which we can associate with age-dependent changes in T-cell populations or show
that they discriminate naive from primed B-cells. In both cases the characteristic CpG signa-
tures vary in their sample-by-sample proportions. Such observations are very important for
the biological interpretation of methylation changes across populations of samples. Many of
the components identied by MeDeCom are likely to carry such biological information that
can be extracted for further exploration.
The decomposition of brain methylomes provided by MeDeCom further supports the use-
fulness of unsupervised exploratory decomposition for the analysis of complex methylome
data. The separation of brain cells into neuronal and non-neuronal fractions has become a
new "standard procedure" for brain-specic epigenetic studies. Our rst nding shows that
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NeuN+/− mixture models do not fully capture the composition of the full brain tissue. In fact,
we identify an additional component that diers from the NeuN+ (neuron) and NeuN− (non-
neuron)-specic components in full brain tissues. This new component is apparently sorted
out or even lost in the enrichment procedure. Our analysis shows that the samples denomi-
nated as NeuN+ and NeuN− contain variable contributions of this unknown cell fraction. Here
MeDeCom opens a new possibility to identify the dierences in cell composition and hence
making data from dierent NeuN separations more comparable. Moreover, a biological analy-
sis of the CpGs and genes associated with this "new" component reveals a strikingly dierent
association of biological terms as compared to NeuN+ and NeuN− fractions.
In summary, our exploratory analysis demonstrates that MeDeCom is a exible and use-
ful reference-free tool allowing to improve the biological interpretation of large-scale DNA
methylation data sets. Although for the pilot demonstration we use Innium 450k data, MeDe-
Com is, in principle, applicable to any complex methylome data set. However, since MeDeCom
requires a low level of technical noise and a high level of biological variation we suggest that
the method is applied to carefully controlled data sets that fulll such requirements. A high
standard technical preprocessing of 450k array data minimizes possible pitfalls of quality, tech-
nical batch eects or other non-biological issues. We therefore recommend to use data after
ltering through available bioinformatic pipelines (see e.g. [Assenov et al., 2014] or [Aryee
et al., 2014]).
6.4 Methods
6.4.1 MeDeCom element I: mixture model for DNA methylation
measurements
Let D ∈ [0, 1]m×n be the matrix of absolute methylation values at m CpGs obtained from n
multicellular specimens, with m typically being much larger than n. Here, entry Dij repre-
sents methylation level at CpG i for specimen j, i = 1, . . . ,m, j = 1, . . . , n. We consider
an approximate low-rank model for D which hinges on the assumption that the cell popu-
lations underlying the specimens consist of a comparatively small number of homogeneous
subpopulations of cells having a similar methylation prole, which is also shared across dif-
ferent specimens. When speaking of homogeneous subpopulations of cells, we typically have
in mind cells of dierent types, e.g. oligodendrocytes of brain tissue or neutrophils of pe-
ripheral blood. We assume further that the methylation proles of the specimen results as a
weighted average (’mixture’) of the methylation proles associated with the underlying cell
types, where the weights equal the proportions of these cell types within the respective spec-
imen (note that we veried this assumption in our analysis with reconstructed cell mixtures).
This lets us propose the matrix factorization model
D = TA+ E, (6.1)
where T ∈ [0, 1]m×k represents the methylation proles of k prototypes (in typical cases
identiable with a specic cell type) and A ∈ Rk×n+ such that A>1k = 1n (i.e. the entries
of A are non-negative and its columns sum up to one). Entry Tis equals the methylation
prole at CpG i of prototype s, i = 1, . . . ,m, s = 1, . . . , k, whileAsi equals equals the relative
abundance (proportion) of prototype s in specimen i. The matrixE represents errors capturing
model misspecication and noise arising from the measurement process.
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6.4.2 MeDeCom element II: model fiing
Using a least squares approach to t model (6.1) yields the optimization problem
min
T,A
‖D − TA‖2F =
m∑
i=1
n∑
j=1
(Dij − (TA)ij)2
subject to 0 ≤ Tis ≤ 1 ∀i, s
Asj ≥ 0 ∀s, j
k∑
s=1
Asj = 1 ∀j.
(6.2)
Here and in the sequel, ‖ · ‖F denotes the Frobenius norm of a matrix, dened as the square
root of the sum of squares of its entries. We may think of the above problem as an instance
of ’blind source separation’, a task that is well-studied in signal processing [Seungjin Choi,
Andrzej Cichocki, Hyung-min Park, 2005]. The attribute ’blind’ expresses the fact that the
source signals as represented by the columns of the matrix T are unknown, as opposed to
the case where they are given in advance and only the mixture coecients in A need to be
recovered.
The minimization problem in (6.2) is not jointly convex in T and A. As a result, one can-
not hope to solve it globally; in fact, it has been shown that constrained matrix factorization
problem of this form are computationally hard in general [Vavasis, 2007].
Once one of T orA is given, problem (6.2) boils down to a convex quadratic program. This
property is the basis of alternating minimization, a common (heuristic) approach to tting
matrix factorization models in which minimization w.r.t. T for xed A and vice versa alter-
nate [Lin, 2007]. While lacking theoretical guarantees, alternating minimization often works
rather satisfactorily in practice.
Besides computational hardness, a second major issue of (6.2) is ill-posedness. In general,
there are multiple optimal solutions to (6.2) (excluding those generated by column respectively
row permutations in T respectively A), as can easily be seen from geometric considerations,
cf. Figure 6.1, f.
In geometric terms, problem (6.2) can be re-phrased as follows: nd a set of k points
{t1, . . . , tk} ⊂ [0, 1]m such that their convex hull T = {y ∈ Rm : y =
∑k
s=1 λsts, λs ≥
0 ∀s, ∑ks=1 λs = 1} minimizes the sum of squared Euclidean distances of the data points
{D:,1, . . . , D:,n} to that convex hull. As shown in Figure 6.1, I, there exist problem instances
for which it is possible to extend or shrink T while keeping the least squares objective (essen-
tially) unchanged. To deal with such ambiguities, we suggest to complement the least squares
objective with a regularizing term pushing the points {t1, . . . , tk} towards the vertex set of
[0, 1]m, i.e. the set of binary vectors {0, 1}m. The rationale behind this idea is as follows. Re-
call that the columns of T take the role of methylation proles of prototypes which in typical
cases represent a (near)-homogeneous subpopulation of cells. Depending on the homogeneity
of the subpopulation, the methylation prole of the corresponding prototype may be close to
binary in view of the fact that at the level of a single cell, methylation proles are exactly binary
(methylated vs. unmethylated) when ignoring the comparatively rare case of half-methylation.
It turns out that incorporating this structure contributes signicantly to the success in nding
biologically meaningful matrices T and A. Specically, we consider the following regularized
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least squares criterion:
min
T,A
‖D − TA‖2F + λ
m∑
i=1
k∑
s=1
ω(Tis), with ω(x) = x(1− x),
subject to 0 ≤ Tis ≤ 1 ∀i, s
Asj ≥ 0 ∀s, j
k∑
s=1
Asj = 1 ∀j.
(6.3)
where λ > 0 is a hyperparameter. Note that ω : [0, 1]→ [0, 1] is a quadratic function symmet-
ric around its mode 0.5 (i.e. ω(x) = ω(1 − x)) and vanishes at the boundary points 0 and 1.
The additional regularization term in (6.3) acts as a ’soft binary constraint’ depending on the
parameter λ. For λ suciently large, any minimizer (T̂ , Â) of (6.3) must satisfy T̂is ∈ {0, 1}
for all i, s. We stress that the proposed form of regularization is much better suited to the
given problem than the popular lasso (`1-regularization with ω(x) = |x|), which promotes ze-
roes, but discourages ones, which is little meaningful for the given problem from a biological
perspective.
From the point of view of computation, the extra term in (6.3) poses an additional challenge
compared to (6.2) as the function ω is non-convex (in fact, it is concave). As a consequence,
when using the alternatization scheme mentioned above, one has to bear in mind that opti-
mizing T for xed A is no longer a convex quadratic program, but a so-called D.C. (dierence
of convex) program in virtue of the concavity of ω. The concave-convex procedure [Tao and
An, 1997; Yuille and Rangarajan, 2003] can be employed to generate a sequence of iterates
ensuring monotonic descent of the objective function before reaching a stationary point. As
detailed in Algorithm 1, it is straightforward to integrate this approach into the alternating
optimization scheme.
The main computational eorts go into the successive solution of the convex quadratic
optimization problems optT and optA which can be done by a variety of ecient solvers.
The update of T follows the concave-convex procedure in which the concave part of the ob-
jective (here given by h(T )) is repeatedly linearized, yielding a sequence of convex ’surrogate’
minimization problems.
6.4.3 MeDeCom element III: parameter selection
The mixture model (6.1) and the tting algorithm (Algorithm 1) involve two free parameters
to be provided by the user. The inner dimension k of the matrix product TA, k ≤ min{m,n}
in (6.1) equals the number of DNA methylation prototypes used to model the given data. The
regularization parameter λ determines how strongly the entries of T̂ are encouraged to take
values in {0, 1}. While the choice of k can be guided by prior knowledge about the composition
of the underlying mixture to some extent, we developed a cross-validation procedure to select
suitable values of both k and λ in a data-driven manner.
Cross-validation
The use of cross-validation in the context of matrix factorization, which is in fact a problem
in unsupervised learning, whereas cross-validation is typically used in supervised settings,
requires additional explanation. A conceptual dierence arises from the fact that as opposed to
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Algorithm 1 Alternating minimization algorithm for objective (6.3)
Denote CT = {T ∈ Rm×k : 0 ≤ Tis ≤ 1, i = 1, . . . ,m, s = 1, . . . , k},
CA = {A ∈ Rk×n : Asj ≥ 0,
∑k
s=1Asj = 1, s = 1, . . . , k, j = 1, . . . , n},
g(T,A) = ‖D − TA‖2F , h(T ) = λ
∑m
i=1
∑s
k=1 ω(Tis), and f(T,A) = g(T,A) + h(T ).
Initialize T 0 ∈ CT and A0 ∈ CA; fix numerical tolerance  > 0.
t← 0, f t ← f(T t, At).
repeat
Update T :
t← t+ 1, T ← T t−1
repeat
Linearize h(T ) around T = T to obtain a function
h˜(T ) = h(T t−1) +
∑m
i=1
∑k
s=1 ω
′(T t−1is )(Tis − T t−1is ).
T ← argminT∈CT g(T,At−1) + h˜(T ) (optT)
until (f(T ,At−1)− f t−1)/f t−1 < 
T t ← T .
Update A:
At ← argminA∈CA g(T t, A). (optA)
f t ← f(T t, At).
until (f t − f t−1)/f t−1 < .
the standard supervised setting, where the object to be predicted is a vector (one-dimensional
array), one now has to deal with a matrix (two-dimensional array). There are multiple ways
of generalizing the principle of leaving out sequentially dierent portions of the given data
when moving from the vector to the matrix case, such as (a) leaving out columns, (b) leaving
out rows, (c) leaving out both rows and columns [Owen and Perry, 2009]. We here use (a)
mainly because it leads to a straightforward scheme as displayed in Algorithm 2. For each fold,
a subset of the samples is left out. The thus column-reduced data matrix Din is factorized as if
one were given the full matrix. The resulting left factor T̂ in is used to t the left-out columns
in Dout as Dout ≈ T̂ inÂout. The squared error of that approximation or cross-validation error
(CVE), is saved and nally combined with the errors from other folds.
Selecting k
The choice of k is canonical as long as the composition of the cell populations is known to a
good extent, as is the case e.g. for synthetic mixtures. Cell populations sampled from human
tissue tend to be considerably more complex. Prior knowledge about the number of cell types
present in the samples may not be available, and even if it is, each cell type may not necessarily
correspond to a perfectly homogeneous subpopulation. As a result, multiple similar, yet not
identical methylation proles may exist per cell type, reecting a hierarchy of cell types and
subpopulations. Furthermore, (sub)clusters can emerge from individual-specic DNA methy-
lation eects, like allele-specic methylation and imprinting, or phenotypic eects, e.g. inu-
ence of age, gender, disease status etc. It is not feasible to capture such ne-grained structure
given a small to moderate number of samples, which are in addition contaminated by noise.
As a rule, k should be chosen such that the estimation error and the approximation error in
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Algorithm 2 Column-based L-fold cross-validation scheme for validation of model (6.1)
Choose an integer L ∈ {1, . . . , bn/2c}.
Let I = {1, . . . , n}. Randomly partition I into disjoint subsets I` so that bn/Lc ≤ |I`| ≤ dn/Le
and
∑L
`=1 |I`| = n.
for ` ∈ {1, . . . , L} do
Form Din = D:,I\I` , D
out = D:,I` .
Solve the matrix factorization problem (6.3) with Din in place of D and λ = λg . Denote the
minimizing T by T̂ in.
Obtain Âout as the minimizer of
min
A
‖Dout − T̂ inA‖2F subject to Asj ≥ 0 ∀s, j,
k∑
s=1
Asj = 1 ∀j.
err(`)g ← ‖D − T̂ inÂout‖2F
end for
return errg ←
∑L
`=1 err
(`)
g .
model (6.1) are roughly balanced. The former results from noise and is incurred when tting
the model to the data, while the latter is a consequence of model misspecication, which, as
discussed above, is inevitable for limited k given the many possible sources of diversity among
methylation proles.
From a more statistical perspective, the issue of choosing k is related to determining the
number of components in principal component analysis (PCA). In fact, the matrix factorization
model (6.1) can be seen as a method of linear dimension reduction applied to D. A common
computational approach to PCA is the singular value decomposition (SVD) which yields a
matrix factorization of rank k ofD by discarding all singular vectors not corresponding to the
top k singular values. A notable advantage of our model (6.1) over the truncated SVD / PCA is
its direct interpretability at a biological level, which is achieved by putting suitable constraints
on the two factors T and A.
For a xed value of the parameter λ, the data-tting term of the factorization problem (6.3)
decreases as k increases. The approximation error of the factorization model decreases since
with more columns in T one has a better chance of capturing dierences between the cluster
methylomes. At the same time, the estimation error increases as the additional degrees of
freedom favour over-adaptation to noise. A suitable choice of k balances both eects. The use
of cross-validation is intended to achieve this balance by tracing the cross-validation error over
a grid of values for k and selecting the one corresponding to the minimum. The nal choice of
k was made by combining visual inspection of the cross-validation results and available prior
information about the most likely number of underlying methylation signatures.
Selecting λ
As illustrated by the example in Figure 6.1B, the regularization parameter λ, which balances
the trade-o between the data delity term and the data-independent regularization term, has
a crucial inuence on the solution of the factorization problem (6.1) delivered by Algorithm
1. Since there is in general no objective criterion to assess the suitability of each solution at a
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biological level, we embark on cross-validation error as for the parameter k. Determining the
value of λ achieving minimum cross-validation error is more dicult as that parameter takes
values in a continuous domain, namely the non-negative real line. We perform a two-stage
grid search, starting with a coarse grid and then concentrating on a smaller range covered by
a ner grid. Details of the procedure are outlined in Algorithm 3. At the beginning of each of
the two rounds of grid search, Algorithm 3 is run for each grid point of λ using multiple (≈50)
random initializations. As the solutions corresponding to nearby grid points can be expected
to be similar, we complement random initializations with a smoothing scheme in which the
solutions of the ve preceding and the ve subsequent grid points are used for initialization.
6.4.4 LMC matching
When interpreting MeDeCom results we matched the recovered methylation prototypes to
available reference methylomes. Given a matrix of k prototypes T̂ estimated from a data set
D and a matrix of k? reference proles T ?, we rst selected a set of rows R corresponding
to the overlap of CpGs present in both T̂ and T ?. We then computed the matrix S = (Si,j)
of Pearson correlation coecients between all pairs of vectors T̂R,i and T ?R,j . We considered
prototype i¯ as a match to reference prole j¯ if Si¯,j¯ = maxi Si,j¯ . We considered the matching
unambiguous in case Si¯,j¯ = maxj Si¯,j = maxi Si,j¯ for all such matching pairs (¯i, j¯). In most
of the cases, we observed better matching when both Tˆ and T ? were centered, i.e. 1
k
Tˆ1k re-
spectively 1
k?
T ?1k? was subtracted from each column. In order to compare sets of prototypes
corresponding to dierent parameter settings, we normalized the total number of unambigu-
ously matching prototypes by the achievable maximum, which yields a score  ∈ [0, 1] given
by  = 1
min(k,k?)
|{(¯i, j¯) ∈ {1, . . . , k} × {1, . . . , k?} : Si¯,j¯ = maxj Si¯,j and Si¯,j¯ = maxi Si,j¯}|
We also performed a combined clustering analysis of prototypes and reference proles. For
that we composed a matrix T † = [T̂R,: T ?R,:], computed a correlation matrix S† analogously
to S, and used it as a similarity matrix for agglomerative hierarchical clustering with average
linkage (procedure hclust in the R package clust).
6.4.5 Functional annotation of LMC-specific CpG positions
For functional annotation of the recovered prototypes we selected component-specic CpG
positions using a xed methylation dierence threshold θ. We considered a CpG position
l ∈ {1, . . . ,m} to be specic to component i if |T̂l,j−
∑
j 6=i T̂l,j| > θ. We investigated each set
Lj of all such CpGs with respect to enrichment of annotation categories using GREAT [McLean
et al., 2010]. We used the default denition for a functional domain of a gene, with maximal
distance of 10 kb upstream or downstream of the transcriptional start site (“two closest genes”
option in GREAT).
6.4.6 Reference-based estimation of the cell type proportions
In case a matrix T of k prototype methylomes is available, e.g. experimentally obtained using
cell separation methods, one can estimate a corresponding matrix of mixing proportions by
solving sub-problem optA in Algorithm 1. From here onwards we refer to this method as “re-
gression”, and we apply it for reference-based estimation of mixing proportions whenever the
reference methylomes are available. This form of proportion estimation is similar to a method
with the name ’Constrained Projection’ proposed for the same purpose in [Houseman et al.,
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Algorithm 3 Choosing the parameter λ by L-fold cross-validation
Let Λ = {λ1, . . . , λG} be a grid of values to be considered for λ, where the spacings between the
grid points is typically linear on a log-scale, e.g. 10−10, 10−9, . . . 10−1
Choose an integer L ∈ {1, . . . , bn/2c}.
Let I = {1, . . . , n}. Randomly partition I into disjoint subsets I` so that bn/Lc ≤ |I`| ≤ dn/Le
and
∑L
`=1 |I`| = n.
for ` ∈ {1, . . . , L} do
for g ∈ {1, . . . , G} do
(1) Form Din = D:,I\I` , D
out = D:,I` .
(2) Solve the matrix factorization problem (6.3) withDin in place ofD and λ = λg usingNit
random initializations. Denote the minimizing T by T̂ ing and the corresponding objective
value by fg .
(3) Obtain Âout as the minimizer of
min
A
‖Dout − T̂ inA‖2F subject to Asj ≥ 0 ∀s, j,
k∑
s=1
Asj = 1 ∀j.
for g′ ∈ {max(g − 5, 1), . . . ,max(g − 1, 1)} do
Solve the matrix factorization problem (6.3) with Din in place of D and λ = λg using
(T̂ ing′ , Â
out
g′ ) for initialization. Denote the solution by (T¯ , A¯) and its objective value by f¯ .
if f¯ < fg then
(T̂ ing , Â
out
g )← (T¯ , A¯) and fg ← f¯
end if
end for
err(`)g ← ‖D − T̂ inÂout‖2F
end for
for g ∈ {G, . . . , 1} do
for g′ ∈ {min(g + 1, G), . . . ,min(g + 5, G)} do
Solve the matrix factorization problem (6.3) with Din in place of D and λ = λg , using
(T̂ ing′ , Â
out
g′ ) for initialization. Denote the solution by (T¯ , A¯) and its objective value by f¯ .
if f¯ < fg then
(T̂ ing , Â
out
g )← (T¯ , A¯) and fg ← f¯
end if
end for
err(`)g ← ‖D − T̂ inÂout‖2F
end for
errg ←
∑L
`=1 err
(`)
g .
end for
return λ∗ = λg∗ with g∗ defined by errg∗ = min1≤g≤G errg .
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2012]. The important dierence is, however, that the analogue of the matrix T in that method
is constructed from a selection of a comparatively small set of cell type-specic marker CpGs.
In the sequel we refer to this method as “houseman2012”, and we compare to its proportion
estimates whenever appropriate.
6.4.7 Simulations
We simulated DNA methylation data by mixing measured proles of puried cell types with
controlled proportions and adding varying levels of Gaussian noise. An m×n matrix of DNA
methylation valuesDsim was generated according to the model in (6.1). The underlying matrix
of LMCs T ∈ [0, 1]m×ksim was obtained by averaging methylation proles for ksim puried blood
cell types from 6 donors of the Reinius et al. study [Reinius et al., 2012]. We tested four dierent
constellations of blood cell types:
• ksim = 2 with two distant cell types (Neutrophils and CD4+ T-cells),
• ksim = 2 with two similar cell types (Neutrophils and Monocytes),
• ksim = 3 with two similar cell types and one distant from the rst two (Neutrophils,
Monocytes and CD4+ T-cells),
• ksim = 5 with all major blood cell types, excluding Eosinophils and B-cells.
The columns of the matrix of mixing proportionsAwere sampled from a Dirichlet distribution
commonly used to model distributions over the probability simplex. The distribution had ksim
parameters vα1, . . . , vαksim . The simplex base α1, . . . , αksim ,
∑
i αi = 1 was chosen to model
the prior expectation about the mixing proportions in a typical individual. We tested two
scenarios: on average equal (“uniform”) proportions across individuals, i.e. αi = 1ksim , i =
1 . . . ksim, and a setting where some concentration parameter values were much larger than
others, which comes closer to the situation one encounters for whole blood. The scaling factor
v was used to control the variability of the mixing proportions, with v = 1 yielding highly
variable, v = 10 moderately variable and v = 100 marginally variable proportions across
individuals. Finally, the additive noise term E was generated by sampling mn values from a
Gaussian distribution with mean 0 and standard deviation 0.05, 0.1, and 0.2 to simulate low,
moderate and high levels of noise, respectively.
6.4.8 Infinium 450k data
Public Infinium 450k data sets
The publicly available data sets used for the validation of the factorization approach are sum-
marized in the Table 6.1. For testing MeDeCom in blood-based data we used one reference
data set and data from two large whole blood-based studies. The data set by Reinius et al.
contained proles of puried blood cell types, as well as mixed samples with known cell
counts [Reinius et al., 2012]. Next, we used data from a large rheumatoid arthritis (RA) EWAS
with 354 cases and 337 controls [Liu et al., 2013]. Finally, we validated the whole-blood re-
sults in the data from the EPIC Italy prospective cohort which provided for 845 Innium 450k
measurements [Palli et al., 2003]. Neuronal data sets were obtained from one reference study,
and one large Alzheimer’s disese (AD) cohort. As reference we used data from the CETS
study [Guintivano et al., 2013] which contained in total 145 Innium 450k proles of vari-
ous neuronal samples from major depression disorder patients and healthy controls, such as
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cortical NeuN+ and NeuN− enriched cell populations, 9 articial NeuN+/− titration mixtures,
as well as 20 intact frontal cortex samples. For validation we used data from a recent AD
study [Lunnon et al., 2014].
Processing and preparation of the Infinium 450k data
The raw Innium 450k data was collected as IDAT les or, if the latter were not available,
from probe-wise intensity matrices (Illumina Genome Studio reports). Loading and primary
processing, such as intensity summarization and methylation ratio (β-value) calling was per-
formed with the help of the RnBeads package [Assenov et al., 2014]. We used dasen as the
primary normalization method [Pidsley et al., 2013]. We used several layers of ltering crite-
ria to eliminate low-quality probes. We required each methylation call to be supported by at
least 5 Innium beads. Since too low and too high probe intensity may indicate measurement
problems, we discarded CpGs where raw intensity at either of methylated and unmethylated
probes was below 0.1 or above 0.9 quantiles of the total intensity distribution in the respective
channel. To diminish the eects of genetic variation we also discarded CpGs with probes that
overlapped with annotated SNP positions (dbSNP132 entries with MAF> 0.05, as dened in
the RnBeads.hg19 annotation) along the whole probe sequence.
6.5 Availability of data and materials
The data sets supporting the conclusions of this article are available in the Gene Expres-
sion Omnibus repository under accessions: GSE35069 (PureBC), GSE42861 (WB1), GSE51032
(WB2), GSE15745 (PureN, ArtMixN and FC1) and GSE15745 (FC2). WGBS data of CD4+ T-cells
are deposited in EGA as a part of the DEEP project submission (accession EGAS00001001624).
WGBS proles of naive and memory B-cells were downloaded in bedGraph format from the
IHEC data portal (sample names S001JP51, C003K951, C003N351 and C0068L51).
6.6 Supplementary Material
Supplementary Notes
“Exact" and “approximate" models for heterogeneous DNA methylation profiles
Model definition Given the negligible measurement error, the methylation data at m CpG
positions from multi-cellular samples of n individuals can be represented as:
Y = CF (6.4)
Here, C is an m × q matrix of all single-cell DNA methylation proles existing in all cell
populations of all individuals, and F is an m × q matrix representing the frequency of given
single cell prole in a measured sample.
Theoretical upper bound for q, given the three possible DNA methylation states in the
cell {0, 0.5, 1}, is 3m. However, the vast majority of potentially possible DNA methylation
proles are not biologically feasible, and q  3m. Nevertheless, in real applications q and m
have comparable order of magnitude, and, quite certainly, q  n. The latter fact makes it
impossible to nd C and Z computationally.
Matrix C is expected to have a complicated correlation structure. Clustering of its columns
should reveal multiple nested groups of single cell DNA methylation patterns, reecting the
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hierarchy of cell types and subtypes. One may than x k as a number of discrete cell popula-
tions with highly similar DNA methylation proles, depending on a certain similarity thresh-
old. Given a set Cs of matrix C columns which represents the s-th such population, one could
decrease the largest dimension in eq. (1), by constructing a summary prole ts of such popu-
lation: ts = 1nC:,CsFCs,:W
−11n, where W is diagonal matrix with diag(W) = FTCs,:1|Cs|, and
then approximating the measured DNA methylation data as:
Y ≈ TA (6.5)
where as = 1T|Cs|FCs,: . In the extreme case of all the columns in C:,Cs being identical prole
ts is obviously also identical to any of these and the approximate model (2) holds exactly. In
fact this could be enforced by selecting a subset of rows Rs, such that all columns of CRs,Cs
are identical (cell type-specic marker selection). Then the model in (2) augmented to the
intersect of all such subsetsRs, s = 1 . . . k, would also hold exactly (see subsection below).
In case k ≤ n, i.e. the selected number of discrete populations is comparable to the number
of proled individuals, both T and A can in theory be recovered computationally.
The approximation error One can estimate the error of this approximation. In case only
one the s-th pattern set is substituted, the error is
errs = ‖tsas −C:,CsFCs,:‖2 =
=
∥∥∥∥ 1nC:,CsFCs,:W−11n1T|Cs|F−C:,CsFCs,:
∥∥∥∥
2
=
=
∥∥∥∥C:,Cs ( 1nFCs,:W−11n1T|Cs| − I|Cs|
)
FCs,:
∥∥∥∥
2
=
∥∥C:,Cs∆F|Cs|,:∥∥2
One can show that r, j-th element of matrix ∆F represents the deviation of the r-th pattern
frequency from the expected frequency based on the average across all individuals:
∆
F
Cs =
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1
n
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1n1
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Here the term 1
n
∑
j′
fr,j′∑
r′ fr′,j′
·
∑
r
fr,j represents the expected frequency of pattern r in the
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individual j, based on the average in all individuals, and each element of ∆FCs reects the
deviation of the actually observed frequency from this average value.
Including prior information
Model tting as outlined in the Methods works satisfactorily for the data sets under consider-
ation herein. In general, performance can be further improved by incorporating prior knowl-
edge about T and/orA if available. Specically, we have the following two forms of such prior
knowledge in mind.
• One or more columns of T may be known in advance given reference proles obtained
from methylation measurements on isolated cell types.
• It is common to have additional knowledge about the cellular composition of the samples
the methylation measurements inD are based on. For example, the composition of blood
cells is well-studied, and the relative abundance of the underlying major cell types can
be narrowed down to intervals.
Both scenarios can be taken advantage of by straightforward modications of Algorithm 1.
• In case some of the columns of T are known, without loss generality, we may partition
T = [T0 T˜ ], where T0 denotes the sub-matrix assumed to be known while T˜ still needs
to be determined. Accordingly, in Algorithm 1 the update of T is conned to T˜ , whereas
T0 is kept xed over all iterations.
• Lower and upper bounds on the proportions of specic cell types directly translate into
identical bounds on the entries of entire rows of A. To give an example, suppose it is
known that the proportion of cell type X ranges between 30% and 45% and that of a
second cell type Y between 10% and 20%. Unless columns of T are known in advance
(see above), problem (6.3) is invariant to the ordering of the rows of A and we may add
the following constraints:
0.3 ≤ A1j ≤ 0.45, 0.1 ≤ A2j ≤ 0.2, j = 1, . . . , n.
If a subset of the columns of T is known, one proceeds accordingly: the row indices inA
associated with the bound constraints either have to match those corresponding to T0 or
can be chosen freely among the rest, depending on whether prior knowledge about cell
type proportions concerns cell types with known respectively unknown methylation
proles.
None of the above modications make the optimization problem (6.3) more dicult. Addi-
tional bound constraints on the rows of A come into play for optimization problem optA
in Algorithm 1 and can be handled in a straightforward manner by most solvers of convex
quadratic programs. Partial knowledge of T makes optimization even easier.
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Figure 6.S1: Eiciency of component recovery in all simulated data sets. v is the scaling parame-
ter used in proportion sampling, while σnoise is the standard deviation of the additive
Gaussian noise. The values show the maximum number of mutually matching Tˆ and T ?
columns in the simulation analyses achieved for any of the tested k and λ values. The
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Figure 6.S2: LMC recovery in a hard simulated test case with ksim = 5, “biological" proportions with
low variability (v = 100) and medium noise (σnoise = 0.1), k = 5, λ = 0.01.
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Figure 6.S3: λ selection for the ArtMixN data set (k = 2)
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complete Liu et al. data set.
178
CHAPTER 6. MEDECOM
l
l
l
l
l
l
l
l
l
l
l
l
l
57
30
05
30
06
57
30
05
30
10
57
30
05
30
11
57
30
05
30
27
57
30
05
30
37
57
30
05
30
41
57
30
05
30
48
57
30
19
20
36
57
30
19
20
48
57
30
19
20
53
57
30
19
20
57
57
30
50
40
14
57
30
50
40
15
57
65
20
50
58
57
65
20
50
59
75
12
56
00
84
75
12
56
01
03
75
12
56
01
04
75
12
56
01
15
75
12
56
01
24
75
12
56
01
28
77
66
13
01
58
77
66
13
01
66
77
96
81
40
16
78
00
24
60
06
78
00
24
60
18
78
00
24
60
24
78
00
24
60
34
78
00
24
60
40
78
00
24
60
41
78
00
24
60
43
78
00
24
60
44
78
00
24
60
46
78
00
24
60
54
78
00
24
60
55
78
00
24
60
57
78
00
24
60
68
78
00
24
60
71
78
00
24
60
79
78
00
24
60
85
78
00
24
60
87
78
00
24
61
23
78
00
24
61
32
78
00
24
61
37
78
00
24
61
40
78
00
24
61
88
0.0
0.2
0.4
0.6
0.8
Sentrix_ID
pr
op
or
tio
n,
 N
eu
tro
ph
ils
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Figure 6.S8: WB1 data set, matching of LMCs recovered with k = 2 and λ = 0.01
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Figure 6.S10: WB1 data set, λ selection (k = 20).
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Figure 6.S11: WB1 data set (k = 20, λ = 0.001), heat map of the recovered mixing proportions.
Rows and columns were clustered to improve readability (hierarchical clustering with
euclidean distance and average linkage).
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Figure 6.S12: Individual-specific LMCs in the WB1 data set (k = 20, λ = 0.001). For each LMC a dif-
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Figure 6.S13: WB1 data set, proportion recovery. a. CD4+ T-cells. b. CD8+ T-cells and NK-cells.
c. Myeloid cell types. Here individual-specific LMCs (see Supplementary Figure 6.S11
and 6.S12) matching the “myeloid cluster" were excluded. d. CD8+ T-cells and NK-cells,
with LMC18 included.
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Figure 6.S14: Matching the T-cell-specific LMCs from WB1 data set to reference WGBS-based CD4+
T-cell profiles. CD4+naive – CD4+ naive T-cells; CD4+CM – CD4+ central memory T-
cells; CD4+EM – eector memory T-cells.
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Figure 6.S15: Preprocessed Infinium 450k methylation calls in PureBC and WB1 data at 15,000 CpGs
with highest cell type specificity. The rows are ordered based on hierarchical clustering
in the purified data only. The whole blood columns are ordered based on hierarchical
clustering in the whole blood data only. The row color code reflects the quantile of em-
pirical CpG-wise variance distribution in the whole blood data into which the variance
of the corresponding CpG falls.
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Figure 6.S16: λ selection for the PureBC data set (k = 16)
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Figure 6.S17: Matching of the LMCs from the PureBC data to average cell type profiles (k = 16,
λ = 10−4).
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Figure 6.S18: Purified blood cells: methylation level of the PTPRCAP locus in dierent purified blood
cells (grey doed lines), LMC2 and LMC13.
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Figure 6.S20: Functional annotation of frontal cortex LMCs. Raw (unadjusted) p-values of the GREAT
binomial test are reported. a. LMC1, hypermethylated CpGs b. LMC1, hypomethylated
CpGs. c. LMC2, hypermethylated CpGs.
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Figure 6.S20: (continued) Functional annotation of frontal cortex LMCs. d. LMC2, hypomethylated
CpGs. e. LMC3, hypermethylated CpGs. f. LMC3, hypomethylated CpGs.
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Figure 6.S21: FC1 data set (k = 3, λ = 0.003), example of an LMC1-specific locus PAX6. Grey doed
lines correspond to the original frontal cortex profiles.
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Figure 6.S22: FC1 data set, MeDeCom solution with k = 4 and λ = 0.005 used for the estimation of
mixing proportions. a. Matching LMCs to the PureN reference. b. Matching LMCs to
the LMCs of the k = 3 case.
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Supplementary Tables
Table 6.S1: Parameters for the simulation runs
Methylation component schemes
Name 2CompDistant 2CompSimilar 3comp1Distant2Similar 5Comp
ksim 2 2 3 5
Cell types Neutrophils
CD4+ T-cells
Neutrophils
Monocytes
Neutrophils
CD4+ T-cells
Monocytes
Neutrophils
CD4+ T-cells
Monocytes
CD8+ T-cells
NK-cells
Proportion model (ksim = 5)
Name “Uniform” “Biological”
αNeutrophils 0.20 0.62
αMonocytes 0.20 0.23
αCD4+T−cells 0.20 0.05
αCD8+T−cells 0.20 0.07
αNK+T−cells 0.20 0.03
Proportion variability
Name Low Moderate High
v 1 10 100
Noise levels
Name Low Medium High
σnoise 0.05 0.1 0.2
Table 6.S2: NeuN+ and NeuN- fraction proportions in the ArtMixN data set
Sample Propotion
NeuN- NeuN+
121_Mix1(P2E1)_7786915074_R01C01 0.90 0.10
122_Mix2(P2E2)_7786915074_R02C01 0.80 0.20
123_Mix3(P2E3)_7786915074_R03C01 0.70 0.30
124_Mix4(P2E4)_7786915074_R04C01 0.60 0.40
125_Mix5(P2E5)_7786915074_R05C01 0.50 0.50
126_Mix6(P2E6)_7786915074_R06C01 0.40 0.60
127_Mix7(P2E7)_7786915074_R01C02 0.30 0.70
128_Mix8(P2E8)_7786915074_R02C02 0.20 0.80
129_Mix9(P2E9)_7786915074_R03C02 0.10 0.90
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Table 6.S3: FC1 data set (k = 3, λ = 3 · 10−3): overlap of the LMC1-specific genes with Moe et
al. hypo-DMRs in telencephalon development markers from Vicel et al.
TF # CTs LMC1 status
Ascl1 3 -
Dbx1 3 -
Ebf1 3 Hypermethylated
Ebf3 3 Hypermethylated
Egr3 3 -
Emx1 3 -
Emx2 3 -
Esrrg 3 -
Fezf2 3 Hypomethylated
Foxp2 3 -
Foxp4 3 -
Gbx2 3 Hypermethylated
Gli3 3 Hypermethylated
Gsx1 3 -
Gsx2 3 -
Hes1 3 -
Hes5 3 -
Id2 3 -
Id4 3 -
Isl1 3 -
Lef1 3 -
Lhx2 3 -
Lhx5 3 -
Lhx8 3 -
Lhx9 3 -
Mafb 3 -
Meis1 3 Hypomethylated
Meis2 3 -
Neurod1 3 -
Neurog1 3 Hypomethylated
Neurog2 3 -
Nkx6-2 3 -
Nr2e1 3 Hypomethylated
Nr2f1 3 Hypomethylated
Nr2f2 3 -
Olig1 3 -
Olig2 3 Hypomethylated
Otx1 3 Hypomethylated
TF # CTs LMC1 status
Pax6 3 Hypomethylated
Pou3f2 3 Hypomethylated
Pou3f3 3 Hypermethylated
Rara 3 -
Sall3 3 -
Six3 3 -
Sox1 3 Hypomethylated
Sox4 3 -
Sp8 3 Hypomethylated
Sp9 3 -
Tle1 3 -
Tle3 3 -
Tle4 3 -
Tshz1 3 -
Vax1 3 -
Zfhx4 3 -
Zfp521 3 -
Zic1 3 Hypomethylated
Bcl11b 2 -
Dlx1 2 Hypomethylated
Dlx2 2 -
Dlx5 2 -
Dlx6 2 -
Eomes 2 -
Fezf1 2 -
Foxg1 2 -
Hmx3 2 -
Lhx6 2 -
Otx2 2 -
Prox1 2 -
Sox11 2 -
Tbr1 2 -
Zic5 2 Hypomethylated
Bcl11a 1 Hypermethylated
Nkx2-1 1 -
Pbx1 1 -
Zfp503 1 -
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Additional Files
Additional file 1— CpGs used for the analysis of memory and naive B-cells
A comma-separated value table le.
Additional file 2 — LMC-specific CpG positions of the FC1 data set
A comma-separated value table le.
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Chapter 7
General Discussion, Conclusions and
Outlook
The present thesis is a collection of several data analysis advances for DNA methylation map-
ping. In this concluding chapter the results presented above will be put into a common con-
text and discussed in respect of their benets for DNA methylation analysis and epigenetics
in general. Section 7.2 conveys a unifying view of how all the contributions of the thesis are
together composing a data analysis framework of a typical DNA methylation proling study.
Next, Section 7.2 deals with a more specic problem of methylome deconvolution. Finally, Sec-
tion 7.3 gives an outlook at the upcoming development of the eld and provides for general
considerations about bioinformatic tool development and perspectives of this research eld.
7.1 An analytical framework of a large DNA methylation
study
Collectively, the contributions presented in Chapters 2 to 6 comprise dierent data analysis
aspects of a typical DNA methylation study. The relationships between particular results are
given in a conceptual diagram (Figure 7.1). In the center is a genome-scale DNA methylation
proling study exemplied by a birth-weight EWAS in birth-weight discordant monozygotic
twins (Chapter 2). A study of such kind usually performs a screen of DNA methylation in
multiple individuals resulting in a high-dimensional DNA methylation data set. The data are
then preprocessed, quality controlled and normalized using the RnBeads package (Chapter 3).
The preprocessed data can be adjusted for heterogeneity eects using the third-party meth-
ods implemented in RnBeads, as well as a marker-based adjustment procedure described in
Chapter 2. The heterogeneity-corrected statistical analysis results in a set of candidate dier-
entially methylated positions or loci. These candidates are, as a rule, veried using a dierent
DNA methylation proling technology. Locus-specic deep bisulte sequencing is a method
of choice due to its high sensitivity and resolution. In addition to normal bisulte sequencing,
the protocols for detection of oxidative modications can be applied to investigate methyla-
tion dynamics at the candidate loci. The obtained verication data set is processed using BiQ
Analyzer HT (Chapter 4) and HiMod (Chapter 5). Finally, DNA methylation heterogeneity in
the genome-scale proles can be exhaustively explored in an unsupervised manner using the
reference-free deconvolution by MeDeCom (Chapter 6). In the remainder of this section each
of these aspects is thoroughly discussed.
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A large-scale DNA methylation study
RnBeads BiQ Analyzer HT/HiMod
Processing and analysis of 
the genome-scale data
Verification of DMRs by 
locus-specific analysis
MeDeCom
Marker-based 
adjustment
Analysis of the cell 
type heterogeneity
Correction Deconvolution
Figure 7.1: Conceptual diagram of the main results.
Study preparation
Proper design and planning are deterministic for the success of a DNA methylation study
[Michels et al., 2013; Rakyan et al., 2011]. The EWAS in birth-weight discordant monozygotic
twins presented in Chapter 2 conrmed that the more thinking is invested into the stages
prior to data retrieval the easier it is to analyze the obtained data and the more reliable are the
ndings. Adequate consideration of variability sources, confounding factors, power limits and
pitfalls of the selected technology allows to avoid potentially deteriorating data preprocessing
and excessively complicated data analysis methods. For the particular case of an EWAS there
are several design aspects requiring thoughtful consideration, namely the selection of a cohort
in the context of potential genetic confounding, heterogeneity-aware choice of the target tissue
or cell type, and the design of the proling procedure minimizing technical batch eects.
Genetic information has a strong inuence upon the methylome, and, therefore, the stud-
ies in case-control cohorts are severely confounded by the genetic variability. Low sample
numbers, still common for many EWAS, are aggravating the problem since the genetic eects,
such as ASM or methQTLs, have very large eects sizes and require a lot of observations to be
eliminated by averaging in the compared groups. Bead arrays, used predominantly in EWAS,
are specically inuenced by SNPs. A popular method of dealing with this problem is to re-
move all potentially aected probes. In case a rather liberal threshold of 3% for the minor allele
frequency is used, such an approach would result in a removal of circa potentially informative
40,000 Innium 450k CpGs, without solving a problem of methQTLs. In this respect, DNA
methylation studies with a genetically matched design, such as those based on monozygotic
twins, successfully avoid this type of confounding and are inherently more powerful.
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The issue of confounding by cell type heterogeneity discussed below, can be avoided or, at
least, minimized by a proper consideration at the early design stages. In due of the costs and
the sample collection eorts EWAS have to rely upon easily accessible tissues and biouids.
The choice of a sampled biological material should, if possible, avoid severely heterogeneous
tissues, in case this is not necessary for testing the main hypothesis. As an example relevant for
the blood-based studies, if one can exclude that the sought eects do not take place in granu-
locytes, sampling the whole blood is not a reasonable choice, since granulocytes contribute for
more than a half of thereby obtained DNA. A comparatively simple and non-invasive PBMC
isolation procedure might be preferable in this case. A pan-somatic eect is better studied us-
ing saliva or buccal epithelium swabs carrying less sources of cell type heterogeneity compared
to whole blood. One should also carefully consider the possibility that the target phenotype
or condition being associated with strong changes of the cell type composition in the sampled
material. In this case the confounding is the most severe and has to be corrected if the “direct”
eects across the sampled tissue are the primary target.
Technical confounding can be as deteriorating as genetic and cell type heterogeneity eects
are, and design precautions are necessary to minimize such eects. Although the noise level is
usually inherent to the particular DNA methylation proling technology and cannot be inu-
enced, the various types of technical biases can and should be accounted for. For instance, the
non-linear intensity increase across the Innium/EPIC microarray plate can translate into a
global bias of methylation values. Hence, any periodicity in sample positioning will inevitably
confound an association analysis of a case-control study, and, therefore, it is highly recom-
mended to randomize the sample layout. On the opposite, under a matched design the sample
pairs should be positioned at neighboring slots to minimize the intra-pair dierences.
Standardized and comprehensive data handling
The results of the EWAS example in Chapter 2 as well as other similar studies mentioned above
emphasize the importance of appropriate data handling. Chapter 3 presents a universal pack-
age RnBeads for the preprocessing and analysis of high-throughput bisulte sequencing and
DNA methylation bead array data. The contribution of the present thesis is encompassing the
core infrastructure of RnBeads, the data import, quality control and normalization modules,
as well as the cell type confounding estimation and adjustment functionality.
One particular problem is the large data volumes typically occupied by the DNA methyla-
tion data. The biggest bisulte sequencing and bead array data sets are approximately equal in
size, due to orders of magnitude dierences in numbers of proled samples. In this respect, the
operating memory is comprising a resource bottleneck, and a large analysis is only possible
when signicant portions of the data are stored on the hard drive space in an easily accessible
form. Such a solution was implemented in RnBeads facilitating simultaneous processing of
the complete set of Innium arrays generated by TCGA.
Quality control is an essential part of any analysis. Low quality samples have to be detected
and removed from the analysis. In case the quality of the whole data acquisition was low, one
should consider repeating it. In many cases, in particular for DNA methylation microarrays,
the data should be properly normalized. RnBeads collects the best available methods for qual-
ity control and normalization into a standardized comprehensive pipeline allowing for easy
testing and comparison of the methods. The modular architecture allows seamless extension
of the pipeline and addition of new methods.
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Correction of the cell-type heterogeneity eects
The issue of methylome heterogeneity is very topical for the current DNA methylation re-
search. It will maintain its actuality until the single-cell methods reach nal development,
making it feasible to obtain methylomes of a representative cell sample from each individ-
ual in a large study cohort. The single-molecule sequencing methods which will be able to
discriminate the DNA modications are also promising.
The birth-weight EWAS presented in Chapter 2 oers a clear-cut example of confounding
by heterogeneity issues. Several samples with a very dierent cellular composition of saliva
inated the eect size at a large bulk of CpG positions. If not accounted for they could have
led to spurious reporting of methylation eects of the restricted in utero growth.
To address this problem in this particular study we developed a simple regression-based
method presented in the same chapter (see Supplementary Methods). The method has two es-
sential steps. The rst step includes marker selection based on values in the reference methy-
lomes as well as on linearity properties in the target data set. In the second step the marker
proles observed in the actual data are used to model the complete target data set by the stan-
dard least-squares regression. The intercept-scaled residuals of the model t are treated as an
adjusted version of the DNA methylation data set, and are directly submitted to an associa-
tion analysis using standard statistical techniques. Our method helped to avoid false positive
ndings and spurious associations.
Our correction approach belongs to the reference-based heterogeneity estimation and ad-
justment methods reviewed in Section 1.3. Most of them use reference methylomes directly
for computing the estimates of cell type proportions which is associated with potential risks.
First, reference methylomes are usually obtained in completely independent proling exper-
iments and can be drastically dierent from the target data from the technical standpoint.
These eects can be partially solved by combined preprocessing of the target and reference
data, which is implemented in available pipelines, e.g. RnBeads or min [Aryee et al., 2014].
However, even if the technical dierences are minimal, the reference data is typically ob-
tained via the cell purication experiments in an independent cohort of individuals. Second,
the estimation method assumes that that the cell type methylomes of the reference and tar-
get individuals are indistinguishable. Failure to fulll this assumption, for instance, due to
genetic or environmental dierences between the target and the reference cohorts, the esti-
mates obtained by the reference-based methods are inherently biased. In this respect, using
the reference methylomes only for marker selection, as suggested in Chapter 2, appears to be
a more reliable procedure, free of such hardly veriable assumptions. This, of course, requires
careful examination of the selected quantitative marker CpGs for potential genetic or technical
confounding.
An additional advantage of selecting a few adjustment markers is that the latter can be
used in the subsequent analysis with a targeted locus-specic technology in a large validation
cohort. The selected markers can be proled together with the loci selected in the primary
analysis and used for the correction of the generated locus-level data.
Based on the considerations above, the reference-free methods for heterogeneity correc-
tion, in particular RefFreeEWAS [Houseman et al., 2014], EWASHER [Zou et al., 2014] and
ReFACTor [Rahmani et al., 2016], are expected to be more robust and bias-tolerant. The com-
parison of all three methods shows almost equivalent performance on the same EWAS data
sets [Rahmani et al., 2016]. All theses methods, except for the very recent ReFACTor, are im-
plemented in RnBeads.
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Verification by locus-specific analysis
A typical genome-scale DNA methylation study aims to nd the candidate loci, potentially
associated with the target biological condition. Once the regions of interest are stratied, a
verication by a high-resolution technology, such as deep bisulte sequencing, should fol-
low. Furthermore, with respect to the heterogeneity problem, locus-specic deep bisulte
sequencing allows for direct visualization of the underlying cell population methylomes as
demonstrated in Chapter 2. Chapters 4 and 5 present two software packages for processing
and analysis of locus-specic DNA methylation data of various types. Both tools are intended
for the life science users and implement an interactive application model allowing a biolog-
ical researcher to visually explore the results from the level of aligned sequence reads down
to summarized results for a complete analysis project. One of the major advances of these
tools compared to their predecessor BiQ Analyzer and similar third-party tools is the project-
oriented architecture which supports a typical investigation scheme of a candidate gene or
EWAS-verication study. BiQ Analyzer HT (Chapter 4) and its successor BiQ Analyzer Hi-
Mod (Chapter 5) are successfully used by DNA methylation researchers worldwide.
7.2 Deconvolution of the mixture methylomes
The specic issue of methylome heterogeneity has received a particular attention here. Apart
from the rst more practical aspect of deconfounding, thoroughly discussed in the previous
section, the methylome heterogeneity problem has another inferential dimension. This latter
aspect can be dened as a deconvolution problem introduced at the end of Section 1.3.
Mathematically this problem was formulated in Chapter 6 (Supplementary Note 1). It is
important to understand that the true entities which are mixed in the average methylomes are
the unique methylomes of single cells (the “exact” model of mixture methylomes). This is why
a model representing measured data as a combination of cell type methylomes is conceptually
ill-posed and can only be seen as an approximation.
Even if the mixture methylomes could be measured by an ideal method, free of any tech-
nical biases and noise, the “exact” problem is computationally intractable until the number
of proled mixtures gets the same order of magnitude as the number of underlying unique
single-cell methylomes. Although, completely unrealistic at the moment, it can be reached in
the near future as the numbers of proled samples grow (currently approaching ten thousand
and more), and the proling methods get increasingly low-input. Once computationally fea-
sible, the exact problem can be provably solved by the method we earlier developed [Slawski
et al., 2013].
At the moment the majority of large DNA methylation studies exploit methods taking hun-
dreds of thousands to millions of cells as input. In this situation the methylome deconvolution
problem can only be pursued in its approximated variant. A meaningful approximation, pre-
serving most of the information about the underlying distribution of the single-cell methyla-
tion patterns, can be seen as a series of nested models where groups (clusters) of highly similar
single-cell methylomes are substituted by their average proles. Since the cell type is one of
the major determinants of the global DNA methylation landscapes, one can expect that in the
low-rank approximation the similarity clusters will be close to the average methylomes of cell
types and cell populations. Nevertheless, other large sources of DNA methylation variability
aecting many CpG positions in multiple cells will inevitably aect the similarity clustering
of the single-cell proles.
Importantly, such a structure-preserving approximation model does not have to be (and
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will most likely not be) the best one in terms of its reconstruction performance, i.e. the dis-
tance between the predicted and the observed data. For the sake of contrast one can consider
PCA. PCA is based on singular value decomposition and is guaranteed to deliver the best pos-
sible low-rank approximation of a data matrix. However, the orthogonality of the returned
principal components is incompatible with the properties of the sought approximation, since
the average methylomes of cell populations are far from being linearly independent due to the
global structure of the DNA methylation landscape. On the opposite, the data of the reference
proling studies shows that even the methylomes of relatively distant cell types maintain a
considerable level of similarity [Horvath et al., 2012].
The computational framework MeDeCom presented in Chapter 6 was designed to achieve
the goal of nding a biologically meaningful, structure-preserving approximation. The model
constraints and the regularization of the tting algorithm limit the reconstruction perfor-
mance, but are supposed to aid in recovering the approximation solution that are more bi-
ologically meaningful compared to those obtained with standard methods. To describe the
elements of the MeDeCom approximation model we introduced the concept of latent methy-
lation components (LMCs). The aim of MeDeCom is that LMCs correspond to clusters of
similar single-cell patterns.
In practice the convoluted methylome matrix is only available through an unideal mea-
surement. The particular proling method has a decisive inuence upon the computational
properties of the deconvolution problem. Currently, reasonably large data sets of multi-cellular
samples are obtained with Innium/EPIC bead arrays. While this technology is comparatively
robust and each called methylation value has a sucient support, the specic problems of the
Innium/EPIC bead arrays such as the augmented probe-specic value range, proneness to
batch eects and sensible noise levels are comprising a substantial limits upon the grade of
deconvolution. Bisulte sequencing methods may prove more useful in this respect. Although
often used as an averaged quantitative prole, conventional bisulte sequencing essentially
delivers sub-sampled snapshots of the single-cell methylome distribution. This information
can be used to recover the cell population methylomes with a much higher eciency and res-
olution. That said, even the summarized bisulte sequencing proles are void of many pitfalls
seen in the microarray data. More specically, the methylation calls, as a rule, have the same
eective value range at all positions, the background is practically absent, allowing for e-
cient removal of invariable CpGs, simultaneously retrievable genetic variants can be used to
eliminate the genetically aected CpGs.
7.3 Outlook
Its involvement into the key regulatory processes and favourable properties of 5-methylcytosine
as an easily accessible mark turn DNA methylation into an attractive target to study regardless
of how causal its role is in controlling the gene activity. Hence, DNA methylation proling will
doubtlessly maintain its high importance for epigenetics and the biological research in gen-
eral. Although the mapping methodology is constantly improving, the data analysis problems
will unlikely get deprecated in the near future. Consequently, a need for new computational
methods, as well as comprehensive and convenient bioinformatic tools will persist. Ideally, the
major bioinformatic eort will be aimed at transforming the cutting edge methods developed
by mathematicians, computer scientists and computational biologists into comprehensive and
user-friendly tools helping a life scientist to get a full understanding of their data and lead
the data analysis to a conclusive result. RnBeads, BiQ Analyzer HT, BiQ Analyzer HiMod and
MeDeCom presented above were all created with this goal in mind.
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It is quite apparent that the current issue of methylome heterogeneity, also addressed in
this thesis, will be substantially simplied and transformed in the long to medium term. The
large-scale proling eorts, such as the International Human Epigenome Consortium [Abbott,
2010], will generate numerous reference methylomes. This will allow massive annotation of
cell type-specic marker CpGs that will further aid the reference-based heterogeneity cor-
rection methods. Furthermore, the anticipated advances in low input and single-cell bisulte
sequencing together with the long-awaited breakthroughs of the third generation sequencing
approaches. The current problem of analyzing the average cell sample methylomes will be suc-
ceeded by a more large-scale setting with hundreds to thousands single-cell DNA methylation
patterns per each biological specimen. Despite that this setting seems much more informative
and easy to analyze, the data analysis focus will most likely shift towards the more intricate
issues, such as estimation of the sampling biases.
One can foresee that the other types of data will become increasingly important as the
respective proling methods are constantly improving. The methodology derived here for the
problem of methylome deconvolution is mathematically generic and can, in theory, be applied
to a range of other epigenomic signals sharing the discreteness properties of DNA methyla-
tion. These include all epigenetic marks and other data types backed by binary phenomena at
the single cell level for instance open chromatin states (open vs. closed), transcription factor
binding proles (bound vs. free), genome physical contact maps (absence vs. presence of a
contact) etc. It is clear, however, that a certain adaptation of the algorithm as well as specic
data preparation will be required.
Last but not least, there are a lot of sings that the very way large epigenomic studies are
carried out will transform in respect of how life scientists collaborate with bioinformaticians
and computational biologist. Current practice in the majority of the DNA methylation studies
is that the division of labor between between them follows the study stages. Typically, life
science researchers conceive, plan and design the studies and generate high-throughput data,
while bioinformaticians enter the study after the data has been generated and take over the
processing and analysis. This model is awed in several respects. First, bioinformaticians can
provide necessary expertise about specic and often subtle issues which have to be considered
during the study design and planning, and should be involved from the start. Second, the life-
science researchers are the most informed about all aspects and subtleties of their study, and
as such should play the most active role in the data analysis. Third, bioinformatic members of
life science groups, which are usually in minority, are overwhelmed with data analysis tasks
which they have little anity with, leading to an overall delay of the study cycle and wastes
of the human and material resources. The issue of perceiving bioinformatic work as a highly
skilled service has earlier received attention from the social standpoint. It is speculated for
creating tensions in the eld [Lewis and Bartlett, 2013].
The situation is gradually improving, as the large epigenomic consortia, such as DEEP
project and its IHEC peers, introduce a qualitatively new collaborative spirit and involve bioin-
formaticians and computational biologists at all stages. One is also tempted to speculate that
in the upcoming future these collaboration aws will be overcome by a change in the proles
of the involved researchers towards the individual interdisciplinarity, as was already expected
at the verge of the Human Genome Project, but comes with a noticeable delay [Lewis and
Bartlett, 2013]. Knowledge of a required statistical minimum, as well as of basic programming
should become necessary skills of every life science experimentalist, just as it is currently the
case for many other natural sciences.
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